Vittorio Cristini

Top Italian Scientist in Mathematics

Modeling and Simulation to Support Drug Development and Optimize Treatment Outcomes

Poetry and Other Writings

Society

Vittorio Cristini, Ph.D.

• Citation metrics (h-index > 60; i10-index > 125): https://scholar.google.com/citations?user=uwl5tw0AAAAJ&hl=en&oi=ao

• Top 0.5% in mathematics 2022. https://scholargps.com/scholars/80178551571443/vittorio-cristini

• ISI Highly-Cited Researcher in the Mathematics category 2014 (Thomson Reuters). http://highlycited.com

• Stanford—Scopus Top 2% Scholars List 2023. https://data.mendeley.com/datasets/btchxktzyw/6

• Top Italian Scientists List. https://topitalianscientists.org/TIS_HTML/Top_Italian_Scientists_Mathematics.htm

• Websites (in progress): https://www.houstonmethodist.org/faculty/1mmune1o-cristini/ https://www.houstonmethodist.org/math-in-medicine/

PRESENT TITLES

• Professor of Computational Biology and Mathematics in Medicine, 2022-present

Department of Medicine, The Houston Methodist Research Institute

• Professor and Chairman, Mathematics in Medicine Program, 2018-present

The Houston Methodist Research Institute

• Professor, Population Health Sciences, 2021-present

Weill Cornell Medicine, Cornell University

• Professor, Physiology, Biophysics and Systems Biology, 2021-present

Weill Cornell Medicine, Cornell University, 2017-present

• Adjunct Professor, Department of Imaging Physics

The University of Texas MD Anderson Cancer Center

Business Address: Houston Methodist Research Institute, R8-123, 6670 Bertner Avenue, Houston Texas- 77030, Email: vcristini@houstonmethodist.org, Phone- 505-934-1813

SHORT BIOGRAPHY AND PERSONAL STATEMENT

Since July 2018, he has been with the Houston Methodist Research Institute (HMRI) as Professor and Chairman of the Mathematics in Medicine Program, while his academic appointments are as Professor of Physiology, Biophysics and Systems Biology at Cornell University Medical School and Professor of Computational Biology and Mathematics in Medicine at the Department of Medicine of Houston Methodist. He is also member of the graduate program and of the promotion and tenure committee at both institutions. Finally, he is currently an Adjunct Professor of Imaging Physics at the MD Anderson Cancer Center. In the past decades, by focusing on clinical translation of mathematical and biophysical models, he has established multiple local, national, and international collaborations, in order to combine forces and work towards multi-faceted and multi-disciplinary studies. More recently, his team has established several collaborations with research scientists and clinicians at the HMRI in different fields of interest, including immunoncology (Dr. Shu-hsia Chen), and clinical translational cancer research (Drs. Jenny Chang, Esnaola Kai and Bernicker, Houston Methodist Cancer Center). These collaborative efforts have resulted in the development of several successful grant applications. Over the years, He's also served as consultant or independent contractor for a number of pharma and biomedical device companies and as CFO for a neuroimaging society.

Scientific recognition

The collaborations and scientific output throughout the years have brought him international recognition as a “thought leader” of research excellence and leadership in the fields of mathematical and computational biology, applied and computational mathematics, physical oncology, complex fluids and microfluidics, and multidisciplinary (bio)materials science. In 2014, He was honored to be recognized ISI Highly-Cited Researcher in Mathematics, and had the privilege to be named one of the World’s “most influential scientific minds,” shared with less than 100 mathematicians worldwide. In his 27 years in research, he has also had the privilege to serve as editor for several scientific journals, including Cancer Research, NeuroImage, Frontiers, and PLOS Computational Biology, he has published over 100 peer-reviewed journal articles, and two book monographs with Cambridge University Press in 2010 and with CRC Press in 2017. He has served as consultant and board member for a number of private companies, and on several faculty committees at various academic institutions.

His work has been recognized through various awards, nationally and internationally. He was the first recipient of the “Andreas Acrivos Dissertation Award in Fluid Dynamics” by the American Physical Society in 2000 for my PhD thesis in Chemical Engineering at Yale University. His 2005 paper in the Bulletin of Mathematical Biology was in the top 0.1% of citations in the field of Mathematics and has been designated as a “New Hot Paper in the field of Mathematics” by the Institute for Scientific Information (ISI) Web of Knowledge; two articles have been featured in the Cancer Research Highlights of the American Association for Cancer Research. His research has been highly recognized internationally and by the media and several science museums in the US, and has been supported by the Cullen Trust for Health Care, Artidis corporation, the National Science Foundation, the National Institutes of Health, the Department of Defense, and the States of California, Texas, and New Mexico, among others.

Funding and strategic development

Over the past 20 years, he has continually served in PI roles on several NSF, NIH, and DoD grants focused on the development of predictive multi-scale, patient-specific computational models of tumor growth and mechanistic mathematical models of tumor response to chemo/immunotherapy, targeted therapy, and nano-therapeutics, most notably as part of multi-institutional grants including two NSF and joint NSF/NIGMS grants (funded in September 2017 and 2013, respectively), two R01s beginning in April and July 2018, two U01 NCI grants on pancreatic and gynecological cancers (funded in August 2015 and July 2017, respectively), two NCI Physical Sciences in Oncology Centers (PS-OC), one NCI Center for Excellence in Cancer Nanotechnology (CCNE), of which he also served as the overall PI in 2015-2016, one NCI Integrative Cancer Biology Program (ICBP) center grant, and one NIGMS P50 grant in systems biology, several additional R01s and one SPORE grant. At UCI, UNM, UTHealth, and HMRI he has developed and taught novel courses in Computational and Precision Biomedicine, and have mentored and trained graduate students, postdocs, and junior faculty, including mentees in the NIGMS Spatio-Temporal Modeling Center (STMC UNM) and the NIGMS-IRACDA Academic Science Education and Research Training (ASERT) program, Weil-Cornell Graduate School, and Rice University Applied Physics. He has also established important collaborations with industrial partners as well, including ARTIDIS (a company based in Basel, Switzerland), and AstraZeneca. One of the major goals behind this type of strategic network of preclinical and clinical collaborations with mathematical, physical scientists, and engineers is to develop new intellectual property (IP) centered around mathematical interpretation of clinically relevant data methods to predict and optimize therapy outcome.

Modeling-supported clinical translation

He pioneered the field of “Physical Oncology”, which aims at using mathematical modeling, physical theories, and engineering approaches to describe and quantify biological mechanisms that play important roles in the growth of cancer and in response to therapies. With a solid background and experience in Applied Mathematics and Chemical Engineering, and specifically in the development of theories and numerical methods in Complex Fluids and Materials, He is dedicated to applying and adapting engineering and physical sciences approaches to the modeling of complex normal and pathologic biological tissue. One important approach he has been leading is focused on investigating the effects of diffusion, perfusion, and transport phenomena on cancer growth and dissemination rate, and on the development of resistance to drug or other systemic therapies. All the models and approaches developed within this framework integrate input from patient and experimental data (ACS Nano 2013, PLOS Computational Biology 2013, 2016, PLOS One 2013, 2016, Scientific Reports 2018, Nature Communications 2018, JCI Insight 2019). These efforts have been supported by the National Cancer Institute’s (NCI) Physical Science in Oncology (PS-OC) and the Center for Excellence in Cancer Nanotechnology funding mechanisms (three U54s funded) and regular R01-type funding from the National Science Foundation and National Institutes of Health. In line with this type of work, I have also made important discoveries on the role of physical transport in drug resistance in patients (JCI 2014, PNAS 2013, 2016, Clin Cancer Res 2018, Science Advances 2020, Nature BME 2021, ELife 2022). Currently, a first-of-kind effort is underway at the MD Anderson Cancer Center, the Baylor College of Medicine, and the Houston Methodist Cancer Center, towards the development of prospective clinical trials (and retrospective clinical studies) based on my mathematical models of physical transport in tumors to elucidate the role of physics in overall resistance to cancer chemotherapy and immunotherapy drugs.

His translational modeling effort is part of an ongoing collaboration with biologists, oncologists, and nanotechnologists at MD Anderson Cancer Center (Drs. Anirban Maitra, Gabriel Lopez-Berestein, Anil Sood, David Hong, Jen Wargo, George Calin, Bulent Ozpolat, Eugene Koay, Subrata Sen, James Welsh, Mary Edgerton, John Hazle, Ahmed Kaseb, and Christopher Crane among the others), Moffitt Cancer Center (Drs. Jason Fleming, Daniel Anaya), Baylor College of Medicine (Drs. Alastair Thompson, Michael Lewis, and Jeff Rosen), UNM (Drs. Jeffrey Brinker, Elaine Bearer, Cheryl Willman), Rutgers University (Drs. Wadih Arap, Renata Pasqualini, Daniela Staquicini), Stanford University School of Medicine (Dr. Sam Gambhir), USC School of Medicine (Dr. David Agus), and Houston Methodist (Drs. Haifa Shen, Shu-hsia Chen, Alessandro Grattoni, and others). To properly account for the purely biological phenomena affecting this tissue physics, they developed data-driven cell signaling and molecular interaction models, including under the umbrella of the NCI ICBP program (one additional U54 funded) in collaboration with the Baylor College of Medicine and also in collaboration with UNM (Cancer Res 2009a,b, Physical Biology 2012, PLOS Comput Biol 2016).

Education and outreach

As a scientific leader, he also contributed to developing outreach and education initiatives to promote novel approaches and results coming from the field of physical oncology. In particular, with the support of the NCI, they have developed a series of educational workshops (most notably: The Ohio State University workshop on “The role of biomedical informatics in overcoming current barriers in cancer research” 2008; and the National Cancer Institute meeting: “Integrating and Leveraging the Physical Sciences to Open a New Frontier in Oncology” 2008). These efforts led to the creation of the PS-OC program by the NCI. An introduction to this new field was developed in my book monograph on multiscale mathematical modeling of tumor growth, Cambridge University Press (2010). A second monograph, titled “An Introduction to Physical Oncology”, was published by CRC Press in 2017, where new mathematical models of physical transport processes (including our recent modeling work) that use patient tissue and imaging data to predict the efficacy of 6mmune/chemotherapy and radiation therapy are introduced and discussed.

In his career, he has also had the pleasure to serve as mentor to ca. 100 trainees, including graduate students, postdocs and junior faculty, and many of them have gone on to successful research and academic careers (e.g., Dr. Paul Macklin, Indiana University; Dr. Steven Wise, The University of Tennessee; Dr. Hermann Frieboes, University of Louisville; Dr. Jennifer Pascal, University of Connecticut, Drs. Wang, Dogra, Nizzero and Butner, HMRI). His current research group is highly interdisciplinary, and includes undergraduate students, graduate students, post-doctoral fellows, research associates, and junior faculty in the field of biophysics, applied physics, engineering, statistics, mathematical modeling, imaging, and immunology.

Citizenship

United States of America, Italy

Undergraduate Education

1989 – 1994 University of Rome – La Sapienza, Laurea Degree, Summa cum Laude, Nuclear Engineering

Graduate Education

1995 – 1996 Yale University, New Haven, Connecticut, M.S., Chemical Engineering

1996 – 1998 Yale University, New Haven, Connecticut, M.Phil., Chemical Engineering

1998 – 2000 Yale University, New Haven, Connecticut, Ph.D., Chemical Engineering, Thesis: “Drop dynamics in viscous flow”

Postgraduate Training

2000 – 2002 University of Minnesota, Minneapolis, Minnesota, Postdoctoral Associate, Chemical Engineering and Materials Science

2001 – 2002 University of Minnesota, Minneapolis, Minnesota, Postdoctoral Associate, Institute for Mathematics and its Applications

Academic and Administrative Appointments

2022-present Houston Methodist Department of Medicine, Professor of Computational Biology and Mathematics in Medicine

2021-present Weill Cornell Medicine, Cornell University, Professor of Population Health Sciences

2020-present Weill Cornell Medicine, Cornell University, Professor, Graduate School of Medical Sciences

2018-present The Houston Methodist Research Institute (HMRI), Professor & Director, Mathematics in Medicine Program

2017-2018 The University of Texas Health Science Center at Houston McGovern Medical School, Co-director of the Nanochemistry and 3D-printing Service Center Institute for Molecular Medicine; Co-director of the Proteomics Service Center, Institute for Molecular Medicine

2017-present The University of Texas MD Anderson Cancer Center, Adjunct Professor, Department of Imaging Physics

2016–2018 The University of Texas Health Science Center at Houston McGovern Medical School, Professor with tenure and Director, Center for Precision Biomedicine, The Brown Institute of Molecular Medicine

2015–2016 The University of Texas Health Science Center at Houston McGovern Medical School, Visiting Professor and Chairman, Department of Nanomedicine and Biomedical Engineering; Professor, Center for Proteomics and Systems Biology, The Brown Institute of Molecular Medicine

2015-2018 Department of Nanomedicine, Full Affiliate Member, HMRI

2014 – 2015 King Abdulaziz University, Jeddah, Saudi Arabia, Distinguished Adjunct Professor, Department of Mathematics

2012 – 2018 The Methodist Hospital Research Institute, Senior Scientist Fellow

2010 – 2015 University of New Mexico, Albuquerque, New Mexico, Professor, Department of Chemical and Nuclear Engineering; Professor, Center for Biomedical Engineering, The Victor and Ruby Hansen Surface Professor in the Molecular Modeling of Cancer, UNM Cancer Center; Director of Computational Biology, Department of Pathology; Professor with Tenure, Department of Pathology

2009 – 2010 University of Texas Health Science Center at Houston, Texas, Professor, Department of Biomedical Engineering; Director, Center for Computational Biomedicine, School of Biomedical Informatics; Professor with Tenure, School of Biomedical Informatics

2009 – 2010 University of Texas MD Anderson Cancer Center, Houston, Texas, Associate Professor, Department of Systems Biology, Division of Cancer Medicine

2009 – 2010 University of Texas at Austin, Texas, Professor, Department of Biomedical Engineering

2009 – present University of Dundee, Scotland, UK, Honorary Professor, Department of Mathematics

2009 – 2010 Scottish Universities Life Sciences Alliance, Scotland, UK, Professor

2009 Auvergne University, Clermont-Ferrand, France, Chair of Excellence in Neurosurgery

2007 – 2009 University of Texas MD Anderson Cancer Center, Houston, Texas, Associate Professor, Department of Systems Biology, Division of Cancer Medicine

2007 – 2009 University of Texas at Austin, Texas, Associate Professor, Department of Biomedical Engineering

2006 – 2009 University of Texas Health Science Center at Houston, Texas, Associate Professor, Department of Biomedical Engineering, Associate Professor, School of Biomedical Informatics

2006 – 2007 University of California, Irvine, California, Associate Professor, Department of Mathematics

2005 University of Naples, Italy, Visiting Assistant Professor, Department of Chemical Engineering

2002 – 2006 University of California, Irvine, California, Assistant Professor, Department of Biomedical Engineering; Assistant Professor, Department of Mathematics

2002 University of Minnesota, Minneapolis, Minnesota, Mentor Faculty, NIH-National Institute of Dental Craniofacial Res., T32 Training Grant; Visiting Assistant Professor, School of Mathematics

Positions at National/International Professional Organizations

2018 – present Consulting History Information available upon request

2016 – 2017 Society for Brain Mapping & Therapeutics (SBMT), Science Committee Member

2006 – 2007 International Brain Mapping and Intra-operative Surgical Planning Foundation, Chief Financial Officer

2005 – 2007 Centre for Molecular (Bio) Medicine, Trieste, Italy, Scientific Advisory Board Member

2004 – 2006 Orqis Medical/Edwards Lifesciences, Consultant

2004 – 2007 International Brain Mapping and Intra-operative Surgical Planning Society, Board of Directors

2004 – 2007 American Institute of Chemical Engineers, Fluids Programming Committee Member

HONORS AND AWARDS

• EnMed Capstone Innovator Award, Texas A&M U & Houston Methodist, 2023/9. (Award recipient: Gayatri Prakash, Mentor: Zhihui Wang)

• Wolfram Innovators Award (an International award by Wolfram Technology); for using Mathematica for mathematical modeling to predict cancer patient response to immune checkpoint inhibitor immunotherapy on a per-patient basis, using only current standard-of-care clinical measures, and at times earlier after start of treatment than current response assessment standards are able to provide, 2021/10. (with Joseph D. Butner and Zhihui Wang)

• Career Cornerstone Award, 2021/4, Houston Methodist. (with Zhihui Wang)

• President’s Award for Excellence in Peer-Reviewed Publication for “A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden,” in Nature Biomedical Engineering, 2021/1, Houston Methodist (with Joseph D. Butner and Zhihui Wang)

• The Cockrell Foundation Professorship Award to support mathematical modeling efforts in infectious diseases research at HMRI. 2021-2024. (with Prashant Dogra)

• News press featuring paper Dogra et al., ACS Pharmacology & Translational Science 2021, DOI: 10.1021/acsptsci.0c00183: New York Times Medical Sciences, News Medical

• News press featuring paper Butner et al., Sci Adv 2020, PMC7190324: AAAS EurekAlert!, Medical Xpress, Science Magazine, 7th floor, News Medical, New Break, Bright Surf, Advanced Science News, MJH Life Science, X-MOL, News Break

• Featured article: “A Multiscale Agent-Based Model of Ductal Carcinoma in Situ,” by Butner et al., IEEE TBME 2020 May.

• Excellence in Mentoring Award 2019. Methodist Association for Postdoctoral and Trainee Affairs. (Postdoc: Sara Nizzero)

• Award for Excellence in Peer-Reviewed Publication for “Establishing the Effects of Mesoporous Silica Nanoparticle Properties on in vivo Disposition Using Imaging-Based Pharmacokinetics,” in Nature Communications 2018, Houston Methodist

• Government of Mexico CONACYT Fellowship, 2018-Present (Student: Maria Jose Pelaez Soni, Rice University)

• Ph.D. Thesis “with distinction” (Student: J. Butner, Center for Biomedical Engineering, UNM), July 2017. · Invited feature in Global Health & Pharma 2016, www.ghp-magazine.com

• Invited contributions to Open Access Government, 2015-2021

• Endowed Chair – Rochelle and Max Levit Chair in the Neurosciences, The University of Texas Health Science Center at Houston McGovern Medical School. 2016-2018

• UT STAR award – The University of Texas System – Science and Technology Acquisition and Retention (STARS). 2015 “Mathematical modeling integrated with experiments and clinical trials to understand tumor heterogeneity, drug delivery and treatment outcome” ($1,000,000)

• V Cristini, EJ Koay, Z Wang. Taking cancer out of the equation. International Innovation 2015 (September) 191: 38-40.

• Named as one of the “World’s Most Influential Scientific Minds” in 2014 by Thomson Reuters. http://highlycited.com

• Named in 2014 by the Institute for Scientific Information (ISI), Thomson Reuters, as one of 99 Highly-Cited Researchers in Mathematics worldwide. http://highlycited.com

• Endowed Professorship – The Victor and Ruby Hansen Surface Professor of Molecular Modeling of Cancer, University of New Mexico Cancer Center, 2010-2015.

• Recent Articles and News Reports, featuring Dr. Cristini’s latest research have appeared in 2013-2015, including in: The Business Journals; ABC News and local TV and radio shows; several daily newspapers; The Morning Brew; AdvanceWeb; Newswise; The Stanford Biomedical Computation Review (see below for detailed media coverage links)

• The New Mexico Cancer Nanoscience and Microsystems Training Center (CNTC) Graduate Fellowship, 2013-2014 (Student: Romica Kerketta, UNM)

• 2013-2014 School of Engineering Award – the Charlotte and William Kraft Graduate Fellowship (Student: Terisse Brocato, UNM)

• The New Mexico Cancer Nanoscience and Microsystems Training Center (CNTC) Graduate Fellowship, 2014-2016 (Student: Terisse Brocato, UNM)

• The New Mexico Center for the Spatiotemporal Modeling of Cell Signaling (STMC) Graduate Student Fellowship, 2014-2016. (Student: Prashant Dogra, Biomedical Sciences, University of New Mexico)

• NIGMS-IRACDA Academic Science Education and Research Training (ASERT) K12GM088021 postdoctoral fellowship (Jennifer Pascal)

• PS-OC Newsletter 2014, “Physical Transport Properties Could Predict Outcomes for Patients with Cancer”

• Young Oncologist Essay Award, American Radium Society’s 95th Annual Meeting, April 27 – May 1, 2013, Scottsdale, Arizona (E Koay)

• Front cover of Physical Biology, October 2012

• Articles by van de Ven et al, AIP Advances 2012, and by Chauviere et al., AIP Advances 2012, selected for inclusion in the Virtual Journal of Nanoscale Science & Technology, April 2012

• Chair of Excellence in Neurosurgery, Auvergne University, Clermont-Ferrand, France, 2009

• Highly Accessed BioMed Central Paper (Sanga, S. et al., BMC Medical Genomics 2009, 2:59)

• SULSA Professor 2009-2010 (Scottish Universities Life Sciences Alliance)

• Front cover of Nonlinearity 2010

• Honorary Professor of Mathematics, University of Dundee, Scotland UK, 2009-present

• Founding Member of International Academy of Nanomedicine (IANM), 2009-present

• Active Member (by invitation) of American Association for Cancer Research (AACR), 2009-present

• Cancer Research Highlights, May 15 2009: “Multi-parameter Computational Modeling of Tumor Invasion.” (Cancer Research 2009 69: 4493-4501)

• Interview on National Public Radio, May 25 2009, “Math Could Help Solve Cancer Tumor Mysteries,” by Jack Williams.

• Special Feature of article: “Prediction of drug response in breast cancer using integrative experimental/computational modeling,” by Frieboes et al., Cancer Research 2009, at the American Association for Cancer Research annual meeting, Denver, CO 2009.

• Special Feature of article: “Multi-parameter Computational Modeling of Tumor Invasion,” by Bearer et al., Cancer Research 2009, at the American Association for Cancer Research annual meeting, Denver, CO 2009.

• Special feature of Dr. Cristini’s project “Virtual Cancer” at the event “Gratias Dono” – Gifts that change life, organized by the University of Texas Health Science Center to honor medical philanthropy. Houston Country Club, February 4 2009.

• 2008 STEP-UP Clinical and Research Internship Award for Research Excellence—MD Anderson Cancer Center (Undergraduate student: Deepa Raghunathan)

• Featured in Forbes magazine – “Can Mathematics Cure Cancer?” 27 October, 2008

• Video exhibit of Cristini’s cancer simulations in the Boston Museum of Science, 2008

• Front cover of Journal of Mathematical Biology 2008

• Featured in the Cancer Bulletin of the National Cancer Institute (“The mathematics of cancer”, Cancer Bulletin July 10, 2007 – Vol. 4 / Number 21)

• Fellow, American Academy of Nanomedicine, 2006-present

• Front cover of Bulletin of Mathematical Biology 2006-2009

• Cancer Research Highlights, Feb 1 2006: “Simulation model predicts tumor invasion in marginal environmental conditions.” (Cancer Res 2006; 66(3):1597-604)

• UNCF-MERCK Graduate Science Research Dissertation Fellowship, 2006-2008 (Student: N DeMagalhaes).

• NIH Graduate Fellowship, 2006-2008 (Student: N DeMagalhaes)

• Biomedical Engineer of the year, The Henry Samueli School of Engineering, University of California at Irvine, 2006 (Student: K. Velasco)

• New Hot Paper in the field of Mathematics, Jul 2006, Thomson-Scientific Essential Science Indicators (Bull Math Biol. 2005; 67(2):211-59)

• B. S. Honors Thesis, U. of Minnesota 2004 (Student: A. Anderson)

• · Physical Sciences Faculty Endowed Award, U.C. Irvine, 2003-4 (Student: X. Zheng,)

• Research Scholarship, Minnesota Supercomputing Institute, Univ of Minnesota, 2001

• Andreas Acrivos Dissertation Award in Fluid Dynamics, American Physical Society—Division of Fluid Dynamics 2000, “For important theoretical and numerical contributions to the description and understanding of drop dynamics and breakup in laminar and turbulent flows”

• Henry Prentiss Becton Dissertation Award, Yale 2000, “For exceptional achievements in the field of Engineering and Appl. Sci.”

• Outstanding Paper Award, American Institute of Chemical Eng 1997

• Harold Cheel Fund Graduate Fellowship, Yale U. 1995

• Ente Nazionale Energia Atomica (ENEA) Fellowship, Italy, 1994-1995

• University of Rome – La Sapienza. Laurea Degree, Summa cum Laude, Nuclear Engineering, 1994

Media coverage (selected)

Dogra, P. et al. JCI Insight 2023 PMC10371350 DOI: 10.1172/jci.insight.169860

Newswise: https://www.newswise.com/coronavirus/study-suggests-longer-time-between-covid-19-vaccines-more-effective-for-some/?article_id=790807

Becker’s Hospital Review: https://www.beckershospitalreview.com/public-health/new-covid-19-bivalent-booster-may-require-customized-dosing-study.html

Houston Methodist Newsroom: https://www.houstonmethodist.org/newsroom/study-suggests-longer-time-between-covid-19-vaccines-more-effective-for-some/

Medical Xpress: https://medicalxpress.com/news/2023-04-longer-covid-vaccines-effective.html

Butner et al., eLife, 2021 PMID: 34749885 DOI: 10.7554/eLife.70130.

eLife Press Release, Model predicts early response to cancer immunotherapy https://elifesciences.org/for-the-press/4e89e409/model-predicts-early-response-to-cancer-immunotherapy

X-MOL https://en.x-mol.com/paper/article/1392261663514148864

Society https://sciety.org/articles/meta/10.1101/2021.05.10.21256419

Technology Networks Mathematical Model Designed to Predict Early Response to Immunotherapy https://www.technologynetworks.com/cancer-research/news/mathematical-model-designed-to-predict-early-response-to-immunotherapy-355667

AAAS EurekAlert!

https://www.eurekalert.org/pub_releases/2021-02/hm-mmd020121.php

ScienceNet.cn by China Science Daily

http://news.sciencenet.cn/htmlpaper/2021/1/202111116585021860733.shtm?id=60733

https://mp.weixin.qq.com/s/vO0S5yqUJEAPW0HusY0z-g

X-MOL

https://www.x-mol.com/paper/1346548820336594944

NewsBreak

https://www.newsbreak.com/news/2138602865734-a-mathematical-model-for-the-quantification-of-a-patients-sensitivity-to-checkpoint-inhibitors-and-long-term-tumour-burden

Nonur.com

https://nonur.com/2021/02/02/mathematical-method-developed-to-predict-cancer-and-drug-specific-immunotherapy-efficacy/

Nature in Facebook

https://m.facebook.com/nature/posts/10158296561028167

Nature Bioengineering Community

Towards providing physicians with a quantitative tool for optimizing immunotherapy treatment protocols for each individual patient https://bioengineeringcommunity.nature.com/posts/towards-providing-physicians-with-a-quantitative-tool-for-optimizing-immunotherapy-treatment-protocols-for-each-individual-patient

Diagnostics World

Mathematical Model of Treatment Response ‘Designed For Clinical Translation’ https://www.diagnosticsworldnews.com/news/2021/03/04/mathematical-model-of-treatment-response-designed-for-clinical-translation

The Naked Scientist (BBC)

https://www.bbc.co.uk/sounds/play/p0915r4r

Science Daily

https://www.sciencedaily.com/releases/2020/12/201210112118.htm

AP News

https://apnews.com/press-release/pr-newswire/business-pandemics-public-health-products-and-services-coronavirus-pandemic-d69af76f4657a6cce42b7600a67fdb39

News Medical

https://www.news-medical.net/news/20201210/Researchers-find-new-method-for-safe-and-effective-delivery-of-medicines-to-the-lungs.aspx

AAAS EurekAlert!

https://www.eurekalert.org/pub_releases/2020-12/cp-ivi120320.php https://www.youtube.com/watch?v=wLi0LciskaY&t=13s https://twitter.com/Gut_BMJ/status/1338527208718131206

Social Media

https://www.youtube.com/watch?v=wLi0LciskaY&t=13s

https://twitter.com/Gut_BMJ/status/1338527208718131206

https://www.facebook.com/permalink.php?id=123423901047095&story_fbid=3718876078168508

News Medical

https://www.news-medical.net/news/20201108/Innate-immunity-key-to-limiting-viral-load-in-COVID-19-cases.aspx

AAAS EurekAlert!

https://www.eurekalert.org/pub_releases/2020-04/hm-cmm042920.php

Medical Press

https://medicalxpress.com/news/2020-04-clinically-applicable-math-patient-outcomes.html

Science Magazine

https://scienmag.com/clinically-applicable-math-model-predicts-patient-outcomes-to-cancer-immunotherapy/

7th floor

http://7thspace.com/headlines/1180408/clinically_applicable_math_model_predicts_patient_outcomes_to_cancer_immunotherapy.html

News Medical

https://www.news-medical.net/news/20200430/New-math-model-predicts-clinical-outcomes-in-cancer-patients-treated-with-immunotherapy.aspx

NewsBreak

https://www.newsbreak.com/texas/houston/news/0Ov2e42o/clinically-applicable-math-model-predicts-patient-outcomes-to-cancer-immunotherapy

Bright Surf

https://www.brightsurf.com/news/article/043020508630/clinically-applicable-math-model-predicts-patient-outcomes-to-cancer-immunotherapy.html

Advanced Science News

https://www.advancedsciencenews.com/a-mathematical-model-to-predict-patient-response-in-cancer-immunotherapy/

The Business Journals

http://www.bizjournals.com/albuquerque/print-edition/2013/08/23/vittorio-cristini-everything-clicked.html

ABC News

http://www.koat.com/news/new-mexico/albuquerque/Cancer-Math/-/9153728/21512452/-/14irq94z/-/index.html

AdvanceWeb

http://laboratory-manager.advanceweb.com/Archives/Article-Archives/Perspectives-in-Pathology-19.aspx

Newswise

http://www.newswise.com/articles/unm-cancer-center-scientist-develops-a-numbers-approach-to-treatment

The Stanford Biomedical Computation Review

http://biomedicalcomputationreview.org/content/cancer%E2%80%99s-crystal-ball-personalized-tumor-models-guide-treatment

Santa Fe New Mexican

http://www.santafenewmexican.com/news/health_and_science/article_905465f9-5772-5c7d-a99e-d73fa07aca41.html

UNM Cancer Center Press Release

http://cancer.unm.edu/files/2013/08/FINAL_20130812_Predictive-Modeling-DrCristini_PR.pdf

UNM Cancer Center Press Release

http://cancer.unm.edu/newsroom/unm-cancer-center-scientist-uses-physics-again-to-fight-cancer/

KSFR SF (radio interview)

http://cancer.unm.edu/newsroom/dr-cristini-fights-cancer-using-an-unconventional-approach/

Albuquerque The Magazine

http://cancer.unm.edu/files/2014/07/Albuquerque-The-Magazine-Dr.-Cristini_2.pdf

The Morning Brew

https://www.youtube.com/watch?v=p9fxhWKnD0g

UNM Cancer Center Press Release

http://cancer.unm.edu/newsroom/unm-cancer-center-scientist-develops-a-numbers-approach-to-treatment/

UNM HSCTV

https://www.youtube.com/watch?v=k-TalZh8y0s

UNM Cancer Center Press Release

http://cancer.unm.edu/newsroom/dr-cristini-named-influential-scientific-mind/

UNM Cancer Center Press Release

http://cancer.unm.edu/newsroom/dr-cristini-uses-math-customize-breast-cancer-therapy/

UNM Cancer Center Press Release

http://cancer.unm.edu/newsroom/unm-cancer-center-scientist-recognized-one-influential-scientific-minds/

International Innovation

http://www.internationalinnovation.com/taking-cancer-out-of-the-equation/

American Physiological Society

https://www.newswise.com/articles/fighting-cancer-with-math

Open Access Government

1. https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=4bc1adac-723d-4261-a012-f8ebe5f8ad14
2. https://www.openaccessgovernment.org/prediction-cancer-treatment-outcome-using-physics-2/21536/
3. https://www.openaccessgovernment.org/prediction-cancer-treatment-outcome-using-physics/21432/
4. https://www.openaccessgovernment.org/profile-combining-biology-physics-solve-cancer-problem/22371/
5. https://www.openaccessgovernment.org/mathematical-relationship-immune-system-cancer-implications-cancer-therapy/22262/
6. https://www.openaccessgovernment.org/profile-mathematical-pathology-determining-surgical-volume-breast-cancer-treatment/23968/
7. https://www.openaccessgovernment.org/cancer-diagnosis-and-treatment/25598/
8. https://www.openaccessgovernment.org/understanding-cancer-physics/25938/
9. https://www.openaccessgovernment.org/spatio-temporal-mathematical-model-cancer/28963/
10. https://www.openaccessgovernment.org/integrated-non-invasive-cancer-diagnosis/31174/
11. https://www.openaccessgovernment.org/tissue-scale-factors-predicting-cancer-treatment-outcome/32302/
12. https://www.openaccessgovernment.org/stem-cell-transdifferentiation/36169/
13. https://www.openaccessgovernment.org/dilemma-diagnosis-pancreatic-cysts/35088/
14. https://www.openaccessgovernment.org/identifying-pancreatic-cysts-might-turn-cancer/34409/
15. https://www.openaccessgovernment.org/multimodal-feedback-control-can-lead-self-organizing-morphogenesis/34429/
16. https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=558600cb-8de9-4616-9242-f8f3b41da315&pnum=78
17. https://www.openaccessgovernment.org/regenerative-medicine-to-trump-cancer/53150/
18. https://www.openaccessgovernment.org/mathematical-modelling-nanoparticle-pharmacokinetics/68801/
19. https://www.openaccessgovernment.org/wp-content/uploads/2019/10/OAG24-WEB.pdf
20. https://www.openaccessgovernment.org/oncology/78946/
21. Nizzero S, Plodinec M, Wang Z, Cristini. Giving oncology its power back: A clinical technology revolution is conquering the US from Texas (December 2019). https://www.openaccessgovernment.org/oncology/78946/
22. https://www.openaccessgovernment.org/graph-theory-in-the-study-of-alzheimers-disease-progression/83621/
23. https://www.openaccessgovernment.org/body-dynamics-of-sars-cov-2-treatment-of-covid-19/86929/
24. Butner et al., “Personalized prediction of immunotherapy efficacy: improving clinical approaches via mechanistic mathematical modeling”, Open Access Government, January 2021: p. 116-117. https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=abe4b9c2-2198-40d4-9b41-c05d7aaff94f
25. Dogra, P., Cristini, V., “Is the Pandemic Obeying the Elliott Wave Principle of Financial Markets?” (April 2021). https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=4bc1adac-723d-4261-a012-f8ebe5f8ad14
26. Peláez, M.J., Dogra, P., Cristini, V. “Impact of mathematical modeling in understanding and controlling the COVID-19 pandemic” (October 2021) https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=eaaa2691-f2e2-4ecd-9e5e-f2985210b663

Open Access Government

1. eBook: http://www.adjacentgovernment.co.uk/wp-content/uploads/2016/01/Uni-of-Texas-ebook-web.pdf
2. eBook: https://www.openaccessgovernment.org/mathematical-modeling-drug-delivery-via-nanoparticles-cancer-treatment/27830/

Global Health & Pharma

Invited e-book: “Mathematical Pathology” in Global Health & Pharma 2016, www.ghp-magazine.com

Editorial Board (selected)

2023 – present Cancers (Guest Editor)

2022 – present Frontiers in Physiology (Guest Editor)

2021 – present Nanomaterials (Guest Editor)

2013 – present PLOS Computational Biology (Guest Editor)

2011 – present Frontiers in Computational Physiology and Medicine

2010 – present World Journal of Clinical Oncology

2009 – present Open Journal of Neuroscience (Ross Science Publishers)

2008 – present Cancer Research (American Association of Cancer Research)

2007 – present Open Biomedical Engineering Journal (Bentham Science)

2007 – present Journal of Serbian Society for Computational Mechanics

2006 – 2007 NeuroImage (Elsevier)

2004 – present Journal of Biomedical Nanotechnology (American Scientific Publishers)

2004 – present Biomedical Microdevices (Springer)

Selected: Invitations for Service on National Grant Review Panels, Study Sections, Committees (mentee involved)

• Early Career Fellowship review, The India Alliance, 5/2023 (Z Wang)

• NIH/NCI Clinical and Translational Cancer Research review meeting on breast cancer (R03/R21), 5/2023 (Z Wang)

• NIH special emphasis panel BBBT for Biodata and Biomodeling, 2/2023 (Z Wang)

• DOD Breast Cancer Program (BCRP) Clinical and Experimental Therapeutics 1 (CET-1) review panel, 7/2022 (Z Wang)

• NIH/NCI Program Project V (P01) Special Emphasis Panel (SEP) for PAR-20-077 (National Cancer Institute Program Project Applications, P01), 6/2022 (Z Wang)

• NIH Modeling and Analysis of Biological Systems (MABS) study section, 2/8-9, 2022 panel member · The Research Foundation Flanders (FWO), Review College. 2022-present

• NIH special emphasis panel for Academic-Industrial Partnerships for Translation of Medical Technologies, ZRG1 SBIB,10/25-26 (Z Wang)

• NIH Modeling and Analysis of Biological Systems (MABS) study section panel on October 21-22, 2021

• European Science foundation reviewer: Research Foundation Flanders call for Junior and Senior Research Projects, 2021

• NIH/NCI Program Project V (P01) Special Emphasis Panel (SEP), for PAR-20-077 (National Cancer Institute Program Project Applications, P01), 6/10-11, 2021 (Z Wang)

• RFS/SRFS, Science, Technology, Engineering and Mathematics Selection Panel (STEM Panel), The Research Grants Council (RGC) of Hong Kong, 4/2021 (Z Wang)

• NIH Special Emphasis Panel ZCA1 RPRB-H (M2), 3/19/21 (P Dogra)

• NIH special emphasis panel, ZRG1 SBIB-Q 57, Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment, 2/22-23, 2021 (Z Wang)

• NIH special emphasis panel, ZRG1 SBIB-Q 57, Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment, 6/29, 2020 (Z Wang)

• NIH Small Business Innovation Research (SBIR) review panel, co-chair, 2/12, 2021

• NIH special emphasis panel, ZRG1 SBIB-Q 57, Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment, 2/3, 2020 (Z Wang)

• European Science foundation: I-SITE ULNE (Université Lille Nord-Europe), Program for Early-stage Researchers in Lille (PEARL). 19-Lille-PEARL-007

• Appel A Projects 2019:Inserm – Département de l’Evaluation et du Suivi des Programmes (DESP)

• NIH special emphasis panel, ZRG1 SBIB-Q 57, Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment, 10/10-11, 2019 (Z Wang)

• NIH special emphasis panel, ZRG1 SBIB-Q 57, Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment, 6/24-25, 2019 (Z Wang)

• NIH MABS Study Section, Special Emphasis Panel/Scientific Review Group, 2/14-15, 2019.

• NIH special emphasis panel, ZRG1 SBIB-Q 57, Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment, 2/8, 2019 (Z Wang)

• NIH special emphasis panel, ZRG1 SBIB-Q 57, Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment, 10/15-16, 2018 (Z Wang)

• NIH special emphasis panel, ZRG1 SBIB-Q 57, Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment, 6/15, 2018 (Z Wang)

• NIH Special Emphasis Panel, 2018/05 ZRG1 BST-H (2), Bioengineering Sciences and Technologies, 4/4 2018

• NIH special emphasis panel, ZRG1 SBIB-Q 57, Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment, 2/22-23, 2018 (Z Wang)

• The Dutch Cancer Society (KWF Kankerbestrijding), external reviewer 2018

• The Netherlands Organisation for Scientific Research (I, the Dutch Research Council), external reviewer 2018

• Cancer TMOI, French National Alliance for Life and Health Sciences (AVIESAN) jointly with the French National Cancer Institute (INCa) – mail reviewer in the field of multidisciplinary approaches in modeling complex biological processes applied to cancer, 2017

• Sinergia funding instrument, Swiss National Science Foundation (SNSF) external reviewer 2018

• Science Committee – Multidisciplinary Project Award 2018, Cancer Research UK

• BSF (United States-Israel Binational Science Foundation), external reviewer 2018

• Medical Research Council (MRC), UK, 2017. Mail reviewer invitation

• Office of Sponsored Research (OSR) Competitive Research Grants (CRG), Mail review 2017, King Abdullah University of Science and Technology (KAUST), Saudi Arabia

• Netherlands Organisation for Scientific Research (I, the Dutch Research Council), Innovational Research Incentives Scheme (Veni), I-Interdivisional Veni round, 2017. Mail reviewer.

• Breakthrough Award Levels 1 and 2 (BTA) peer review panel member invitation, 2017 Breast Cancer Research Program (BCRP), the Department of Defense Congressionally Directed Medical Research Programs (CDMRP).

• NIH special emphasis panel for U01 Multiscale Modeling (MSM) program, 2016, 2017 (Z Wang)

• NCI Provocative Questions PQ8: What cancer models or other approaches can be developed to study clinically stable disease and the subsequent transition to progressive disease? 2017. Ad hoc reviewer.

• Cancer Research UK mail reviewer, 2015-2016.

• Army Medical Research and Material Command (MRMC) Online Reviewer, 2016.

• Pathobiology – 2 (PB-2) peer review panel member, 2016 Breast Cancer Research Program (BCRP), the Department of Defense Congressionally Directed Medical Research Programs (CDMRP).

• NIH reviewer, 2016.

• The Wellcome trust/DBT India Alliance Fellowship application reviewer, 2016.

• NIGMS special panel to review a number of “Support of Competitive Research (SCORE)”. Bethesda, Maryland, on June 30 – July 1, 2015.

• NIH special emphasis panel for Mathematical Modeling, Cancers and Cell Signaling systems, February 26, 2015.

• Mail and Panel Reviewer, NIH CSR Oncology 1-Basic Translational Integrated Review Group, 2013-2015.

• Mail and Panel Reviewer, NIH ZRG1 OTC-X(80) AREA: Oncological Sciences study section, 2013-2015.

• Mail Reviewer, AIRC Italian Association for Cancer Research, 2013.

• Center Advisory Committee (CAC): NCI Physical Sciences in Oncology Center (PSOC) U54: “The Center for Transport Onco-Physics”.

• Senior Investigator Committee: NCI Physical Sciences in Oncology Center (PS-OC) U54: “The Center for Multiscale Complex Systems Transdisciplinary Analysis of Response to Therapy”.

• Senior Leadership Committee; Pilot Grant Review Committee: Integrative Cancer Biology Program (ICBP) NCI U54: “The Center for Systematic Modeling of Tumor Development”.

• OSU Mathematical Biosciences (MBI) program review, 2012.

• Reviewer for German and French government grant funding agencies, 2012.

• Mail Reviewer for several EU agencies, 2011-2013.

• UNM Cancer Center P30 Senior Leadership Committee, 2011-2012.

• Reviewer, Texas Center for Cancer Nanomedicine – Pilot Projects, 2011.

• Reviewer, Center for Systematic Modeling of Cancer Development (Methodist Hospital Research Institute, Houston, TX and Baylor College of Medicine, Houston, TX) – Pilot Projects, 2011.

• European Partnership for Alternatives Approaches to Animal Testing – Annual Workshop, Brussels, July 5-7, 2010.

• Panel Member, 2010 DoD Congressionally Directed Medical Research Program (CDMRP), Breast Cancer Research Program (BCRP); Clinical and Experimental Therapeutics 5 (CET-5).

• NIH mail reviewer (SBIR), 2010.

• Panel Member, European Commission Research Directorate General Unit F5: Biotechnology for Health, FP7-Health-2010-single-stage – Alternative Testing Strategies, Brussels, March 15-19, 2010.

• DoD Breast Cancer Idea Award review panel member, 2009, 2010.

• DoD Breast Cancer Concept Award review panel member, 2009, 2010.

• Reviewer, Medical Research Council, United Kingdom, 2010.

• NIH review panel member, 2009.

• Reviewer, Israel Science Foundation, 2009.

• Department of Defense—Congressionally Directed Medical Research Program (CDMRP), Concept awards, 2008 Breast Cancer funding cycle.

• Joint National Science Foundation-DMS/National Institutes of Health-NIGMS panel member 2008. Mathematical Biology.

• NIH review panel member 2008. R01: Multi-scale modeling of physiome in health and disease.

• National Cancer Institute—The Ohio State University: workshop on “The role of biomedical informatics in overcoming current barriers in cancer research”, 2008.

• National Cancer Institute meeting – “Integrating and Leveraging the Physical Sciences to Open a New Frontier in Oncology”, 2008.

• Reviewer, U.S. – Israel Bi-National Science Foundation, 2008.

• Reviewer, American Chemical Society, 2007.

• Reviewer, WWTF Vienna Science and Technology Fund 07. Program: Mathematics and Cancer Nanotechnology.

• Reviewer, Dept of Energy-Office of Science 03. Program: Innovative and Novel Computational Impact on Theory and Experiments.

• Panel member, Telemedicine and Advanced Technology Research Command (TATRC)/American Institute of Biological Sciences (AIBS) panel to conduct independent scientific review to the Alliance for NanoHealth (ANH) program. Houston, TX, 2006.

• Reviewer, Department of Energy-Office of Science, 2005. Program: Basic Energy Sciences.

• Reviewer, National Science Foundation-Division of Mathematical Sciences, 2005.

EDUCATION AND OUTREACH

Service on Graduate School Committees

2022 – Present Houston Methodist Academic Institute and University of Naples Federico II (Italy) International Academic Affiliation

2021 – Present Weill Cornell Medicine, Cornell University, Professor, Graduate School of Medical Sciences

2017 – 2018 Regular Member, Graduate School of Biomedical Sciences (GSBS) Medical Physics Program, The University of Texas Health Science Center at Houston

2003 – 2006 University of California, Irvine, California, Member and Co-Founder, Mathematical and Computational Graduate Program

Service to the Community

Selected: Conference Organization Invitations (mentee involved)

• Conference Program Co-Chair, The 6th International Conference on Computational Biology and Bioinformatics (ICCBB 2023), December 2023 (Z Wang)

• Editorial group discussion on Research Integrity, Springer Nature, July 2023 (Z Wang)

• Editorial meeting on how to improve IEEE publications, IEEE, June 2023 (Z Wang)

• Discussion Leader, Gordon Research Seminar (Physical Science of Cancer), Galveston, TX, February 2023 (P Dogra)

• Gordon Research Seminar on Physics of Cancer, Elected Chair (S Nizzero)

• Scientific and Health Care outreach platform in support of Covid-19 vaccination (90k members; S Nizzero Founder and Administrator, see Media coverage) https://www.facebook.com/groups/433459851127376/

• 5th International Conference on Computational Biology and Bioinformatics (ICCBB 2021), December 2021, Technical Program Committee Member (Z Wang)

• NCI-DOE Collaboration 2021 Virtual Workshops: Accelerating Precision Radiation Oncology Through Advanced Computing and Artificial Intelligence. Discussion Leader (DL) for “Multimodal Patient Trajectories: Individual Predictive Modeling,” March 2021 (Z Wang)

• Abstract Screening Committee Track Leader, American Association of Pharmaceutical Scientists PharmSci 360 Conference 2021, Track: Clinical Pharmacology (P Dogra)

• Guest Editor, Nanomaterials. Special issue: Delivery of Nanoformulations for Cancer Diagnosis and Treatment, 2021. With Z Wang and P Dogra)

• Translational Engineering and Healthcare Innovation (TEHI) committee election, IEEE EMBS, 2019 (Z Wang)

• Symposium on “Imaging in Tumor Modeling,” American Association of Physicists in Medicine (AAPM) Annual Meeting (Nashville TN | July 29 – August 2, 2018)

• Symposium on “Imaging in Tumor Modeling, World Molecular Imaging Congress (WMIC), 2018.

• Organizing Committee Member, “2nd International Conferences on Clinical Oncology and Molecular Diagnostics,” June 11-13, 2018, Dublin, Ireland. Theme: Enlightening the Future Panorama of Clinical Oncology

• Organizing Committee member, “28th Euro congress on Cancer Science and Therapy,” August 09-10, 2018, Madrid, Spain. Theme: To codify a responsive discussion on cancer science and therapy

• Innovate Cancer Research 2017, International Colloquium on Cancer Research, advisory board member, November 29-30, Brisbane, Australia.

• World Brain Mapping 2017, Society for Brain Mapping & Therapeutics (SBMT), Science Committee Member.

• National Science Foundation (NSF) merit review survey 2016 “Satisfaction of Investigators and Reviewers with the Merit Review Process.”

• Los Alamos National Labs, New Mexico Consortium Workshop to launch NMC/LANL joint initiatives in Biomedical Technology, May 9, 2013.

• Co-organized the U54 NCI-ICBP Center for Systematic Modeling of Tumor Development symposium at The Methodist Hospital Research Institute, Houston, TX, February 12, 2012.

• Session Organizer, Sandia / UNM Cancer Center Symposium on Nanoparticle Human Interactions, June 2-3, 2011.

• Organizer, NIMBioS Investigative Workshop on Solid Tumor Modeling. University of Tennessee, Knoxville, January 19-21, 2011.

• Mini-symposium on Tumor Growth Modeling.

• Chair and Organizer, World Congress on Computational Mechanics, Sydney, 2010.

• Joint EU & US Workshop on Virtual Tissues in RTP. Focus: modeling tissue level outcomes from molecular and cellular scales, April 21-24, 2009.

• Chair and Organizer, Educational Session: “Mathematical Models in Pharmacology,” American Association for Cancer Research (AACR) Annual Meeting, Boulder, Colorado, April 18, 2009.

• Program Committee Member, joint BME symposium UT Austin, UT Health Science Center Houston, UT MD Anderson Cancer Center; Director, computational bioengineering session. Institute for Molecular Medicine, Houston, TX, January, 15, 2009.

• 15th US National Congress on Theoretical & Applied Mechanics (USNCTAM06), Biomechanics of Tissues Mini-symposium, University of Colorado, Boulder, 2006.

Session Chair, “Cells and Materials: At the Interface between Mathematics, Biology and Engineering,” Microfluidics symposium, Institute for Pure and Applied Mathematics, UCLA, 2006.

• Program Committee Member, Cells and Materials Conference, Institute for Pure and Applied Math, UCLA, 2006.

• Program Committee Member, International Brain Mapping and Intra-operative Surgical Planning Symposium, University of Southern California, 2005-2007.

• Session Chair, International Brain Mapping and Intra-operative Surgical Planning Symposium, University of Southern California, 2005-2006.

• Editor of the conference proceedings, European Conference on Mathematics and Theoretical Biology (ECMTB), 2005.

• Session Chair, Stability and Non-linear Hydrodynamics, American Institute of Chemical Engineers Annual Meeting, 2005

• Session Chair, Dynamics Days, University of California at Irvine, 2005.

• Program Committee Member, Dynamics Days, University of California at Irvine, 2005.

• Program Committee Member, 4th IEEE International Symposium on Bioinformatics and Bioengineering, Taichung, Taiwan, 2004.

• Session Chair, International Biofluid Mechanics Conference, Caltech, 2003.

Sponsorship and Mentorship of Candidates for Postgraduate Degrees

1. Gayatri Prakash, MD student, EnMed Program, Texas A& University. April 2023-Present (not primary advisor; with Z Wang)

2. Joseph Cave, PhD student, Weill Cornell-Houston campus. August 2022-Present. (primary advisor, with Prashant Dogra and Z Wang)

3. Carmine Schiavone, PhD student in Chemical Engineering, Università degli Studi di Napoli Federico II, Naples, Italy. 2022-Present. (Co-advisor)

4. Rishi Ramesh, MD student, EnMed Program, Texas A& University. March 2023-Present (not primary advisor; with Z Wang and Prashant Dogra)

5. Gregory Zaugg, Masters student in Nanoscience, University of Basel, Basel, Switzerland. August 2022-Present. (primary advisor with S Nizzero)

6. Giacomo Doglio, Masters student in Physics, Università degli Studi di Milano, Milan, Italy. 2022-Present. (Not primary advisor)

7. Meitham Amereh, PhD student, University of Victoria, British Columbia, Canada, 2022-Present (not primary advisor).

8. Verya Gavili Kilaneh, MS, University of Kurdistan, Iran. 2022 (not primary advisor)

9. Yu Shen, PhD student, Johns Hopkins University, 2022 (not primary advisor)

10. Nithin Kumar Goona, PhD student, National Institute of Technology, Goa, India, 2022 (not primary advisor)

11. Maria Jose Pelaez Soni, PhD student in Applied Physics at Rice University. 2021-Present. (primary advisor)

12. Akash Awasthi, PhD student in Electrical and Computer Engineering, University of Houston. 2021-2022. (not primary advisor)

13. Ishaan Duggal, PhD student in Pharmaceutical Sciences at The University of Texas at Austin. 2021-2022. (not primary advisor)

14. Bandita Karki, Masters student in Statistics, University of Idaho. 2021-2022. (not primary advisor)

15. Garima Khanna, Masters student in Nanomedicine at Université de Paris, France. 2021-2022. (not primary advisor)

16. Carmine Schiavone, Masters student in Chemical Engineering, Università degli Studi di Napoli Federico II, Naples, Italy. 2021-Present. (Not primary advisor)

17. Maria Jose Pelaez Soni, Masters in Applied Physics at Rice University. Graduated May 2021. Title: Mechanistic modeling of pathological biomarkers to study Alzheimer’s disease progression. (primary advisor)

18. Giorgia Migliaccio, Masters in Bioengineering, Università degli Studi di Napoli Federico II, Naples, Italy. Graduated January 2021. Title: Calibration of wound healing assay in silico lattice model with experimental data. (Not primary advisor)

19. Luca Messina, Masters in Bioengineering, Università degli Studi di Napoli Federico II, Naples, Italy. Graduated January 2021. Title: A hybrid cellular automata for cancer cells growth and chemotaxis. (Not primary advisor)

20. Mingee Kim, Undergraduate in Biochemistry at Rice University. 2018-2021. (Not primary advisor)

21. Si Qi Tong, Undergraduate in Kinesiology at Rice University. 2018-2021. (Not primary advisor)

22. Sara Nizzero, PhD in Applied Physics at Rice University. 2018-2019. (Not primary advisor)

23. Rosalia Ferraro, PhD ,Department of Industrial Engineering, at University of Naples Federico II. (Not primary advisor)

24. Naomi Hasegawa, M.D., McGovern Medical School, UTHealth, 1st year, 2017-present. Webber award candidate

25. Terisse Brocato, Ph.D. Center for Biomedical Engineering, University of New Mexico, August 2012-December 2017. 2013-2014 School of Engineering Award – the Charlotte and William Kraft Graduate Fellowship; The New Mexico Cancer Nanoscience and Microsystems Training Center (CNTC) Graduate Fellowship, 2014-Present. Graduated in December 2017. Title: “Mathematical Modeling for the Use of Predicting Chemotherapy and Nanoparticle Treatment Efficacy in Breast Cancer”

26. Prashant Dogra, Ph.D. Biomedical Sciences, University of New Mexico, August 2012-December 2017; The New Mexico Center for the Spatiotemporal Modeling of Cell Signaling (STMC) Graduate Student Fellowship, 2014-2016. Graduated in May 2018. Title: “Multiscale Modeling of Nanoparticle Biodistribution”

27. Joseph Butner, Ph.D. (Center for Biomedical Engineering, UNM), August 2012-July 2017. Graduated in July 2017 with distinction. Title: “A Multiscale Modeling Study of the Mammary Gland: Using mathematical modeling and computer simulation to study the roles of cell phenotypic dynamics and molecular signaling in the pubertal end bud and postmenopausal DCIS initiation”

28. Romica Kerketta, Ph.D. (Biomedical Sciences, UNM), October 2012-May 2017 (Co-Advisor). The New Mexico Cancer Nanoscience and Microsystems Training Center (CNTC) Graduate Fellowship, 2013-2014. Graduated in May 2017. Title: “Exploring biological heterogeneity and its consequences at tissue and cellular scales through mathematical and computational modeling"

29. Kuan Feng, Ph.D. Biomedical Sciences, University of New Mexico, January 2014-2015 (not primary mentor)

30. Neelima Shrestha, Undergraduate researcher, Biochemistry, University of Idaho, Summer 2012 (not primary advisor)

31. Armin Day, Joint B.A. / M.D. Program, UNM 2011-2015

32. Nzola DeMagalhaes, Ph.D. Biomedical Engineering, University of California at Irvine 2009 — UNCF-MERCK Graduate Science Research Dissertation Fellow –NIH graduate Dissertation Fell

33. Xiaoqin Yuan, PhD, MD Anderson Cancer Center, 2009-2010 (not primary advisor)

34. Srimahita Kaliki, Ph.D. student, Biomed Engineering, The University of Texas at Austin, 2009-2010

35. Sandeep Sanga, Ph.D. Biomed Engineering, The University of Texas at Austin, 2009

36. Deepa Raghunathan, B.S. MD Anderson Cancer Center, 2008; STEP-UP Clinical and Research Internship Award for Research Excellence (not primary advisor)

37. Xiangrong Li, Ph.D. Applied Mathematics, University of California at Irvine, 2008 (not primary advisor)

38. Jahun Kim, Ph.D. Student, School of Health Information Sciences, The University of Texas Health Science Center, 2007-2010

39. Kaveh Azartash, M.S. Biomedical Engineering, University of California at Irvine, 2006

40. Hermann Frieboes, Ph.D. Biomedical Engineering, U.C. Irvine, 2006

41. Shuwang Li, Ph.D. Aerospace Engineering and Mechanics, University of Minnesota, 2005 (not primary advisor)

42. Ryan Hainley, M.S. Biomedical Engineering, University of California at Irvine 2005

43. Balakrishnan Sivaraman, M.S. Chemical Engineering and Materials Science, U.C. Irvine 2005

44. John Sinek, Ph.D. Applied Mathematics, University of California at Irvine, 2005

45. Xiaoming Zheng, Ph.D. Applied Mathematics, University of California at Irvine, 2005 – Physical Sciences Faculty Endowed Award, 2003-2004

Sponsorship and Mentorship of Postdoctoral Fellows and Faculty

1. Vrushaly Shinglot, Ph.D, Postdoctoral Fellow, Mathematics In Medicine Program, HMRI, July 2022- June 2023

2. Maguy Farhat, Postdoctoral Fellow in Radiology and Computational Imaging, Department of Gastrointestinal (GI) Radiation Oncology, MD Anderson Cancer Center, 2021-Present. (With JD Butner and Z Wang)

3. Arturas Zyemis, Non-Tenure-Track Assistant Professor, Mathematics in Medicine Program, HMRI, 2018-2022.

4. Sara Nizzero, Ph.D., Consultant, ARTIDIS, INC, 2021-present.

5. Sara Nizzero, Ph.D., Faculty Fellow, Mathematics in Medicine Program, HMRI, 2021-present.

6. Joseph Butner, Ph.D., Faculty Fellow, Mathematics in Medicine Program, HMRI, 2021-present.

7. Prashant Dogra, Ph.D., Non-Tenure-Track Assistant Professor, Mathematics in Medicine Program, HMRI, 2021-present.

8. Sara Nizzero, Ph.D., Postdoctoral Research Fellow, Mathematics in Medicine Program, HMRI, 2019-2021.

9. Sara Nizzero, Ph.D., Visiting Postdoctoral Fellow, Radiation Oncology, MD Anderson Cancer Center, 2020-2021.

10. Javier Ruiz Ramirez, Ph.D., Postdoctoral Research Fellow, Mathematics in Medicine Program, HMRI, 2018-2021.

11. Prashant Dogra, Ph.D., Postdoctoral Research Fellow, Mathematics in Medicine Program, HMRI, 2018-2021.

12. Joseph Butner, Ph.D., Research Associate, Mathematics in Medicine Program, HMRI, 2018-2021.

13. Zhihui Wang, Non-Tenure-Track Associate Professor, Mathematics in Medicine Program, HMRI, 2018-present.

14. Martina Mugnano, PhD candidate at University of Naples Federico II. (Not primary advisor)

15. Geoff V Martin, MD. Radiation Oncology Resident, MD Anderson. 2016-2018 (not primary mentor)

16. Yoo-shin Kim, Ph.D., Senior Research Scientist, Center for Proteomics and Systems Biology, The Brown Institute of Molecular Medicine, 2016-2017.

17. Angela Rugiano, PhD, Department of Mathematics, Univ/Calabria, Italy, 2015-2016 (not primary mentor).

18. Huaming Yan, Ph.D., Department of Mathematics, Department of Mathematics, University of California at Irvine, 2015-present (not primary advisor).

19. Greg von Winckel, Ph.D., Postdoctoral student, Chemical Engineering, UNM, Skinfrared, LLC, Albuquerque, NM, 2013-2015(not primary advisor).

20. Zhihui Wang, Non-Tenure-Track Assistant Professor, Department of Pathology, The University of New Mexico Health Science Center, 2011-2015.

21. Jennifer Pascal, ASERT Postdoctoral Student, Department of Pathology, The University of New Mexico Health Science Center, 2011-2013. NIGMS K12GM088021 postdoctoral fellowship.

22. Yao-Li Chuang, Postdoctoral Student, Department of Pathology, The University of New Mexico Health Science Center, 2010-2014; The University of Texas Health Science Center, 2009-2010.

23. Arnaud Chauviere, Non-Tenure-Track Assistant Professor, Department of Pathology, The University of New Mexico Health Science Center, 2010-2012; The University of Texas Health Science Center, 2009-2010.

24. Fang Jin, Postdoctoral student, Department of Pathology, The University of New Mexico Health Science Center, 2010-2011; The University of Texas Health Science Center, 2008-2010.

25. Babis Hatzirikou, Postdoctoral student, Department of Pathology, The University of New Mexico Health Science Center, 2010-2012; The University of Texas Health Science Center, 2009-2010.

26. Paul Macklin, Non-Tenure-Track Assistant Professor, School of Health Information Sciences, The University of Texas Health Science Center, 2007-2010.

27. Hermann Frieboes, Postdoctoral student, School of Health Information Sciences, The University of Texas Health Science Center, 2007-2010.

28. John Sinek, Ph.D., Postdoctoral student, Applied Mathematics, University of California at Irvine, 2005-2007.

29. Lan Pham, Postdoctoral student, Applied Mathematics, University of California at Irvine, 2003-2005.

30. Xiaoming Zheng, Postdoctoral student, Applied Mathematics, University of California at Irvine, 2005-2006.

31. Steven Wise, Postdoctoral student, Applied Mathematics, University of California at Irvine, 2003-2006.

Others (non-graduate/postgraduate)

• Kelan Wu (Undergraduate student), University of Houston, Houston, TX, USA (02/23 – 06/23), Research topic: Machine learning applications to determine nanoparticle properties for tumor targeting and safety (with P Dogra & Z Wang)

• Elisa Misuri (Undergraduate student), Politecnico di Torino, Italy (01/22 – 08/23), Research topic: Multiobjective optimization to guide immunosuppressive therapy in kidney transplant recipients to prevent BK virus infection (with P Dogra)

• Ruchi Birur, Texas Academy of Mathematics and Science – summer 2022 (not primary advisor)

• Sri Gouri Rajaram, B.S. Biomedical Engineering, Indian Institute of Technology, Kharagpur, India. 2021-2022. (not primary advisor)

• Syed Asad Rizvi, B.S. Computer Science, University of Houston. 2021-2022. (not primary advisor)

• Meinee Chiu, B. Pharmacy, Panjab University, India. Summer 2021. (not primary advisor)

• Ananya Singh, B. Pharmacy, Panjab University, India. Summer 2021. (not primary advisor)

• Jack Delk, B.S. Biomedical Engineering, Texas A&M University – summer 2021 (Not primary advisor)

• Jorge Tito, Pre-Baccalaureate Trainee (High school student) at UTHealth – summer 2017

• Josh Begay, Undergraduate researcher (Mechanical Engineering, Southwestern Indian Polytechnic Institute), Summer 2012 (co-advisor)

• Zachariah Harris, B.S. Chemical Engineering, University of New Mexico, 2011-2012

• Kristine Velasco, B.S. Biomedical Engineering, University of California at Irvine 2006 – BME Engineer of the Year

• Anthony Anderson, B.S. Chemical Engineering and Materials Science, University of Minnesota 2004 – Honors Thesis.

Teaching Responsibilities

• ‘Strategic Consideration for Healthcare Informatics’ Course, Master’s in Clinical Translation Management, University of St. Thomas, Houston, TX, USA, 10/30/2023 – Present. (Instructor: P Dogra)

• Physiology, Biophysics & Systems Biology qBio Bootcamp 2021, 2022, 2023 (& 2024 expected), Houston Methodist Research Institute and Weill Cornell Medicine, Houston, TX, the first two weeks of August, 2021, 2022, 2023. Instructors: Joseph Butner, Prashant Dogra. Supervision: Vittorio Cristini, Zhihui Wang, Henry Pownell, John Cooke.

• GS21 1331: Precision BioMedicine and Nanotechnology. Instructors: David Volk and Vittorio Cristini. (Institute of Molecular Medicine, The University of Texas Graduate School of Biomedical Sciences at Houston, 2017-2018, graduate)

• Cristini, V. Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements. 2017 nBME Scholarly Concentration Summer Seminar Series, UTHealth McGovern Medical School, Houston, TX, US. June 13, 2017. (invited lecture)

• California State Summer School for Mathematics and Science (COSMOS) guest lecture 2017, UC Irvine.

• Introduction to Computational Biomedicine (BIOM 505-004, The University of New Mexico, Albuquerque, 2012, graduate) Developed and taught a multi-disciplinary class in collaboration with the Spatio-Temporal Modeling Center and the New Mexico Cancer Nanoscience and Microsystems Training Center.―In this course, students are engaged in novel peer-reviewed research at the interface of medicine and the engineering and physical sciences, e.g., knowledge of literature relevant to a specific study and understanding of the corresponding biological background, soundness of the mathematical formulation of equations modeling the biological problem, insight into novel biology obtained from model investigations. The course consists of 3, 3-week long modules: a general one covering tools for computational biomedicine; one focused on modeling tumor spread (with guest instructor cell biologist Prof. Bridget Wilson); and one devoted to modeling intracellular transport (with guest instructor cell biologist Prof. Elaine Bearer). One class meeting/week includes both lecture and assessment of progress to provide feedback/help.

• Foundations of Health Information Sciences II: Mathematical Modeling in Biomedicine (Health Information Sciences, The University of Texas Health Science Center, Houston; Biomedical Engineering, The University of Texas at Austin, 2009, graduate)

• Numerical Analysis (Health Information Sciences, The University of Texas Health Science Center, Houston; Biomedical Engineering, The University of Texas at Austin, 2007-2010, graduate)

• Advanced Engineering Mathematics (Biomedical Engineering, The University of Texas at Austin, 2007-2009, graduate)

• Math modeling and computer simulation for Health Sciences (Health Information Sciences, The University of Texas Health Science Center, Houston; Biomedical Engineering, U.T. Austin, 2007, graduate)

• Bio-Mass Transport (Biomedical Engineering, University of California at Irvine, 2004-2006, undergraduate)

• Introduction to Predictive Oncology (Biomedical Engineering, University of California at Irvine, 2005-2006, graduate)

• Introduction to Math and Computational Biology (COSMOS Program Physical Sciences, University of California at Irvine, 2004-2005, high school)

• Applied Engineering Math II—Numerical Analysis (Biomedical Engineering, University of California at Irvine, 2003-2006, graduate)

• Math Modeling and Computer Simulation of Complex Biology Systems (Biomedical Engineering, University of California at Irvine, 2003-2004, graduate)

• Virtual Cancer: A Computer Model of Cancer Progression and Treatment (Engineering, University of California at Irvine, 2003, Freshman Semester)

• Calculus I (School of Mathematics, University of Minnesota, 2002, undergraduate)

• Transport Phenomena (Chemical Engineering and Materials Science, University of Minnesota, 2000, undergraduate)

GRANT SUPPORT

Current Grant Support

• Golfers Against Cancer, Fund #37384: Predicting immunotherapy outcomes from noninvasive blood measures before start of treatment. 9/1/23–8/31/24. 60,000/yr DC. Role: Collaborator (PI: Z Wang)

• Brown, Smith & Raymond EnMed Capstone Innovator Award (Texas A&M U & Houston Methodist). Predicting Cancer Immunotherapy Response by combining Mechanistic Modeling and Machine Learning. 9/1/23–8/31/25. 12,000/yr DC. Role: Collaborator (PI: Prakash, Mentor: Z Wang)

• NIH/NINDS T32 Postdoctoral Fellow Training Grant (PI: P. Horner). Houston Methodist Neurological Institute’s Department of Neurosurgery. 05/01/2022-04/30/2027. Role: Faculty Mentor

• ARTIDIS Ltd./MD Anderson Cancer Center/Houston Methodist Research Institute: Strategic Alliance for Biomechanics Marker Discovery in Clinical Trials. 7/1/2021–6/30/2026. Role: HMRI PI, 10% time, $50,000/yr DC.

• NIH/NCI, R01CA253865: Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer. 3/4/2021- 2/28/2026. Role: Co-Investigator, 10% time, 111,569/yr DC. PI: Z Wang

• NIH/NIBIB, 1R03EB033576: Physiologically based pharmacokinetic modeling of silica nanoparticles. 7/1/22 – 6/30/24. Role: Collaborator. PI: Yellepeddi; co-I: Dogra

• ARTIDIS Ltd.—Sponsored Research Agreement: Predicting chemotherapy and immunotherapy outcome using measurements of tissue stiffness.8/1/2021- 12/31/2024. Role: PI, 5% time, $165,000/yr DC.

• NIH/NCI, P50CA217674: The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma. 9/25/2019 – 8/31/2024. Role: Co-Investigator, 3% time. $7,807/yr DC. PI: Bereta, Kaseb.

• The Cockrell Foundation Professorship Award/HMRI: Mathematical modeling to support infectious diseases research. 3/1/21-2/29/24. 102,400/yr DC. (Awardee: Prashant Dogra.)

Pending Grant Support

• NIH IRCN R01 (MPIs: Pasqualini, Wadih, Brinker, Cristini). 4/1/24–3/31/29. Rutgers U (NIH). Methodist Funds Requested: $928,626. Title: Antibody-targeted nanoparticles for therapeutic gene editing in aggressive variant prostate cancer. Role: MPI (1.2 calendar)

• NIH RM1 (MPIs: Burley, Pasqualini). 4/1/24–3/31/29. Rutgers U (NIH). Methodist Funds Requested: $1,125,000. Title: Integration of In Vivo Phage Display & Machine Learning: A Multidisciplinary Approach for Ligand-Receptor Mapping of the Mammalian Vasculature. Role: Co-I & Methodist PI (1.2 calendar)

• NIH/NIBIB R01 (MPIs: Dogra, Noureddine). 4/1/24–3/31/29. NIH. Total Funds Requested: $2,712,699. Title: Artificial intelligence-integrated mechanistic modeling for rational design of nanoparticles to improve organ targeting and safety. Role: Co-I (0.6 calendar).

• NIH/NIAID 1R21AI178508-01A1 (PI: Dogra). 4/1/24–3/31/26. NIH. Total Funds Requested: $444,125. Title: Mechanistic modeling-based clinical trial simulator to support vaccine development. Role: Co-I (0.6 calendar)

• NIH/NCI (PI: Dogra). 4/1/24–3/31/26. NIH. Total Funds Requested: $161,500. Title: Multiscale modeling to improve efficacy of microRNA therapy in pancreatic ductal adenocarcinoma. Role: Co-I (0.3 calendar)

• CPRIT Individual Investigator Research Awards for. Computational Systems Biology of Cancer (MPIs: Welsh, Cristini). 3/1/24–2/28/27. CPRIT. Total Funds Requested: $300,000. Title: Development of immune biomarkers related to PET SUV through computational modeling for prediction of treatment response to Immunotherapy. Role: MPI (1.2 calendar)

• NIH R01 (MPIs: Wang, Ozpolat). 7/1/24–6/30/29. NIH. Total Funds Requested: $2,913,640. Title: A mathematical model for simulating and predicting miRNA-873-based nanotherapeutics for pancreatic ductal adenocarcinoma. Role: Co-I (1.2 calendar)

• NIH R01 (MPIs: Wang, Chung). 7/1/24–6/30/27. NIH. Total Funds Requested: $2,215,754. Title: Developing a mathematical model-based tool to predict immunotherapy outcomes in melanoma brain metastases. Role: Co-I (1.2 calendar)

• NIH R01 (MPIs: Welsh, Cristini). 7/1/24–6/30/29. NIH. Total Funds Requested: $305,477. Title: Development of immune biomarkers related to PET SUV through computational modeling for prediction of treatment response to Immunotherapy. Role: MPI (1.2 calendar)

• NIH 1R01CA285524-01A1 (MPIs: Wang, Ozpolat). 7/1/24–6/30/29. NIH. Total Funds Requested: $2,925,210. Title: Optimizing novel miR-873 nanotherapeutics for targeted cancer treatment using a combination of experimental and mechanistic modeling approaches. Role: Co-I (2.4 calendar)

• NIH U01 (MPIs: Wang, Chung). 7/1/24–6/30/27. NIH. Total Funds Requested: $1,466,223. Title: Development of a clinically applicable tool for physicians to predict checkpoint inhibitor immunotherapy outcome in patients with melanoma brain metastases. Role: Co-I (1.2 calendar)

Past Grant Support

• NIH/NCI, R01CA222007: miR-155 targeted therapeutics for precision medicine in lung cancer. 07/01/2018–06/30/2023. Role: MPI, 15% time. 64,153/yr DC.

• NIH/NCI, R01CA226537: A targeted nanomedicine prototype against enzalutamide-resistant prostate cancer. 04/01/2018–03/31/2023. Role: MPI, 15% time. 108,654/yr DC.

• NIH/NCI, U01CA213759: Targeted Therapeutics for ovarian cancer and its microenvironment treatment and theoretical modeling. 06/01/2017-05/31/2022. Role: Co-Investigator, 5% time. 20,655/yr DC. PI: Lopez-Berestein

• NIH/NCI, U01CA196403: Imaging and Molecular correlates of progression in cystic neoplasms of the pancreas. 09/01/2015-08/31/2021. Role: Co-Investigator, 5% time. 20,008/yr DC. PI: Maitra

• NIH/NCI, U54CA210181: Center for Immunotherapeutic Transport Oncophysics: 07/2017- 07/2021. Role: Collaborator, 10% time, 13,012/yr DC.

• National Science Foundation‒Mathematical Sciences (Role: Overall PI, 5% time; 09/01/2017-08/31/2020). “Collaborative Research: A new multiscale methodology and application to tumor growth modeling,” $250,000. DMS-1930583

• NIH/NIGMS P50GM085273 (PI: Wilson), The New Mexico SpatioTemporal Modeling Center (STMC) 09/01/2014-08/31/2019, 1.2 calendar. Role: Co-Investigator

• UT STAR award - The University of Texas System – Science and Technology Acquisition and Retention (STARS). “Mathematical modeling integrated with experiments and clinical trials to understand tumor heterogeneity, drug delivery and treatment outcome” ($1,000,000). Cristini PI. 07/01/2015-06/30/2018.

• Rochelle and Max Levit endowment for Chair in the Neurosciences ($500,000)– UTHealth 2016-2018

• Pilot project (PIs: Koay, Cristini 2% effort), Center for Immunotherapy in Transport Oncophysics (CITO), overall PI: Ferrari. “Effects of VEGF and collagen signaling on biodistribution of tumor associated macrophages in pancreatic ductal adenocarcinoma (PDAC)” 2017-2018

• National Science Foundation‒Mathematical Sciences/National Institute of General Medical Sciences (overall PI, 10% time; 09/15/2013-08/31/2017). “Collaborative Research: Multiscale Modeling of Mammary Gland Development,” $422,472. DMS-1562068

• The New Mexico Cancer Nanoscience and Microsystems Training Center (CNTC) Graduate Fellowship, 2014-2017 (Student: Terisse Brocato, UNM)

• University of New Mexico Cancer Center Institutional Support.(1 full-time graduate student) Clinical trial: The Use of Mathematical Modeling to Predict Response to Neoadjuvant Anthracycline / Taxane Based Chemotherapy in Women with HER2 negative Stage II and III Breast Cancer. 12/3/2014-12/3/2016. Co-PI.

• The New Mexico Center for the Spatiotemporal Modeling of Cell Signaling (STMC) Graduate Student Fellowship, 2014-2016. (Student: Prashant Dogra, Biomedical Sciences, University of New Mexico)

• NIH 5U54CA151668-05 (PIs: Ferrari, Gorenstein, Cristini), Texas Center for Cancer Nanomedicine, 8/1/15-7/31/16, 2.4 calendar. Cristini Overall PI

• 2014 Pancreatic Cancer Action Network – AACR Cancer Development Award: “Changes in Mass Transport as a Biomarker of Response in Pancreatic Cancer.” $200,000; PI: E Koay (VC Mentor, 2% time). 07/01/2014-06/30/2016.

• Radiological Society of North America (RSNA) Seed Grant (PI: E Koay), Predicting gemcitabine delivery in human pancreatic cancer with mass transport, (VC Co-Investigator, 2.0% time) 2014-2015.

• King Abdulaziz University Grant 54-130-35-HiCi. “A Multiscale Approach to Developing and Optimizing γδ T Cell-Based Breast Cancer Treatment” $50,000. (Consultant, 10% time) 6/1/2014-3/31/2015.

• National Cancer Institute, CCNE: Texas Center for Cancer Nanomedicine, VC (Core co-I, 4% time). Biosimulation Core (Total Budget of Core: $750,000), 2010-2015.

• National Cancer Institute, U54: Physical Science—Oncology Center (PS-OC): Multiscale Complex Systems Transdisciplinary Analysis of Response to Therapy, VC (Project PI, 19% time). Multiscale Cancer Modeling: From Cell Phenotype to Growth and Therapy Response (Total Budget of Project $852,000), 2009-2015.

• National Cancer Institute, U54: Physical Science—Oncology Center (PS-OC): Center for Transport Oncophysics, VC (Core PI, 18% time) (Total Budget of Core $1,000,000), 2009-2015.

• National Cancer Institute, U54; Integrative Cancer Biology Program (ICBP): Center for Modeling of Cancer Development, VC (Project PI, 15% time) Computational Biology: Mathematical Modeling and Computer Simulation (Total Budget of Project $750,000), 2010-2015.

• Baylor College of Medicine (BCM): Agent Based Modeling of Cell Lineages in Breast Cancer, VC (Scientific Advisor, 0%) (Total Budget $253,948), 12/1/2010 – 02/28/2015.

• National Cancer Institute, U54: Physical Science—Oncology Center (PS-OC): Center for Transport Oncophysics (PI: Ferrari) - Project 3: Genomic Correlates of Mass Transport Differentials, VC (Co-Investigator, 10% time), 2009-2015.

• National Cancer Institute, U54: Physical Science—Oncology Center (PS-OC): Center for Transport Oncophysics, supplemental grant: “Clinical implications of mass transport in colorectal liver metastasis,” (VC PI, 20% time). (Total Budget $80,000). 2013-2014.

• “Mathematical Model of Drug Transport to Determine Chemotherapeutic Outcomes in Patients with Colorectal Liver Metastases,” The New Mexico Cancer Nanoscience and Microsystems Training Center Graduate Fellowships, 2013-2014 by (Ph.D. student mentored: Romica Kerketta)

• 2013-2014 School of Engineering Award – the Charlotte and William Kraft Graduate Fellowship (Ph.D. student mentored: Terisse Brocato).

• NIH/NIGMS P50GM085273 (PI: Oliver), University of New Mexico Spatio Temporal Modeling Center (STMC), 0.5 calendar. Role: Co-Investigator, 08/01/11–07/31/2014.

• NIH/NIGMS K12GM088021 (PI: Pascal), 0 calendar, Role: Research mentor, 09/01/11–08/31/2014.

• National Science Foundation SBIR (Academic PI: VC), ($49,000), “Dynamic Infrared Imaging of Skin Cancer”, 7/1/2013-12/31/2013.

• National Cancer Institute CTO PS-OC Pilot Project (PI: Cristini), 0.25 calendar, NIH/NCI, $100,000. Title: Predictive physical modeling of chemotherapeutic drug transport and tumor response, 04/01/2012-03/31/2013.

• National Science Foundation—Mathematical Sciences, VC PI (6%), “Collaborative Research: Multiscale modeling of solid tumor growth,” (Total Budget $225,000), 2008-2012.

• UNM STMC Grand Challenge Award: Modeling the spatiotemporal motor-cargo dynamics in the squid giant axon. VC (PI, 0% time). $50,000. 03/2011 – 07/2011.

• MD Anderson Cancer Center Award: Quantification of diffusion barriers to chemotherapy in patient tissue. VC (PI, 1% time). $114,300. 11/2010 – 10/2011.

• United States Department of Defense Innovator Award, M. Ferrari (PI, UT Health Science Center), VC (Co-I, 5%). Towards individualized breast cancer therapy: Leveraging molecular medicine with multi-stage vector technology. (Total Budget $7 Million). 03/01/2009-02/28/2010.

• Cullen Trust for Health Care, VC PI (60%), “Virtual cancer: Reducing cancer recurrence and progression – new paradigms in cancer diagnostics and treatment through computational modeling of biological systems” (Total Budget $1.5 million). 2008-2010.

• United States Department of Defense - Telemedicine and Advanced Research Technology Center (TATRC) / Alliance for Nanohealth (ANH). VC PI (10%), “Optimizing Delivery of Paclitaxel in Head and Neck Cancer Treatment Through Nanoparticle Delivery and Interactive Biomathematically Based Nanoparticle Designs,” (Total Budget: $45,000). 2008-2010.

• Komen Foundation. F. Symmans (PI, MD Anderson), VC (Collaborator, 2%). Prospective Evaluation of Molecular Triaging with Pharmacogenomic Tests to Select Neoadjuvant Treatment. ($45,000). 04/01/2008 – 03/31/2009.

• NIH—Bioengineering Research Partnerships, VC Co-I (5%), “Nanovectors for characterization and destruction of breast tumor vasculature,” (Total Budget $400,000). 2007-2010.

• United States Department of Defense - Telemedicine and Advanced Research Technology Center (TATRC). VC Co-PI (5%), “Medical Nanovector Research and Development Center of Alliance for Nanohealth,” (Total Budget: $1.768 Million). 2007-2010.

• United States Department of Defense - U.S. Army Medical Research and Materiel Command (USAMRMC)—The Texas Training and Technology Against Trauma and Terrorism (T5) program NCE. VC Co-PI (38%), (Total Budget $4,792,000). 2007-2008.

• Dekk-Tech. VC PI, “Computer simulations of drug delivery to brain tumors,” ($25,000). 2007.

• United Negro College Fund - MERCK Graduate Science Research Dissertation Fellowship, VC Mentor, “An integrated biological and computational tumor model,” $52,000 (PI: Graduate Student N DeMagalhaes). 2007-2009.

• NIH Graduate Fellowship, VC Mentor, $60,000 (PI: Graduate Student N DeMagalhaes). 2007-2009.

• NIH—National Cancer Institute, VC Co-PI (10%, “R01: Clinical and Microarray Data Predict Lung Cancer Outcomes”. (Total Budget: $1 million). 2006-2009.

• University of California Discovery Grant - IT for life sciences/ORQIS Medical, VC PI, “Analysis and Optimization of Blood Circuit Components Using Adaptive CFD,” $188,000. 2005-2007.

• NIH - National Cancer Institute, VC Co-PI, “R01: Multidisciplinary studies of tumor vascularity and microenvironment,” $180,000. 2005-2006.

• National Science Foundation—Mathematical Sciences, VC PI (10%), “Collaborative Research: Analysis and properties of co-continuous blends-A numerical and experimental investigation,” $132,000. 2003-2006.

• University of California at Irvine, Center for Complex Biological Systems Seed Grant, VC PI, “Computational and Experimental Modeling of Tumor Spheroid Growth and Photodynamic Therapy: A First Step Towards an In Vivo Model,” $11,000. 2003-2004.

• University of California at Irvine, Biomedical Engineering/College of Medicine Seed Grant, VC PI, “Modeling breast tumor morphology to predict drug response,” $15,000. 2003-2004.

Submitted Proposals (since I joined HMRI on 07/09/2018; selected)

• NIH/R01 (MPIs: Wang, Ozpolat). 7/1/23–6/30/28. NIH. Total Funds Requested: $2,814,645. Title: Development of KRAS-targeted siRNA- or miRNA-mediated nanotherapeutics for pancreatic ductal adenocarcinoma. Role: Co-I (1.2 calendar)

• NIH/R01 (MPIs: Ozpolat, Wang). 7/1/23–6/30/28. NIH. Total Funds Requested: $3,305,000. Title: Dual-targeting of KRAS and PDL1 with novel miRNA nanotherapeutics for targeted cancer treatment. Role: Co-I (1.2 calendar)

• NIH/R01 (MPIs: Ozpolat, Wang). 7/1/23–6/30/27. NIH. Total Funds Requested: $2,962,660. Title: Novel therapeutic approach for co-targeting of two oncogenic kinases in Triple negative breast cancer. Role: Co-I (1.2 calendar)

• NIH/U01 resubmission (MPIs: Wang, Chung). 7/1/23–6/30/26. NIH. Total Funds Requested: $1,466,223. Title: Development of a clinically applicable tool for physicians to predict checkpoint inhibitor immunotherapy outcome in patients with melanoma brain metastases. Role: Co-I (1.2 calendar)

• NIH/R21 (PI: Dogra). 7/1/23 – 6/30/25. NIH. Total Funds Requested: $444,125. Title: Mechanistic modeling-based clinical trial simulator to support vaccine development. Role: collaborator

• NIH/R01 (PI: Goel). 7/1/23 – 6/30/28. NIH. Total Funds Requested: $198,202. Title: Ultrasmall chemo-radiopharmaceutical nanoconjugates for triple negative breast cancer. Role: collaborator

• NIH R01 (MPI: Villapol, Leonard). 4/1/23 – 3/31/28. NIH. Total Funds Requested: $3,114,617. Title: Non-viral CRISPR-lipid nanoparticles-based treatment for traumatic brain injury-induced inflammation in vivo. Role: Collaborator

• NIH R01 (MPIs: Staquicini, Dogra). 4/1/23 – 3/31/28. NIH. HM budget: $494,910. Title: Targeted Phage Display Technology for Pulmonary Delivery and Immunotherapy Approaches. Role: Collaborator

• NIH R21 (PI: Puri; co-I: Dogra). 4/1/23 – 3/31/25. NIH. HM budget: $81,660. Title: Development of an iontophoresis-coupled microneedle skin patch of naloxone for rapid and sustained reversal of fentanyl overdose. Role: Collaborator

• NIH/R01 (MPIs: Wang, Chung). 4/1/23–3/31/28. NIH. Total Funds Requested: $3,097,714. Title: Integration of multimodal imaging and biofluid laboratory measurements for mathematical prediction of checkpoint inhibitor immunotherapy outcome in patients with melanoma brain metastases. Role: Co-I (1.2 calendar)

• NIH 1R01CA269639-01A1 (MPIs: Wang, Chen). 9/1/22–8/31/27. NIH. Total Funds Requested: $3,463,440. Title: Development of quantitative early indicators for predicting breast cancer response to immunotherapy treatment using mathematical modeling and preclinical models. Role: Co-I (1.2 calendar)

• Concept Award (PI: Filgueira). 9/1/22 – 8/31/24. DoD. Funds Requested: $161,499. Title: Nanoparticle-mediated Zonal Delivery of Therapeutics to the Tumor Microenvironment. Role: Co-Investigator

• DoD/ Investigator-Initiated Research Award. 7/1/22-6/30/26. DoD. Total Funds Requested: $1,285,542. Title: Microneedle dermal patch for amiloride in animals. Role: Co-I (0.24 calendar)

• DOD W81XWH-21-MRP-TRA (PI: Ekmekcioglu). 4/1/22–3/31/25. DOD. Total Funds Requested: $1,050,000. Title: Innate immune markers contribution in the tumor microenvironment architecture predicts response to immunotherapy in acral melanomas. Role: MPI (0.6 calendar)

• NIH/U54 ROBIN (MPIs: Koay, Azad, Javle, Cristini). 7/1/22–6/30/27. NIH. Total Funds Requested: $ 8,109,461. Title: MD Anderson/Johns Hopkins Cholangiocarcinoma ROBIN Center. Role: MPI/Data Science Core Co-Leader (1.2 calendar)

• NIH/U01 (MPIs: Wang, Chung). 4/1/22–3/31/25. NIH. Total Funds Requested: $1,453,500. Title: Development of a clinically applicable tool for physicians to predict patient outcome in melanoma brain metastases. Role: Co-I (1.2 calendar)

• NIH/R01 (MPIs: Wang, Chung). 4/1/22–3/31/27. NIH. Total Funds Requested: $3,671,180. Title: Identification of immunotherapy response indicators in breast cancer treatment through mathematical modeling and preclinical testing. Role: Co-I (1.2 calendar)

• NIH/R01 Resubmission (MPIs: Ozpolat, Wang). 4/1/22–3/31/27. NIH. Total Funds Requested: $2,250,000. Title: Development of targeted therapeutics for pancreatic cancer. Role: Co-I (1.2 calendar)

• Delta Tissue Program (PIs: Cristini, Plodinec). 10/1/21–9/30/24. Wellcome Leap Foundation. Total Funds Requested: $2,976,000. Title: Predicting cell states and transitions within the tumor microenvironment in the breast cancer response to chemotherapy and immunotherapy using a combined nanomechanical profiling, imaging, and mathematical modeling approach. Role: PI (1.2 calendar)

• NIH/K25 (PI: Butner). 9/1/2021-8/30/2026. NIH. Total Funds Requested: $436,275. Title: Designing a predictive clinical tool to improve patient treatment strategies: integration of multiparametric imaging and mathematical modeling to predict patient outcome in melanoma brain metastases

• NIH/R01 (MPIs: Chung, Hussein, Cristini). 7/1/21–6/30/26. NIH. Total Funds Requested: $4,120,000. Title: Personalized multimodality treatment of melanoma brain metastases following immunotherapy using mathematical modeling. Role: MPI (1.2 calendar)

• NIH/R01 (MPIs: Wang, Ozpolat). 7/1/2021 – 6/30/2026. NIH. Total Funds Requested: $2,306,675. Title: Understanding and optimizing EF2K-targeted nanotherapeutics for pancreatic ductal adenocarcinoma. Role: Co-I (1.2 calendar)

• NIH/R01 (MPIs: Wang, Chen). 7/1/2021 – 6/30/2026. NIH. Total Funds Requested: $3,671,180. Title: Development of mathematical markers for early identification of immunotherapy response in ovarian cancer treatment with preclinical testing. Role: Co-I (1.2 calendar)

• NIH/U01 (MPIs: Cristini, Chen, Wang, Thompson). 7/1/21–6/30/26. NIH. Total Funds Requested: $4,120,000. Title: Clinically validated physical biomarkers drive treatment outcome prediction in breast cancer and lung metastases. Role: Contact PI (1.2 calendar)

• NIH/P20 (MPIs: Chang, Esnaola, Gomez). 7/1/21–6/30/26. NIH. Total Funds Requested: $4,120,000. Title: The Houston Methodist Cancer Health Disparity P20 SPORE planning grant. Role: Co-I of Project 2 (1.2 calendar)

• NIH/R01 (MPIs: Chung, Cristini). 7/1/21–6/30/26. NIH. Total Funds Requested: $4,127,000. Title: Personalization of Treatment for Patients Receiving Immunotherapy for Melanoma Brain Metastases using Imaging and Fluid-Based Mathematical Modeling. Role: MPI (1.2 calendar)

• NIH/U01 (MPIs: Cristini, Chen, Wang, Thompson). 9/1/20–8/31/25. NIH. Total Funds Requested: $4,120,000. Title: Clinically validated physical biomarkers drive treatment outcome prediction in breast cancer and lung metastases. Role: Contact PI (1.2 calendar)

• NIH/R01 (MPIs: Wang, Sood). 9/1/20–8/31/25. NIH. Total Funds Requested: $2,155,000. Title: Development, experimental testing, and retrospective clinical validation of a mechanistic model of immunotherapy in ovarian cancer treatment. Role: Co-Investigator (1.2 calendar)

• DOD/BCRP (MPIs: Thompson, Plodinec). 9/1/20–8/31/23. DOD. Total Funds Requested: $2,000,000. Title: Proteogenomic and nanomechanical biomarkers in primary breast cancer. Role: Collaborator (1.2 calendar)

• NIH/R01 (MPIs: Wang, Ozpolat). 4/1/21–3/31/26. NIH. Total Funds Requested: $2,306,675. Title: Understanding and optimizing EF2K-targeted nanotherapeutics for pancreatic ductal adenocarcinoma. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (MPIs: Wang, Chen). 4/1/21–3/31/26. NIH. Total Funds Requested: $3,671,180. Title: Development of "mathematical markers" for early identification of immunotherapy response in ovarian cancer treatment with preclinical testing. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (PIs: Wang, Ozpolat). 4/1/20–3/31/26. NIH. Total Funds Requested: $2,55,000. Title: Naonparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (PIs: Ozpolat, Wang). 7/1/20–6/30/25. NIH. Total Funds Requested: $2,250,000. Title: Novel combinatorial therapies for pancreatic cancer. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (MPIs: Ozpolat, Calin). 4/1/20–3/31/25. NIH. Total Funds Requested: $2,770,000. Title: miR-484 targeted therapeutics for breast cancer. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (MPIs: Chen, Wang, Chang). 4/1/20–3/31/25. NIH. Total Funds Requested: $3,550,000. Title: Identification of clinically relevant tumor immune microenvironment biomarkers for predicting immunotherapy outcome in lung and breast cancer patients. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (PI: Ozpolat). 4/1/20–3/31/25. NIH. Total Funds Requested: $2,500,000. Title: Development of EF2K targeted Dual effect nanotherapeutics for breast cancer. Role: Co-Investigator (0.5 calendar)

• NIH/R01 (PIs: Wang, Ozpolat). 7/1/20–6/30/25. NIH. Total Funds Requested: $2,250,000. Title: A combined experimental and mathematical modeling approach to optimizing EF2K-targeted nanotherapeutics for pancreatic ductal adenocarcinoma. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (PIs: Wang, Ozpolat). 7/1/20–6/30/25. NIH. Total Funds Requested: $2,55,000. Title: Naonparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer. Role: Co-Investigator (1.8 calendar)

• CPRIT IIRA (MPIs: Chang, Chen). 3/1/20–2/28/23. NIH. Total Funds Requested: $3,550,000. Title: A translational approach to identification of clinically applicable biomarkers for predicting immunotherapy outcome in lung and breast cancer patients. Role: Co-Investigator (1.2 calendar)

• NIH/U54 RFA-CA-19-013 (MPIs: Cristini, Chen, Hong). 9/1/19–8/31/24. NIH. Total Funds Requested: $7,161,919. Title: Houston Center for Cancer ImmunoTherapy Engineering (HC-CITE). Role: Overall PI, contact (3.0 calendar)

• NIH/R01 (PI: Ozpolat). 7/1/19–6/30/24. NIH. Total Funds Requested: $3,500,000. Title: Development of KRAS targeted dual effect nanotherapeutics. Role: Co-Investigator (1.2 calendar)

• NIH/P01 (PI: Calin, Croce, Slack). 7/1/18–6/30/23. NIH. Total Funds Requested: $5,000,000. Title: MicroRNA targeted therapeutics for precision medicine in human cancers. Role: Bioinformatics & Biostatistics and Mathematics Core Director (1.2 calendar)

• NIH/R01 IRCN, PAR-17-240 (MPIs: Ozpolat, Maitra, Volk, Cristini, Wang). 4/1/19–3/31/24. NIH. Total Funds Requested: $3,250,000. Title: Development of miR-based nanotherapeutics for precision medicine in pancreatic cancer. Role: MPI (1.44 calendar)

• NIH/R01 (MPIs: Calin, Ozpolat, Wang). 4/1/19–3/31/24. NIH. Total Funds Requested: $3,500,000. Title: Development of KRAS targeted dual effect nanotherapeutics. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (MPIs: Lopez-Berestein, Ozpolat). 4/1/19–3/31/24. NIH. Total Funds Requested: $2,750,000. Title: Development of EF2K targeted Dual effect nanotherapeutics for breast cancer. Role: Co-Investigator (1.2 calendar)

• CPRIT/IIRA (PI: Ozpolat, Wang). 3/1/19–2/28/22. NIH. Total Funds Requested: $900,000. Title: Development of Dual effect nanotherapeutics for Breast Cancer. Role: Collaborator (0.5 calendar)

Other Submitted Proposals

• DOD BCRP Breakthrough Award Level 2 Award (PIs: Sen). 6/1/18–5/31/21. DOD. Total Funds Requested: $1,540,000. Title: EF1A2-SCF Complex Regulated Ubiquitination Pathway as Predictor of Prognosis and Drug Response in Breast Cancer. Role: Co-I (10% effort)

• NIH/R01 (PI: Zhou). 10/1/18 – 9/30/23. NIH. Total Funds Requested: $2,250,000. Title: Systematically understanding the immunity leading to castration-resistant prostate cancer progression. Role: Co-I (10% effort)

• DOD PCRP Impact Award (PI: Wadih, Brinker, Cristini). 10/1/18 – 9/30/21. DOD. Total Funds Requested: $2,000,000. Title: Development of a targeted nanoparticle prototype in treating enzalutamide-resistant prostate cancer. Role: Partnering PI (2.4 calendar)

• NIH/R01 (PIs: Ozpolat, Lopez-Berestein, Volk, Cristini, Wang). 7/1/18 – 6/30/23. NIH. Total Funds Requested: $2,402,996. Title: Highly Targeted therapies for pancreatic cancer. Role: MPI (10% effort)

• NIH/U01 MSM (PI: Cristini, Wang, Lowengrub). 4/1/18 – 3/31/23. Title: Multiscale Modeling of the Progression of Pancreatic Neoplasms to Invasive Pancreatic Cancer. Role: Overall PI (15% effort)

• CPRIT Computational Biology (PI: Cristini, Koay). 3/1/18 – 2/28/21. Title: Modeling Immunotherapy Response in Lung and Colorectal Cancers. Role: PI (10% effort)

• NIH/U01 IRCN (PIs: Pasqualini, Arap, Brinker and Cristini). 9/1/17 – 8/31/22. NIH. Total Funds Requested: $2,500,000. Title: A targeted nanomedicine prototype against enzalutamide-resistant prostate cancer. Role: Co-PI (1.8 calendar)

• NIH/R01 (PIs: Ozpolat, Volk, Cristini, Wang). 9/1/17 – 8/31/22. NIH. Total Funds Requested: $1,850,000. Title: Highly Targeted Therapies for Pancreatic Cancer. Role: Co-PI (15% effort)

• DOD LCRP Translational Research Partnership (PI: Welsh, Cristini), Pre-application. Title: Quantitative understanding of molecular and cellular characteristics of responders and non-responders in small cell lung cancer treatment. Role: PI

• NIH/R21 (PIs: Fuentes, Elsayes, Wang). 9/1/17 – 8/31/19. NIH. Total Funds Requested: $$275,000. Title: Mathematical modeling of treatment response of hepatocellular carcinoma. Role: Co-I (5% effort)

• NIH/R01 (PI: Ozpolat). 7/1/17 – 6/30/21. NIH. Total Funds Requested: $1,850,000. Title: Development of Targeted Therapies for Pancreatic Cancer. Role: Co-Investigator (6% effort)

• NIH R01 (PIs: Cristini, Wang, Curley). 7/1/17 – 6/30/22. NIH. Total Funds Requested: $2,929,866. Title: Development of a quantitative method for predicting drug response of hepatocellular carcinoma (HCC) to non-invasive radiofrequency hyperthermia (Ni-RFH) and chemotherapy. Role: PI (2.4 calendar)

• NIH/U01 CTSA (PIs: Ozpolat, Volk). 6/1/17 – 5/31/22. NIH. Total Funds Requested: $2,250,000. Title: Highly Targeted Therapies for Pancreatic Cancer. Role: Co-I (15% effort)

• DOD BCRP Breakthrough Level 3 (PI: Sen). 5/1/17 – 4/30/21. NIH. Total Funds Requested: $1,250,000. Title: Integrated Molecular and Imaging Biomarker Signatures of Prognosis for High Risk Breast Ductal Carcinoma In Situ (DCIS). Role: Co-I (8% effort)

• Human Frontier Science Program, International (PIs: Caserta, Cristini, Curley). 4/1/17 – 3/31/22. Total Funds Requested: $1,000,000. Title: A novel microfluidic approach to investigate tumor micro-metabolism and invasion. Role: PI (1.2 calendar)

• NIH/U01 PSOP (PI: Ennio Tasciotti). 4/1/17 – 3/31/22. NIH. Total Funds Requested: $2,500,000. Title: Dietary impact on osteosacroma cellular, metabolic and pharmaceutical transport. Role: Co-Investigator (10% effort)

• NIH/U01 MSM (PIs: Cristini, Wang, Lowengrub, Koay). 4/1/17 – 3/31/22. NIH. Total Funds Requested: $2,500,000. Title: Multiscale Modeling of the Progression of Pancreatic Neoplasms to Invasive Pancreatic Cancer. Role: PI (15% effort)

• NIH/R21 (PIs: David Fuentes, Khaled Elsayes, Zhihui Wang). 4/1/17 – 3/31/19. NIH. Total Funds Requested: $275,000. Title: Mathematical modeling of drug response of hepatocellular carcinoma to targeted therapy. Role: Co-I (5% effort)

• NIH/R21 (PIs: Wang, Kesari). 4/1/17 – 3/31/19. NIH. Total Funds Requested: $275,000. Title: A multiscale analysis to initial selection, testing, and validation of drug targets in glioblastoma. Role: Co-I (10% effort)

• CPRIT Computational Biology (Co-PIs: Cristini, Koay). 12/1/16 – 11/30/19. CPRIT. Total Funds Requested: $900,000. Title: Modeling Immunotherapy Response in Lung Cancer. Role: PI (1.8 calendar)

• NIH/U01 Early Detection (PI: Subrata Sen). 9/1/16 – 8/31/21. NIH. Total Funds Requested: $2,000,000. Title: Early Detection Biomarkers of Pre-malignant High-risk Breast Atypical Ductal Hyperplasia (ADH) and Ductal Carcinoma In Situ (DCIS). Role: Co-Investigator (5% effort)

• NIH U01 (PIs: Cristini, Freyer, Shreve). 7/1/16 – 6/30/21. NIH. Total Funds Requested: $2,727,200. Title: An Integrated Model of Chemical, Physiological and Metabolic Gradients in Solid Tumors. Role: PI (3.0 calendar)

• NIH U54 (PIs: Curley, Wilson). 7/1/16 – 6/30/21. NIH. Total Funds Requested: $11,483,811. Title: Center for Translational Electromagnetic Oncology (CTEO). Role: Mathematical Modeling Core PI (3.0 calendar)

• NSF Division of Mathematical Sciences (PIs: Cristini, Wang). 7/1/16 – 6/30/19. NSF. Total Funds Requested: $270,000. Title: Multiscale modeling of tumor growth, invasion and microenvironmental interactions. Role: PI (1.2 calendar)

• CPRIT Computational Biology (Co-PIs: Cristini, Koay). 3/1/16 – 2/28/19. CPRIT. Total Funds Requested: $450,000. Title: Integrated mechanistic mathematical modeling and quantitative imaging analyses for human. Role: PI (1.2 calendar)

• NIH U54 CCNE (Co-PIs: Sood, Lopez, Gorenstein). 9/1/15 – 8/31/20. NIH. Total Funds Requested: $ 13,000,000. Title: Texas Center for Cancer Nanomedicine. Role: Co-Investigator (Biomathematics Core; 1.2 calendar)

Proposals Planned (to be submitted)

(Ongoing)

• DOD W81XWH-resubmission (MPIs: Ekmekcioglu, Koay, Cristini). DOD. Total Funds Requested: $1,050,000. Title: Innate immune markers contribution in the tumor microenvironment architecture predicts response to immunotherapy in acral melanomas. Role: MPI (0.6 calendar)

• R01 (Wang, Ozpolat, Cristini) (Houston Methodist), PAR-20-284. Research topic: To optimize miR-873-based nanotherapeutics and complete preclinical safety and efficacy studies in clinically relevant TNBC and PDAC models. To be submitted in February 2024

• R01 (Chung, Wang, Cristini) (MD Anderson). Research topic: Development of a multiscale mathematical model for optimizing combination therapy based on immunotherapy and radiation therapy in patients with melanoma brain metastases. To be submitted in February 2024

• NIH/R01 resubmission (MPIs: Chung, Hussein, Cristini). NIH. Total Funds Requested: $4,127,000. Title: Personalization of Treatment for Patients Receiving Immunotherapy for Melanoma Brain Metastases using Imaging and Fluid-Based Mathematical Modeling. To be submitted March 2024

• R01 (Wang, Ozpolat, Cristini) (Houston Methodist), PAR-22-071. Research topic: To develop clinically applicable, safe, effective and highly specific KRAS-targeted RNAi-nanotherapeutics for the molecular targeting of mutated KRAS oncogene and translate them to clinical trials for treatment of pancreatic cancer patients. To be submitted in February 2024

• NIH/R01 (Resubmission) (MPIs: Wang, Sood). Title: Development, experimental testing, and retrospective clinical validation of a mechanistic model of immunotherapy in ovarian cancer treatment. To be submitted March 2024

• R01 (Wang, Chen, Cristini) (Houston Methodist). Research topic: Development of quantitative early indicators for predicting breast cancer response to immunotherapy treatment using mathematical modeling and preclinical models. To be submitted in February 2024

• NIH/R01 (MD Anderson) (Koay, Cristini et al.). Topic: Prediction of the therapeutic efficacy of immunotherapy for pancreatic cancer by accounting for the principles of physics and biology in cancer treatment. To be submitted February 2024

• NIH/R01 (MD Anderson) (Wang, Ozpolat, Calin et al.). Topic: A systems biology approach to understand cell to cell communication by TP53 regulation of exosomal non-coding RNAs in human cancers. To be submitted February 2024. (Ongoing)

• NIH/ R21, RFA-CA-22-021 (Butner, Wang, Chung, Cristini). Topic: Hybridizing mechanistic mathematical model with deep learning methods to predict individual cancer patient survival after immune checkpoint inhibitor therapy. To be submitted October 2023

• NIH/R01, PAR-21-166: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (AIP – R01). With MD Anderson Cancer Center (Plodinec, Koay, Hong, Welsh et al.). Topic: Development of clinically measureable mathematical markers for prognostic identification of patient response to immunotherapy. To be submitted February 2024

• NIH/U01, PAR-22-242: Bioengineering Research Grants (BRG). With HM (Chen et al.), MD Anderson Cancer Center (Plodinec, Koay, Hong, Welsh et al.), Baylor College of Medicine (Thompson et al.). Topic: An integrated mathematical modeling and clinical approach to cancer treatment prediction. To be submitted June 2024

• NSF 22-1 (MPIs: Cristini, Lowengrub). NSF. Total Funds Requested: TBD. Title: Mathematical modeling of biophysical transport of immune infiltrates in lung cancer. Role: Co-Leader. To be submitted September 2024

• NIH/U54 ROBIN (MPIs: Koay, Azad, Javle, Cristini). NIH. Total Funds Requested: $8,109,461. Title: MD Anderson/Johns Hopkins Cholangiocarcinoma ROBIN Center. Role: MPI/Data Science Core Co-Leader (1.2 calendar). To be submitted October 2024

PUBLICATIONS

Abstracts (selected)

1. P. Dogra, J. Cave, J.D. Butner, V. Cristini, Z. Wang. Multiscale Modeling-Identified Synergistic Combinations of Anti-microRNA-155 and Standard-of-Care Drugs for Improved Outcomes in Non-small Cell Lung Cancer, in AAPS PharmSci 360 Conference. 2023: Orlando, FL.

2. M. Farhat, J.D. Butner, Z. Wang, M. Shanker, W. Talpur, S. Thrower, L. Erickson, J. Bronk, H. Langshaw, B.L. Tran, D. Yadav, A. Elliott, C. Wang, H.A. Tawbi, V. Cristini, C. Chung. Evaluating novel imaging-based mathematical modeling prediction of immunotherapy response by individual melanoma brain metastasis and patient prognosis. Journal of Clinical Oncology, 2023. 41(16_suppl): p. e14013-e14013.

3. Peláez MJ, Ramírez JR, Shen Y, Birur RM, Schiavone C, Cristini V, Puri A, Wang Z, Dogra P*. “Mechanistic modeling for optimal design of dissolvable microneedle-based patches for transdermal drug delivery” Proceedings of the 2021 45th Annual International Conference of the IEEE Engineering in Medicine and Biology Society;2023 Jul; Sydney, Australia.

4. Cave J, Shinglot V, Butner JD, Cristini V, Bulent O, Calin GA, Dogra P*, Wang Z*. “Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer” Proceedings of the 2021 45th Annual International Conference of the IEEE Engineering in Medicine and Biology Society;2023 Jul; Sydney, Australia.

5. Dogra P, Shinglot V, Cave J, Cristini V, Wang Z. Muliscale Mechanisic Modeling of Nanoparticle-Delivered Anti-microRNA-155 Therapy and Its Combination With Standard-of-Care Drugs in Lung Cancer. 17th U. S. National Congress on Computational Mechanics, Albuquerque, NM, USA. July 23-27, 2023.

6. M. Farhat, J. D. Butner, M. Shanker, W. Talpur, S. Thrower, L. Erickson, D. Yadav, B. Tran, J. Bronk, H. Langshaw, A. Elliott, Z. Wang, V. Cristini, and C. Chung. Evaluating novel imaging-based mathematical modeling prediction of immunotherapy response by individual melanoma brain metastasis and patient prognosis. ASCO Annual Meeting 2023, June 2-6, 2023.

7. Akeemat T, Puri A, Peláez MJ, Dogra P, Rapidly Development of an Iontophoresis-Coupled Microneedle Skin Patch of Naloxone for Emergency Treatment of Opioid Overdose. 2023 Appalachian Student Research Forum, Johnson City, TN, USA. April 25, 2023

8. Capuani S, Hernandez N, Paez-Mayorga J, Dogra P, Wang Z, Cristini V, Chua CYX, Nichols JE, Grattoni A. Local Delivery of Drugs in a 3D Bioengineered Subcutaneous Niche: Biodistribution and Pharmacokinetics. 8th Nano Today Conference. April 22-25, 2023. San Diego, CA, USA

9. Nizzero S, Zaugg G, Zhang L, Xu Y, Peláez MJ, Mariam Gachechiladze Gchechiladze M, Dogra P, Menegaz BA, Jordan LB, Purdie CA, Quinlan PR, Nagi C, Sepulveda KA, Oertle P, Appenzeller A, Chen SH, Loparic M, Wang Z, Cristini V, Plodinec M, Thompson AM. Heterogeneity of Mechano-Physical Biomarkers Drive Outcome in Breast Cancer: A Quantitative Spatial Analysis Approach. Gordon Research Conference Physical Sciences of Cancer: Physical Oncology Across Biological Scales: Signals, Systems, Forces and Fluxes, Galveston, TX, USA. Feb 5-10 2023. Invited talk.

10. Nizzero S, Gchechiladze M, Zaugg G, Zhang L, Xu Y, Peláez MJ, Dogra P, Menegaz BA, Jordan LB, Purdie CA, Quinlan PR, Nagi C, Sepulveda KA, Oertle P, Appenzeller A, Chen SH, Loparic M, Wang Z, Cristini V, Plodinec M, Thompson AM. Highly Multiplexed Spatial Analysis of Breast Cancer Tissues Reveals Functional Mechanical Drivers for Long Term Patient Outcome. Gordon Research Seminar Physical Sciences of Cancer: Quantitative Hallmarks of the Tumor Microenvironment, Galveston, TX, USA. Feb 5-10 2023. Invited talk.

11. Nizzero S, G Srivastava, P Oertle, M Wasley, M Kim, Appenzeller T, Barsoumian H, Loparic M, Wang Z, A Cortez, N Puebla, P Dogra, Cristini V, M Plodinec M, Welsh. Nanomechanical Signature of Low Dose Radiation-induced Tumor Stroma Remodulation Mediates Tumor Response in Lung Adenocarcinoma. Gordon Research Seminar Physical Sciences of Cancer: Quantitative Hallmarks of the Tumor Microenvironment, Galveston, TX, USA. Feb 5-10 2023. Invited talk.

12. Capuani S, Hernandez N, Paez-Mayorga J, Dogra P, Wang Z, Cristini V, Chua CYX, Nichols JE, Grattoni A. Biodistribution of locally delivered drugs in a 3d bioengineered subcutaneous niche. 7th Bioengineering & Translational Medicine Conference, Boston, MA, USA. December 14-16, 2022.

13. Nizzero S, Zhang L, Xu Y, Peláez MJ, Dogra P, Menegaz BA, Jordan LB, Purdie CA, Quinlan PR, Nagi C, Sepulveda KA, Oertle P, Appenzeller A, Chen SH, Loparic M, Wang Z, Cristini V, Plodinec M, Thompson AM. Spatial patterns of microenvironmental biomarkers drive long-term breast cancer outcome. American Association of Cancer Research, New Orleans, LA, USA. April 8-13 2022. Cancer Research 82 (12S), 1963, 2022.

14. Dogra P, Schiavone C, Caserta S, Wang Z, Cristini V. Mathematical modeling identifies optimal dosing schedules for COVID-19 vaccines to minimize breakthrough infections. American Association of Pharmaceutical Scientists PharmSci 360 Conference, Boston, MA, USA. October 16-19, 2022.

15. Farhat M., JD Butner, S Thrower, L Erickson, Z Wang, V Cristini, D Yadav, B Tran, J Bronk, H Langshaw, A Elliott, C Chung, Growth Kinetic Mathematical Modeling to Predict Individual Melanoma Brain Metastasis Response to Immunotherapy, in Radiological Society of North America 108th Scientific Assembly and Annual Meeting. 2022: Chicago, IL.

16. Dogra P, Ruiz Ramírez J, Butner JD, Peláez MJ, Cristini V, Wang, Z, 2021. A Multiscale Model to Identify Limiting Factors in Nanoparticle-Based miRNA Delivery for Tumor Inhibition. Proceedings of the 2021 43nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society;2021 Oct-Nov; Guadalajara, Mexico.

17. Dogra P., Peláez J. M., Ramirez, J.R., Sinha, K., Butner, J.D., Cristini, V., Wang Z. “Investigating the role of innate immunity in the control of SARS-CoV-2 infection using a mathematical model” American Association of Pharmaceutical Scientists PharmSci 360 Conference. 2021.

18. Dogra, P., Ramírez, J.R., Peláez, M.J., Butner, J.D., Cristini, V., Wang, Z. Translational mechanistic modeling for treatment optimization of nanoparticle-delivered miRNA-22 therapy in triple negative breast cancer. 9th Annual Houston Methodist Cancer Symposium. Virtual. 2021.

19. KCE Tallawi, D Kitkungvan, J Xu, V Cristini, EY Yang, MA Quinones, ... Potential explanation for disproportionate left ventricular enlargement in Barlow's disease: insights from cardiovascular magnetic resonance. Journal of the American College of Cardiology 75 (11_Supplement_1), 2128-2128, 2020

20. Dogra, P., Peláez J. M., Ramirez, J.R., Butner, J.D., Cristini, V., Wang Z. “Identifying parameters to improve the pharmacokinetics and tumor delivery efficiency of nanomedicine”. Special poster presentation session at the American Association of Pharmaceutical Scientists PharmSci 360 Conference. 2020.

21. D.A. Anaya, J.G. Wilkes, P. Dogra, Z. Wang, M. Haider, J. Ehab, D.K. Jeong, M. Ghayourim, G.Y. Lauwers, K. Thomas, R. Kim, J.D. Butner, S. Nizzero, J.R. Ramirez, J.B. Fleming, V. Cristini, Tumor-Site Chemotherapy Concentration Predicts Response To Treatment In Patients With Colorectal Liver Metastasis: A New Paradigm For Individualized Cancer Care. HPB, 2020, 22(10).

22. P Dogra, MJ Peláez, JR Ramírez, JD Butner, V Cristini, Z Wang, “Identifying parameters to improve the pharmacokinetics and tumor delivery efficiency of nanomedicine.” PharmSci360, 2020.

23. Dogra P, Chuang Y-L, Butner JD, Cristini V, Wang Z. 2020. Investigating the Effect of Aging on the Pharmacokinetics and Tumor Delivery of Nanomaterials using Mathematical Modeling. 42nd Annual International IEEE Engineering in Medicine and Biology Society (EMBC) Conference. Montreal, Canada. July 20-24, 2020.

24. Dogra P, Chuang Y-L, Butner JD, Ramirez JR, Cristini V, Wang Z. 2019. A multiscale mathematical model to study nanomedicine delivery in solid tumors. American Association of Pharmaceutical Scientists (AAPS) 2019 PHARMSCI 360 Conference. San Antonio, TX, USA. November 3-6, 2019.

25. Dogra P, Chuang Y-L, Butner JD, Cristini V, Wang Z. 2019. Development of a Physiologically-Based Mathematical Model for Quantifying Nanoparticle Distribution in Tumors. 41st Annual International IEEE Engineering in Medicine and Biology Society (EMBC) Conference. Berlin, Germany. July 23-27, 2019.

26. C Wang, D Elganainy, M Zaid, J Butner, V Cristini, E Koay. “Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer”. International Journal of Radiation Oncology• Biology• Physics, 103:5, E48–E49, April 2019.

27. Butner JD, Cristini V, Wang Z. Multiscale modeling of ductal carcinoma in situ. The 63rd Annual Meeting of the Biophysical Society. Baltimore, MD. March 2-6, 2019. Biophysical J 116(3), 322a, 2019.

28. Butner JD, Cristini V, Wang Z. 2018. Understanding Ductal Carcinoma In Situ Invasion using a Multiscale Agent-Based Model. The 40th Annual International IEEE EMBS Conference. Honolulu, HI, USA.

29. S Curley, V Cristini, A novel mechanistic mathematical model of the heat equation and energy balance for absorption of non-invasive radiofrequency (RF) energy in biologic tissues. Society for Thermal Medicine annual meeting 2018.

30. Butner JD, Cristini V, Wang Z. 2017. Development of a Three Dimensional, Multiscale Agent-Based Model of Ductal Carcinoma In Situ. 39th Annual International IEEE Engineering in Medicine and Biology Society (EMBC) Conference. Jeju Island, Korea. Pp. 86-89.

31. Y Lee, V Cristini, GR Varadhachary, M Katz, H Wang, P Bhosale, EP Tamm, JB Fleming, EJ Koay, 2016/10/1, Quantitative Computed Tomography Analysis Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. International Journal of Radiation Oncology• Biology• Physics, 96, 2, E199, Elsevier

32. Butner, J., Cristini, V., Wang, Z. Development of a Three Dimensional, Lattice-free Multiscale Model of the Mammary Terminal End Bud. 38th Annual International IEEE EMBS Conference, Orlando, FL, US. August 16-20, 2016

33. Butner, J., Cristini, V., Wang, Z. A Modeling Approach to Study the Normal Mammary Gland Growth Process. 37th Annual International IEEE EMBS Conference. Milan, Italy. August 25-29, 2015.

34. Simbawa, E., Cristini, V. 2015 The 4th International Conference on Pure and Applied Mathematics (ICPAM 2015). Roma, Italy, July 16-17, 2015.

35. Koay, E.J., Cristini, V., Fleming, J.B., Ferrari, M., Crane, C.H. Advanced imaging analysis and mechanistic mathematical oncology in human pancreatic cancer. 36th Annual International IEEE EMBS Conference Chicago, IL, US. August 26-30, 2014.

36. Wang, Z., Kerketta, R., Chuang, Y.L., Cristini, V. Development of a Diffusion-Based Mathematical Model for Predicting Chemotherapy Effects. 36th Annual International IEEE EMBS Conference. Chicago, IL, US. August 26-30, 2014.

37. Dogra, P., Townson, J., Chuang, Y.L., Wang, Z., Brinker, C.J., Cristini, V. “Understanding and Optimizing Intravascular Nano-Bio Interactions with Mathematical Modeling.” The Eighth q-bio Conference. Santa Fe, NM, US. August 13-16, 2014.

38. Kerketta, R., Butner, J., Brocato, T., Dogra, P., Day, A., John, J., Chuang, Y.L., Wang, Z., Curley, S., Cristini, V. Predicting chemotherapeutic outcomes in patients with colorectal cancer liver metastases. The Eighth q-bio Conference. Santa Fe, NM, US. August 13-16, 2014.

39. Bearer, E.L., Wang, Z., Cristini, V. Mathematical modeling and correlation of Histopathology with perfusion-contrast CT for prediction of vascular permeability and chemotherapeutic diffusion parameters. Minisymposium - Cancer Inflammation Immunity and Angiogenesis. American Society for Investigative Pathology Meeting. San Diego, CA, US. Apr 26-30, 2014.The FASEB J 28, 397.7, 2014.

40. Loewenberg, M., Pascal, J., Chauviere, A., Cristini, V. Modeling Motor-Assisted Intracellular Cargo Transport, AIChE Annual Meeting. San Francisco, CA, US. November 6, 2013.

41. Kerketta, R., Wang, Z., Cristini, V. Mathematical Modeling of Diffusion Barriers in Colorectal Cancer Metastases to the Liver. Nanoparticle Synthesis and Applications to Cancer Imaging and Treatment Symposium (CNTC), Science & Math Learning Center, Main Campus, UNM. Albuquerque, NM, US. August 16, 2013.

42. Kerketta, R., Wang, Z., Cristini, V.Mathematical Modeling of Diffusion Barriers in Colorectal Cancer Metastases to the Liver. The Seventh q-bio Conference, St. John’s College, Santa Fe, NM, US. August 8, 2013.

43. Chuang, Y.L., Lewis, M.T., Wang, Z., Cristini, V., Chauviere, A. Self-organization and pattern formation in mammary gland development. The Seventh Annual q-bio Conference on Cellular Information Processing. Santa Fe, NM, US. August 7-10, 2013.

44. Chuang,Y.L., Wang, Z., Cristini, V., Lewis, M.T., Chauviere, A. Modeling mammary ductal morphogenesis: self-organization and pattern formation in mammary gland development. The Society for Mathematical Biology Annual Meeting and Conference. Phoenix, AZ, US. June 10-13, 2013.

45. Chuang, Y.L., Cristini, V., Chen, Y.L., Li, X., Frieboes, H.B., Lowengrub, J.S. Modeling growth and dissemination of lymphoma in a co-evolving lymph node: a diffuse-domain approach. Bulletin of the American Physical Society Vol 58, 2013.

46. Frieboes, H.B., Wu, M., Lowengrub, J., Decuzzi, P., Cristini, V. Analysis of nanoparticle uptake by tumor vasculature using computational modeling. Poster at ASME 2nd Global Congress on Nanoengineering for Medicine & Biology. Boston, MA, US. February 4-6, 2013.

47. Koay, E., Cristini, V., et al. Novel CT-derived biophysical markers describe gemcitabine delivery and chemoradiation response in human pancreatic adenocarcinoma. American Radium Society Annual Meeting. Scottsdale, AZ, US. April 27 - May 1, 2013.

48. Wang, Z., Pascal, J., Chuang, Y.L., Das, H., Gurcan, M., Cristini, V. Impact of Diffusion Barriers to IFN-γ on Breast Cancer Immunotherapy. Poster presentation. Physical Sciences in Oncology (PSOC) 4th Annual Meeting, Scottsdale, AZ, US. April 17-19, 2013.

49. Gehlot, P., Pascal, J., Cristini, V., Curley, S. Biomathematical Modeling of Diffusion Barriers in Gottingen Mini Pigs. Poster Presentation. Physical Sciences in Oncology (PSOC) 4th Annual Meeting, Scottsdale, AZ, US. April 17-19, 2013.

50. Pascal, J., Wang, Z., Curley, S., Bearer, E. L., Cristini, V. Diffusion Properties Limit Effectiveness of Chemotherapy in Metastatic Colorectal Cancer. Poster presentation. Physical Sciences in Oncology (PSOC) 4th Annual Meeting, Scottsdale, AZ, US. April 17-19, 2013.

51. Pascal, J., Ashley, C., Wang, Z., Brinker, C.J., Cristini, V. Predictive Biophysical Modeling of Dose Response of Tumor Cells Treated with Free Drug and Protocells. Selected for Oral Presentation at Young Investigator’s Meeting. Physical Sciences in Oncology (PSOC) 4th Annual Meeting, Scottsdale, AZ, US. April 17-19, 2013.

52. Chuang, Y.L., Cristini, V., Chen, Y., Li, X., Frieboes, H.B., Lowengrub, J.S. Modeling tumor growth in an evolving tissue structure: a diffuse domain approach. 57th Annual Meeting of Biophysical Society. Philadelphia, PA, US. February 2-6, 2013. Biophysical J 104(2), 496a-497a, 2013.

53. Spatio-Temporal Modeling Center workshop, University of New Mexico, Understanding Cell Behavior through Single Cell and Single Molecule Biology. Poster Presentation. University of New Mexico, Albuquerque, NM, US. January 10-12, 2013.

54. Frieboes, H.B., Wu, M., Lowengrub, J., Decuzzi, P., Cristini, V. Analysis of nanoparticle uptake by tumor vasculature using computational modeling. Poster Presentation. Physical Sciences in Oncology Annual Conference, Phoenix, AZ, US. 2013.

55. Cristini, V., Koay, E., Bearer, E., Curley, S., Ferrari, M., Gambhir, S.S., Frieboes, H.B., Smith, B., Pascal, J., Wang, Z. Mathematical Models of Tumor Microenvironment Transport Accurately Predict Limitations to Chemo/Radiation Delivery and Outcome. Poster Presentation. Physical Sciences in Oncology Annual Conference, Phoenix, AZ, US. 2013.

56. Dogra, P, Wang, Z., Cristini, V. ‘Cancer Research at the Interface of Physical Sciences and Biology.’ Biomedical Sciences Graduate Program Symposium, UNM. Albuquerque, NM, US. 2013.

57. Pascal, J., Loewenberg, M., Gonzales, A., Adair, E., Cristini, V., Bearer, E.L. Measurements and modeling of axonal transport: Amyloid precursor protein wins over negative charge in the race to the synapse. The American Society for Cell Biology Annual Meeting. San Francisco, CA, US. Dec 15-19, 2012.

58. Frieboes, H.B., Wu, M., Lowengrub, J.S., Decuzzi, P., Cristini, V. Biomathematical Modeling of Nanoparticle Transport in Tumor Tissue. NCI Alliance for Nanotechnology in Cancer Annual Meeting. Houston, TX, US. November 13-17, 2012.

59. Chuang, Y.L., Cristini, V., Chen, Y., Li, X., Frieboes, H., Lowengrub. J. Modeling Lymphoma Growth in an Evolving Lymph Node Using a Diffuse Domain Approach. 65th Annual Meeting of the APS Division of Fluid Dynamics. San Diego, CA, US. November 18-20, 2012.

60. Pascal, J., Ashley, C., Wang, Z., Brinker, C.J., Cristini, V. Overcoming Transport Barriers to Deliver Drugs to Tumors. AIChE National Meeting. Pittsburgh, PA, US. October 28-November 2, 2012.

61. Pascal, J, Loewenberg, M., Chauviere, A., Seamster, P., Bearer, E., Cristini, V. Mathematical Modeling of Intracellular Transport in the Squid Giant Axon. AIChE National Meeting. Pittsburgh, PA, US. October 28-November 2, 2012.

62. Bearer, E.L., Pascal, J., Seamster, P., Harris, Z., Loewenberg, M., DeGiorgis, J., Cristini, V. Mathematical Modeling of Competitive Cargo Motor Receptors in the Squid Giant Axon. STMC site visit, Albuquerque, NM. August 2012.

63. Chuang, Y.L., Cristini, V., Chen, Y., Li, X., Frieboes, H., Lowengrub, J. Adapting a Tumor Growth Model to an Evolving Domain Using a Diffuse-Domain Approach. The Society for Mathematical Biology Annual Meeting and Conference. Knoxville, TN, US. July 25-28, 2012.

64. Pascal, J., Loewenberg, M., Chauviere, A., Seamster, P., Bearer, E., Cristini, V. Mathematical Modeling of Intracellular Transport in the Squid Giant Axon. the Society for Mathematical Biology Annual Meeting and Conference. Knoxville, TN, US. July 25-28, 2012.

65. “Cell Migration Features in Brain Tumor Invasion: Mathematical Modeling and Analysis.” 9th AIMS International Conference on Dynamical Systems, Differential Equations and Applications. Submitted to the special session: “Mathematical Models of Cancer and Cancer Therapy.” Orlando, FL, US. July 2012 (A. Chauviere).

66. "Dynamical Systems, Differential Equations and Applications," 9th AIMS International Conference. Invited to mini-symposium: "Mathematical Models of Cancer and Cancer Therapy." Orlando, FL, US. July 2012 (A. Chauviere).

67. "Data-driven Modeling in Mathematical Oncology," Annual meeting of Society for Mathematical Biology, NIMBioS, Invited in mini-symposium, Knoxville, TN, US. July 2012 (A. Chauviere).

68. Bearer, E.L., Pascal, J., Seamster, P., Harris, Z., Loewenberg, M., DeGiorgis, J., Cristini, V. Mathematical Modeling of Competitive Cargo Motor Receptors in the Squid Giant Axon. Department of Pathology Research Day, Embassy Suites, Albuquerque, NM, US. May 2012.

69. van de Ven, Wu, M., Lowengrub, J., Cristini, V., Ferrari, M., Frieboes, H.B. Optimization of Nanotherapeutics Delivery via an Integrated Intravital Microscopy/Mathematical Modeling Approach. Physical Sciences in Oncology Annual Conference. Tampa, FL, US. April 16-18 2012.

70. Frieboes, H.B., Wu, M., Lowengrub, J., Decuzzi, P., Cristini, V. Modeling of Biobarriers to Nanoparticle Transport in Tumors. Physical Sciences in Oncology Annual Conference, Tampa, FL, US. April 16-18, 2012.

71. Pascal, J., Loewenberg, M., Chauviere, A., Seamster, P., Bearer, E., Cristini, V. Mathematical Modeling of Intraceullar Transport in the Squid Giant Axon. Poster presentation. IRACDA Annual Meeting. Philadelphia, PA, June 2012.

72. Bearer, E.L., Cristini, V. Mathematical Modeling of Competitive Cargo Motor Receptors in the Squid Giant Axon. The New Mexico SpatioTemporal Modeling Center. Invited Presentation. March 2012.

73. Chauviere, A., Hatzikirou, H., Kevrekidis, I.G., Lowengrub, J.S., Cristini, V. Multiscale Modeling of Interacting Multicellular Systems: Preliminary Models of Solid Tumor Growth. Workshop: "Mathematics of ICBP”, Tampa, FL, US. March 2012.

74. Chuang, Y.L., Edgerton, M.E., Macklin, P., Yang, W., Bearer, E.L., Cristini, V. Predicting Tumor Sizes of Ductal Carcinoma in situ from Immunohistochemical Images Using a Novel Approach of Mathematical Pathology: Preliminary Results, Potentials and Challenges Ahead. American Physical Society Annual Meeting. Boston, MA, US. February 27- March 2, 2012.

75. Chuang, Y.L., Cristini, V., Chen, Y., Li, X., Frieboes, H.B., Lowengrub, J. A Cahn-Hilliard Model of Vascularized Tumor Growth in a Complex Evolving Confinement Using a Diffuse Domain Approach. American Physical Society Annual Meeting. Boston, MA, US. February 27-March 2, 2012.

76. J Pascal, M Loewenberg, A Gonzales, E Adair, V Cristini, EL Bearer. Measurements and modeling of axonal transport: Amyloid precursor protein wins over negative charge in the race to the synapse. Molecular biology of the cell 23, 2012

77. Cristini. V. A Novel, Patient-Specific Mathematical Pathology Approach for Prediction of Tumor Growth. Annual Interdisciplinary Symposium of the NCI-ICBP Center for Modeling Cancer Development. Houston, TX, US. February 2012.

78. Chauviere, A. Cristini, V. From Normal Mammary Gland Development to Breast Tumor Growth: Development of Well-Suited Multiscale Modeling Approach. Annual

Interdisciplinary Symposium of the NCI-ICBP Center for Modeling Cancer Development. Houston, TX, US. February 2012.

79. Frieboes, H.B., Smith, B., Chuang, Y.L., Ito, K., Roettgers, A., Gambhir, S.S., Cristini, V. Integrated Computational/Experimental Modeling of Lymphoma Growth. Physical Sciences in Oncology Annual Conference. Tampa, FL, 2012.

80. Wang, Z., Chauviere, A., Lewis, M., Cristini, V. Multiscale Modeling of Mammary Gland Development. The Methodist Hospital Research Institute. Houston, TX, US. 2012.

81. Cristini, V. Multiscale in-silico modeling of drug/nanoparticle transport barriers and tumor response. Sandia/UNM Cancer Center Symposium on Nanoparticle Human Interactions. June 2-3, 2011

82. Chuang, Y., Lowengrub, J., Chen,Y., Li, X., Frieboes, H., Cristini,V. Modeling tumor growth in a complex evolving confinement using a diffuse domain approach. Conference Abstract: 64th Annual Meeting of the American Physical Society’s Division of Fluid Dynamics. Baltimore, Maryland. 2011.

83. EL Bearer, V Cristini. Physical laws predict that tumor eradication by systemic therapy is limited. The FASEB Journal 25, 243.12-243.12, 2011

84. Bearer, E., Seamster, P., Z. Harris, Z., Loewenberg, M., DeGiorgis, J.,Cristini, V. Mathematical Modeling of Competitive Cargo Motor Receptors in the Squid Giant Axon. Conference Abstract: American Society for Cell Biology Annual Meeting. Denver, Colorado. 2011.

85. Bearer, E., Cristini, V. Predictive modeling of chemotherapy. Annual Meeting of the American Society for Investigative Pathology. Washington, D.C. 2011.

86. PE Seamster, EL Bearer, Z Harris, M Loewenberg, J DeGiorgis, V Cristini. Analysis of competition between cargo motor receptors during active transport in the squid giant axon: Evidence for a hierarchy of motor-affinities. Molecular biology of the cell 22, 2011

87. Chuang, Y., Edgerton, M., Macklin, P., Yang, W., Bearer, E., Cristini, V. A Novel, Patient-Specific Mathematical Pathology Approach for Accurate Prediction of Tumor Growth. Conference Abstract: 5th Annual q-bio Conference on Cellular Information Processing. Santa Fe, New Mexico. 2011. (Presenter: Cristini, V.)

88. Chauviere, A., Hatzikirou, H., Cristini, V. The Go-or-Grow hypothesis in glioma growth: mathematical modeling and analysis. 8th European Conference on Mathematical and Theoretical Biology / Annual Meeting of the Society for Mathematical Biology (ECMTB/SMB). Krakow, Poland. 2011.

89. Ito, K., Smith, B., Frieboes, H., Cristini, V., Gambhir, S. Determination of molecular and cellular characteristics in drug-resistant and –sensitive lymphoma using multiple co-localized marker immunohistostaining for accurate multiscale model calibration. Second Annual National Cancer Institute Physical Sciences-Oncology Centers (NCI PS-OCs) Network Investigators' Meeting. La Jolla, California. 2011.

90. Macklin, P., Edgerton, M., Evans, A., Purdie, C., Jordan, L., Thompson, A., Cristini, V. Patient-calibrated modeling of ductal carcinoma in situ (DCIS): From microscopic measurements to macroscopic predictions of clinical progression. Second Annual National Cancer Institute Physical Sciences-Oncology Centers (NCI PS-OCs) Network Investigators' Meeting. La Jolla, California. 2011

91. Frieboes, H., Cristini, V. 3D Mathematical Modeling and Simulation of Lymphoma. Poster Presentation: Second Annual National Cancer Institute Physical Sciences-Oncology Centers (NCI PS-OCs) Network Investigators' Meeting. La Jolla, California.2011

92. Chauviere, A., Cristini, V. Multiscale modeling of the role of stem cells in mammary gland development and carcinogenesis. The Methodist Hospital Research Institute Integrative Cancer Biology Program Seminar Series. Houston, Texas. 2011.

93. Macklin, P., Edgerton, M., Thompson, A., Cristini, V. An illustration of patient-specific cancer modeling: from microscopic data to macroscopic, quantitative predictions. 8th European Conference on Mathematical and Theoretical Biology / Annual Meeting of the Society for Mathematical Biology (ECMTB/SMB). Krakow, Poland. 2011.

94. Macklin, P., Edgerton, M., Thompson, A., Cristini, V. Mechanistic cell-scale modelling of ductal carcinoma in situ (DCIS): impact of cell biomechanics. 8th European Conference on Mathematical and Theoretical Biology / Annual Meeting of the Society for Mathematical Biology (ECMTB/SMB). Krakow, Poland. 2011

95. Cristini, V. Multiscale Modeling of Cancer Stem Cells. The Center for Modeling Cancer Development Annual Interdisciplinary Symposium. Houston, Texas. 2011.

96. Edgerton, M., Chuang, Y., Macklin, P., Kim, J., Tomaiuolo, G., Broom, A., Sanga, S., Cristini, V. Simulations of Growth of DCIS Parameterized from IHC. Lab. Invest. 89:37A. 2011.

97. Wong, A., Macklin, P., Chuang, Y., Cristini, V., Sanders, M., Schuyler, P., Dupont, W., Page, S., Edgerton, M. Development of a Population Based Model for Progression of DCIS to Invasion. Lab. Invest. 90:78A. 2010.

98. Le, S., Sanga, S., Broom, B., Aldape, K., Cristini, V., Edgerton, M. Analysis of Microarray Data from High Grade Gliomas across Multiple Institutions. Lab. Invest. 90:425A. 2010.

99. Wong, A., Macklin, P., Chuang, Y., Cristini, V., Sanders, M., Schuyler, P., Dupont, W., Page, D., Edgerton, M.. “Development of a Population Based Model for Progression of DCIS to Invasion.” Modern Pathol. 23(1):78A. 2010

100. Le, S., Sanga, S., Broom, B., Aldape, K., Cristini, V., and M. Edgerton, M. Analysis of Microarray Data from High Grade Gliomas across Multiple Institutions. Modern Pathol. 23(1):425A. 2010.

101. Frieboes, H., Cristini, V. Integrated Computational/Experimental Modeling of Cancer. Poster Presentation: Second Annual Univ. of Southern California PS-OC Symposium. Los Angeles, California. 2010.

102. Kumar, A., Chuang, Y., Macklin, P., Sanga, S., Kim, J., Tamaiuolo, G., Cristini, V., Edgerton, M.A model to predict the proliferation index of ductal carcinoma in situ. Proceedings of the 100th AACR Annual Meeting. 50:592. 2010. Cancer Res 69 (9S), 2444, 2009.

103. Edgerton, M., Chuang, Y., Macklin, P., Sanga, S., Kim, J., Tamaiuolo, G., Yang, W., Broom, A., Do, K.,Cristini, V. Using mathematical models to understand the time dependence of the growth of ductal carcinoma in situ. Cancer Research. 62(2):156S. 2009.

104. Thomas C Chen, Sandeep Sanga, Tina Y Chou, Vittorio Cristini, Mary E Edgerton. Neural network with K-means clustering via PCA for gene expression

profile analysis. 2009/3/31 2009 WRI World Congress on Computer Science and Information Engineering 3 670-673 IEEE

105. M Chaplain, P Macklin, Steven Robert McDougall, A Anderson, V Cristini, J Lowengrub. Multiscale modelling of vascular tumour growth. 2009/7 International Conference on Mathematical Biology and Annual Meeting of the Society for Mathematical Biology

106. Edgerton, M., Sanga, S., Downs-Kelley, E., Cristini, V. Does Androgen Receptor Have a Role in a Subgroup of ER Negative Breast Cancer? Lab. Invest. 89:370A. 2009.

107. Edgerton, M., Sanga, S., Downs-Kelley, E., Cristini, V. Cristini. Does Androgen Receptor Have a Role in a Subgroup of ER Negative Breast Cancer? Modern Pathol. 89:370A. 2009.

108. Cristini, V., Bearer, E. Computational modeling identifies morphologic predictors of tumor invasion. The FASEB J. 22(321.7) 2008

109. Cristini, V., Bearer, E. Computational modeling identifies morphologic predictors of tumor invasion. Neuro-oncology. 9(4):512. 2007

110. Li, X., Cristini, V., Nie, Q., Lowengrub, J. Nonlinear three-dimensional simulation of solid tumor growth. Discr. and Contin. Dynam. Syst. Series B. 7(3):581-604. 2007.

111. Trapp, V., Han, E., Cristini, V., Fruehauf, J. Thrombospondin-1 modulation of response to antiangiogenic agents determined in vitro using a melanoma-vascular endothelial cell spheroidal co-culture model. Proceedings of the 98th AACR Annual Meeting. 48:1100. 2007. Cancer Res 67 (9S), 4648, 2007.

112. Cristini, V., Bearer, E. Computational modeling identifies morphologic predictors of tumor invasion. Proceedings of the 98th AACR Annual Meeting. 48:936. 2007. Cancer Res 67 (9S), 3952, 2007.

113. B Badie, EL Bearer, E Bullitt, V Cristini, ZH Cho, VR Edgerton, ...Board of Directors of IBMISPS and IBMISPS-Foundation. NeuroImage 37, S2, 2007

114. V Cristini, H Frieboes, J Fruehauf, Predictive computer simulations of tumor drug response demonstrate that 3-D hypoxic gradients significantly increase drug resistance. Journal of Clinical Oncology 24 (18_suppl), 2071-2071, 2006

115. V Trapp, E Han, V Cristini, JP Fruehauf, The use of vascularized spheroids to evaluate the in vitro activity of antiangiogenic drugs. Cancer Research 66 (8_Supplement), 1202-1202, 2006

116. S Liu, JL Gaudiot, V Cristini, Prototyping virtual cancer therapist (VCT): a software engineering approach. 2006 International Conference of the IEEE Engineering in Medicine, 2006

117. Cristini, V. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulations. Nanomedicine: Nanotechnology, Biology, and Medicine 4 (2), 276, 2006

118. V Cristini, Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles. Journal of Clinical Oncology 23 (16_suppl), 2118-2118, 2005

119. HB Frieboes, ES Han, V Cristini, JP Fruehauf, Modeling breast cancer tumor morphology to predict drug response. Cancer Res 65 (9 Supplement), 1403-1403, 2005

120. S Li, X Li, J Lowengrub, P Leo, V Cristini, Nonlinear crystal growth and control of the Mullins-Sekerka instability. 2004 MRS Fall Meeting, 88-93, 2004

121. X Zheng, V Cristini, J Lowengrub, A Anderson, Adaptive numerical simulation of drop/interface and drop/drop interactions. APS Division of Fluid Dynamics Meeting Abstracts 57, NB. 004, 2004

122. YN Young, F Ham, N Riemer, M Herrmann, V Cristini, Drop Size Distribution in Turbulent Mixing of Two-Phase Flows. APS Division of Fluid Dynamics Meeting Abstracts 57, FJ. 009, 2004

123. V Cristini, P Leo, S Li, X Li, J Lowengrub, Nonlinear Crystal Growth and Control of the Mullins-Sekerka Instability. Materials research society symposium proceedings 859, 88, 2004

124. L Pham, V Cristini, JS Lowengrub, Computer simulations of blood flow. APS Division of Fluid Dynamics Meeting Abstracts 56, AR. 007, 2003

125. S Wise, V Cristini, J Lowengrub, X Zheng, A fluid model of cancer progression and treatment. APS Division of Fluid Dynamics Meeting Abstracts 56, KE. 004, 2003

126. J Lowengrub, V Cristini, The effect of flow on the morphology of growing crystals. APS Division of Fluid Dynamics Meeting Abstracts 56, JQ. 010, 2003

127. J Lowengrub, V Cristini, JS Kim, X Li, J Galloway, C Macosko, Numerical simulation of co-continuous fluids. APS Division of Fluid Dynamics Meeting Abstracts 56, JG. 005, 2003

128. J Lowengrub, V Cristini, JS Kim, X Zheng, Z Mohammed-Kassim, ...Studies of Drop/Drop and Drop/Interface Impact. APS Division of Fluid Dynamics Meeting Abstracts 56, AF. 010, 2003

129. X Zheng, V Cristini, J Lowengrub, T Anderson, An algorithm for adaptive remeshing of 2D and 3D domains: Application to the level-set method. APS Division of Fluid Dynamics Meeting Abstracts 56, KH. 009, 2003

130. V Cristini, J Lowengrub, H Zhou, C Macosko, Numerical simulation of drop breakup and coalescence with soluble. APS Division of Fluid Dynamics Meeting Abstracts 56, AQ. 008, 2003

131. A Anderson, J Lowengrub, C Macosko, V Cristini, An adaptive unstructured tetrahedral mesh. APS Division of Fluid Dynamics Meeting Abstracts 55, JA. 003, 2002

132. X Zheng, J Lowengrub, E Longmire, V Cristini, Adaptive simulations of drop/interface impact and rupture. APS Division of Fluid Dynamics Meeting Abstracts 55, FC. 007, 2002

133. V Cristini, H Zhou, J Lowengrub, C Macosko, The effect of surfactants on drop deformation, collisions and breakup. APS Division of Fluid Dynamics Meeting Abstracts 54, FM. 004, 2001

134. J Lowengrub, V Cristini, JS Kim, C Macosko, Numerical simulation of co-continous emulsions. APS Division of Fluid Dynamics Meeting Abstracts 54, KA. 012, 2001

135. V Cristini, J Lowengrub, Q Nie, Self-similar tumor growth with angiogenesis. APS Meeting Abstracts 46, C2. 005, 2001

136. V Cristini, R Hooper, J Lowengrub, S Shakya, Three-dimensional multiphase flows. APS Division of Fluid Dynamics Meeting Abstracts 53, ML. 009, 2000

137. Y Renardy, V Cristini, Numerical simulations of a drop under simple shear. APS Division of Fluid Dynamics Meeting Abstracts 53, MM. 004, 2000

138. X Zheng, V Cristini, J Lowengrub, Adaptive mesh simulations of very viscous multi-component flows. APS Division of Fluid Dynamics Meeting Abstracts 53, GP. 002, 2000

139. J Blawzdziewicz, V Cristini, M Loewenberg, Near-critical behavior and critical conditions for drop breakup in linear flows with rotation. APS Division of Fluid Dynamics Meeting Abstracts, FK. 02, 1999

140. J Blawzdziewicz, V Cristini, M Loewenberg, Surfactant-covered constant-shape interfaces. APS Division of Fluid Dynamics Meeting Abstracts, LJ. 04, 1998

141. J Blawzdziewicz, V Cristini, M Loewenberg, Critical conditions for drop breakup in linear flows. APS Division of Fluid Dynamics Meeting Abstracts, JA. 07, 1998

142. J Blawzdziewicz, V Cristini, M Loewenberg, LR Collins Direct numerical simulation of three-dimensional drop breakup in isotropic turbulence. Microgravity Fluid Physics & Transport Phenomena Conference, 4 th, Cleveland …, 1998 5

143. J Blawzdziewicz, V Cristini, M Loewenberg, Analysis of drop breakup in creeping flows. APS Division of Fluid Dynamics Meeting Abstracts, Af. 07, 1997

Refereed Original Articles in Journals

1. Messina L, Ferraro R, Peláez MJ, Wang, Z, Cristini, V, Dogra, P, Caserta, S. Hybrid Cellular Automata Modeling Reveals the Effects of Glucose Gradients on Tumour Spheroid Growth. Cancers. 2023, 15, 5660. doi: 10.3390/cancers15235660. PMC10705082

2. Migliaccio G, Ferraro R, Wang Z, Cristini V, Dogra P, Caserta S. Cellular Automata Modelling Reveals Dynamics of Wound Healing Assay. Cancers. 2023 Nov 3;15(21). doi: 10.3390/cancers15215284. PMC10647277

3. Staquicini DI, Cardó-Vila M, Rotolo JA, Staquicini FI, Tang FHF, Smith TL, Ganju A, Schiavone C, Dogra P, Wang Z, Cristini V, Giordano RJ, Ozawa MG, Driessen WHP, Proneth B, Souza GR, Brinker LM, Noureddine A, Snider AJ, Canals D, Gelovani JG, Petrache I, Tuder RM, Obeid LM, Hannun YA, Kolesnick RN, Brinker CJ, Pasqualini R, Arap W. Ceramide as an endothelial cell surface receptor and a lung-specific lipid vascular target for circulating ligands. Proc Natl Acad Sci U S A. 2023 120(34):e2220269120. doi: 10.1073/pnas.2220269120. PMID: 37579172

4. Dogra P, Schiavone C, Wang Z, Ruiz-Ramírez J, Caserta S, Staquicini DI, Markosian C, Wang J, Sostman HD, Pasqualini R, Arap W, Cristini V. A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection. JCI Insight. 2023 8(13):e169860. doi: 10.1172/jci.insight.169860. PMC10371350

5. Sarkar S, Mishra A, Periasamy S, Dyett B, Dogra P, Ball AS, Yeo LY, White JF, Wang Z, Cristini V, Jagannath C, Khan A, Soni SK, Drummond CJ, Conn CE. Prospective Subunit Nanovaccine against Mycobacterium tuberculosis Infection-Cubosome Lipid Nanocarriers of Cord Factor, Trehalose 6,6' Dimycolate. ACS Appl Mater Interfaces. 2023 15(23):27670-27686. doi: 10.1021/acsami.3c04063. Epub 2023 Jun 1. PMID: 37262346

6. Butner JD, Dogra P, Chung C, Pasqualini R, Arap W, Lowengrub J, Cristini V, Wang Z. Mathematical Modeling of Cancer Immunotherapy for Personalized Clinical Translation. Nature Computational Science 2, 785–796 (2022 Dec). https://doi.org/10.1038/s43588-022-00377-z

7. J.D. Butner, M. Farhat, V. Cristini, C. Chung, and Z. Wang, Protocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy. STAR Protocols, 2022 Dec. 3(4): p. 101886.

8. Terracciano R, Carcamo-Bahena Y, Royal ALR, Messina L, Delk J, Butler EB, Demarchi D, Grattoni A, Wang Z, Cristini V, Dogra P, Filgueira CS. Zonal Intratumoral Delivery of Nanoparticles Guided by Surface Functionalization. Langmuir. 2022 Nov 1;. doi:10.1021/acs.langmuir.2c02319. PubMed PMID: 36318182.

9. Syed M, Cagely M, Dogra P, Butner JD, Cristini V, Koay EJ. Immune-checkpoint inhibitor therapy response evaluation using oncophysics-based mathematical models. WIREs Nanomedicine and Nanobiotechnology 2022 Sep 23;:e1855. doi: 10.1002/wnan.1855. [Epub ahead of print] Review. PubMed PMID: 36148978.

10. Capuani S, Hernandez N, Paez-Mayorga J, Dogra P, Wang Z, Cristini V, Chua CYX, Nichols JE, Grattoni A. Localization of drug biodistribution in a 3D-bioengineered subcutaneous neovascularized microenvironment. Materials Today Bio. 2022 Dec;16:100390. doi: 10.1016/j.mtbio.2022.100390. eCollection 2022 Dec. PubMed PMID: 36033374; PubMed Central PMCID: PMC9403502.

11. Puri A., Tijani A, Dogra P, Peláez MJ, Wang Z, Cristini V, Mechanistic modeling-guided optimization of microneedle-based skin patch for rapid transdermal delivery of naloxone for opioid overdose treatment. Drug Deliv Transl Res. 2022 Jul 25;. doi: 10.1007/s13346-022-01202-w. [Epub ahead of print] PubMed PMID: 35879533.

12. Butner JD, Dogra P, Chung C, Ruiz-Ramírez J, Nizzero S, Plodinec M, Li X, Pan PY, Chen SH, Cristini V, Ozpolat B, Calin GA, Wang Z. Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study. Cell Death Dis. 2022 May 21;13(5):485. doi: 10.1038/s41419-022-04939-x. PubMed PMID: 35597788; PubMed Central PMCID: PMC9124196.

13. Wang, C.X., D. Elganainy, M.M. Zaid, J.D. Butner, A. Agrawal, S. Nizzero, B.D. Minsky, E.B. Holliday, C.M. Taniguchi, G.L. Smith, A.C. Koong, J.M. Herman, P. Das, A. Maitra, H. Wang, R.A. Wolff, M.H. Katz, C.H. Crane, V. Cristini, and E.J. Koay, Mass transport model of radiation response: calibration and application to chemoradiation for pancreatic cancer. Int J Radiat Oncol Biol Phys, 2022. PMID 35643254.

14. Markosian C, Staquicini DI, Dogra P, Dodero-Rojas E, Lubin JH, Tang FHF, Smith TL, Contessoto VG, Libutti SK, Wang Z, Cristini V, Khare SD, Whitford PC, Burley SK, Onuchic JN, Pasqualini R, Arap W. Genetic and Structural Analysis of SARS-CoV-2 Spike Protein for Universal Epitope Selection. Mol Biol Evol. 2022 May 3;39(5). doi: 10.1093/molbev/msac091. PubMed PMID: 35511693.

15. AO Kaseb, E Hasanov, HST Cao, L Xiao, JN Vauthey… Cristini V, J Allison, P Sharma, Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. The Lancet Gastroenterology & Hepatology, 7(3), 208-218, 2022

16. Ferraro R, Ascione F, Dogra P, Cristini V, Guido S, Caserta S. (2022), Diffusion-induced anisotropic cancer invasion: a novel experimental method based on tumour spheroids. AIChE J. e17658. doi: 10.1002/aic.17678

17. Dogra P, Ramírez JR, Butner JD, Peláez MJ, Chung C, Hooda-Nehra A, Pasqualini R, Arap W, Cristini V, Calin GA, Ozpolat B, Wang Z. Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer. Pharm Res. 2022 Mar 16;. doi: 10.1007/s11095-022-03176-3. [Epub ahead of print] PubMed PMID: 35294699.

18. Butner JD, Martin GV, Wang Z, Corradetti B, Ferrari M, Esnaola N, Chung C, Hong DS, Welsh JW, Hasegawa N, Mittendorf EA, Curley SA, Chen SH, Pan PY, Libutti SK, Ganesan S, Sidman RL, Pasqualini R, Arap W, Koay EJ, Cristini V. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. ELife. 2021 Nov 9;10:e70130. doi: 10.7554/eLife.70130. PMID: 34749885. PMC8629426

19. Gok Yavuz B, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, Cristini V, Kaseb AO. J Hepatocell Carcinoma. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021 Sep 24;8:1195-1207. doi: 10.2147/JHC.S322289. PMC8478438

20. FI Staquicini, RL Zemans, BK Dray, M Cardo-Vila, J Ruiz-Ramirez, P Dogra, Z Wang, V Cristini, DI Staquicini, RL Sidman, R Pasqualini, W Arap. Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer. ELife. 2021;10:e65145. doi: 10.7554/eLife.65145. PMID: 34060472. PMC8169110

21. P Dogra, EJ Koay, Z Wang, FS Vahidy, M Ferrari, R Pasqualini, W Arap, ML Boom, HD Sostman, V Cristini. Is the worst of the COVID-19 global pandemic yet to come? Application of financial mathematics as candidate predictive tool. Translational Psychiatry. 2021;11(1):299. doi: 10.1038/s41398-021-01429-0. PMID: 34016952. PMC8134815

22. P Amero, GLR Lokesh, R Cardenas-Zuniga, RR Chaudhari, YM Attia, E Montalvo-Gonzalez, Z Wang, V Cristini, V de Franciscis, S Zhang, DE Volk, R Mitra, Cristian Rodriguez-Aguayo, AK Sood, G Lopez-Berestein. Translation of RNA aptamer into modified DNA aptamers provide for prolonged stability and enhanced antitumor activity. Journal of the American Chemical Society. 2021;143(20):7655-7670. doi: 10.1021/jacs.9b10460. PMID: 33988982

23. Corradetti B, Dogra P, Pisano S, Wang Z, Ferrari M, Chen S-H, Sidman RL, Pasqualini R, Arap W, Cristini V. Comparing and Contrasting Amphibian Tissue Regeneration to Mammalian Cancer: An Evolutionary Perspective. BioEssays. 2021. e2000339. doi: 10.1002/bies.202000339. PMID: 33751590

24. D Anaya, P Dogra, Z Wang, M Haider, J Ehab, D Jeong, M Ghayouri, R Kim, JB Fleming, V Cristini. Chemotherapy Concentration at the Tumor Site Predicts Response to Chemotherapy in Patients with Liver Metastasis: Application of a Mechanistic Mathematical Model. Cancers. 2021; 13(3):444. doi: 10.3390/cancers13030444. PMC7866038

25. Carlos El-Tallawi, Kitkungvan D, Xu J, Cristini V, Yang EY, Quinones MA, Lawrie GM, Zoghbi WA, and Shah DJ. Resolving the Disproportionate Left Ventricular Enlargement in Mitral Valve Prolapse Due to Barlow Disease: Insights from Cardiovascular Magnetic Resonance. JACC: Cardiovascular Imaging. 2021 Mar;14(3):573-584. doi: 10.1016/j.jcmg.2020.08.029. PMID: 33129724

26. Dogra P, Ruiz-Ramírez J, Sinha K, Butner JD, Peláez MJ, Rawat M, Yellepeddi VK, Pasqualini R, Arap W, Sostman HD, Cristini V, Wang Z. Innate immunity plays a key role in controlling viral load in COVID-19: mechanistic insights from a whole-body infection dynamics model. ACS Pharmacology & Translational Science. 2021; 4: 248-265. DOI: 10.1021/acsptsci.0c00183. PMCID: PMC7805603

27. A Gorur, R Bayraktar, C Ivan, P Kanlikilicer, N Kahraman, E Bayraktar, HA Mokhlis,N Kabil, C Rodriguez, L Tamer, B Aslan, Z Wang, V Cristini, G Calin, G Lopez-Berestein, B Ozpolat. ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Molecular Therapy Nucleic Acids. 2021 Jan 20;23:930-943. doi: 10.1016/j.omtn.2021.01.016. PMC7868999

28. M Zaid, D Elganainy, P Dogra, A Dai, L Widmann, P Fernandes, Z Wang, MJ Pelaez, JR Ramirez, AD Singhi, AK Dasyam, RE Brand, WG Park, S Rahmanuddin, MH Rosenthal, BM Wolpin, N Khalaf, A Goel, DD Von Hoff, EP Tamm, A Maitra, V Cristini, EJ Koay. Imaging-based subtypes of pancreatic ductal adenocarcinoma exhibit differential growth and metabolic patterns in the pre-diagnostic period: implications for early detection. Frontiers in Oncology. 2020; 10:596931. DOI: 10.3389/fonc.2020.596931. PMC7738633

29. G Brachi, J Ruiz-Ramirez, P Dogra, Z Wang, V Cristini, R Rostomily, G Ciardelli, M Ferrari, A Mikheev, E Blanco, C Mattu. Intratumoral injection of hydrogel-embedded nanoparticles enhances retention in glioblastoma. Nanoscale. 2020; 12(46):23838-23850. DOI: 10.1039/d0nr05053a. PMID: 33237080

30. DI Staquicini, EM Barbu, RL Zemans, BK Dray, FI Staquicini, P Dogra, M Cardó-Vila, CK Miranti, WB Baze, LL Villa, J Kalil, G Sharma, ER Prossnitz, Z Wang, V Cristini, RL Sidman, AR Berman, RA Panettieri Jr, RM Tuder, R Pasqualini, W Arap. Targeted Phage Display-based Pulmonary Vaccination in Mice and Non-human Primates. Cell Med. 2021; 2(3):321-342. 10.1016/j.medj.2020.10.005

31. JD Butner, Z Wang, D Elganainy, KA Feghali, M Plodinec, GA Calin, P Dogra, S Nizzero, J Ruiz Ramirez, GV Martin, HA Tawbi, C Chung, EJ Koay, JW Welsh, DS Hong, V Cristini, A mechanistic immunotherapy model provides patient-specific quantification of immune response and associated long-term tumor burden. Nature Biomedical Engineering. 2021; 5(4):297-308. 10.1038/s41551-020-00662-0.

32. E Simbawa, S Alharbi, J Aljohani, H Abosamra, S Aboushoushah, Cristini V, Mathematical model of immunotherapy response to antibodies as a treatment for cancer. Commun. Math. Biol. Neurosci. 2020, Article ID 23, 2020

33. S Goel, G Zhang, P Dogra, S Nizzero, J Gu, V Cristini, Z Wang, Z Li, X Liu, H Shen, M Ferrari. Sequential deconstruction of composite drug transport in metastatic breast cancer. Science Advances. 2020; 6(26):eaba4498. doi: 10.1126/sciadv.aba4498. PMC7314527

34. Butner JD, Fuentes D, Ozpolat B, George CA, Zhou X, John J, Cristini V, Wang Z. A Multiscale Agent-Based Model of Ductal Carcinoma in Situ. IEEE Trans Biomed Eng. 2020 May;67(5):1450-1461. PMID: 31603768

35. JD Butner, D Elganainy, CX Wang, Z Wang, S-H Chen, NF Esnaola, R Pasqualini, W Arap, DS Hong, J Welsh, EJ Koay, V Cristini, Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. Science Advances. 2020; 6(18):eaay6298. PMC7190324

36. Dogra P, Butner J, Ruiz-Ramirez J, Pelaez MJ, CJ Brinker, Cristini V, Wang Z. A Mathematical Model to Predict Nanomedicine Pharmacokinetics and Tumor Delivery. Computational and Structural Biotechnology Journal. 2020;18:518-531. PMC7078505

37. Dogra P, Ruiz-Ramirez J, Butner J, Nizzero S, Elganainy D, Pelaez MJ, Noureddine A, Le A-D, Koay E, Leong H-S, CJ Brinker, Cristini V, Wang Z. Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies. WIREs Nanomedicine and Nanobiotechnology. 2020. Apr 21;e1628. PMID: 32314552

38. Pichler M, Rodriguez-Aguayo C, Nam SY, Anfossi S, Knutsen E, Fuentes-Mattei E, Lee SK, Ling H, Ivkovic TC, Huang G, Huang L, Okugawa Y, Bayraktar E, Bhattacharya R, Paola A, Vychytilova-Faltejskova P, Klec C, Escobar DB, Zhang X, Kapitanovic S, Bozo L, Gafà R, Wang Z, Cristini V, Ivan C, Bar-Eli M, Lanza G, Slaby O, Goel A, Rigoutsos I, Lopez-Berestein G, Calin GA. FLANC, a novel primate-specific long non-coding RNA, is involved in colorectal carcinogenesis and holds potential as a novel therapeutic target. Gut. 2020. pii: gutjnl-2019-318903. doi: 10.1136/gutjnl-2019-318903. PMID: 31988194

39. Dogra P, Ramírez JR, Pelaez MJ, Wang Z, Cristini V, Parasher G, Rawat M. Mathematical Modeling of Pancreatic Cancer: Applications in Diagnosis, Prognosis, and Treatment. Current topics in medicinal chemistry. 2020;20(5):367-376.. doi: 10.2174/1568026620666200101095641. PMID: 31893993

40. OD Lara, S Krishnan, Z Wang, S Corvigno, Y Lyons, R Dood, W Hu, L Qi, J Liu, RL Coleman, SN Westin, N Fleming, V Cristini, A Rao, J Burks, AK Sood. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Scientific Reports. 2019; 9(1):17589. doi: 10.1038/s41598-019-53872-1. PMC6879510

41. S Goel, C Ferreira, P Dogra, B Yu, C Kutyreff, C Siamof, J Engle, T Barnhart, V Cristini, Z Wang, W Cai. Size-optimized Ultrasmall Porous Silica Nanoparticles Depict Vasculature-based Differential Targeting in Triple Negative Breast Cancer/Tumor Targeting. Small. 2019;e1903747. 10.1002/smll.201903747. PMC6854296

42. Brocato TA, Glaberman-Brown U, Wang Z, Selwyn RG, Wilson CM, Wyckoff EF, Lomo L, Saline J, Hooda-Nehra, A, Pasqualini R, Arap W, Brinker CJ, Cristini V. Predicting breast cancer response to neoadjuvant chemotherapy based on tumor vascular features in needle biopsies. JCI Insight. 2019;4(8):e126518. PMC6538356

43. Dogra P, Butner JD, Chuang YL, Caserta S, Goel S, Brinker CJ, Cristini V, Wang Z. Mathematical modeling in cancer nanomedicine: a review. Biomed Microdevices. 2019 21(2):40 [PMC6449316] (Invited)

44. Dogra P, Adolphi NL, Wang Z, Lin YS, Butler KS, Durfee PN, Croissant JG, Noureddine A, Coker EN, Bearer EL, Cristini V**, Brinker CJ**. Establishing the effects of mesoporous silica nanoparticle size and surface chemistry on in vivo disposition using imaging-based pharmacokinetics. Nature Communications. 2018 Oct 31;9(1):4551. doi: 10.1038/s41467-018-06730-z.PubMed PMID: 30382084; PubMed Central PMCID: PMC6208419. (**Co-senior Authors).

45. TA Brocato, EN Coker, PN Durfee, Y-S Lin, J Townson, EF Wyckoff, V Cristini, CJ Brinker, Z Wang. Understanding the Connection between Nanoparticle Uptake and Cancer Treatment Efficacy using Mathematical Modeling. Scientific Reports 2018. 8(1):7538. PMC5967303

46. Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB: A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-5894, 2018

47. Butner, J.D., Chuang, Y-L., Simbawa, E., AL-Fhaid, A.S., Mahmoud, S.R., Cristini, V., Wang, Z. (2016). A hybrid agent-based model of the developing mammary terminal end bud. Journal of Theoretical Biology. 407:259-270. [PMC5010453].

48. Wang, Z., Kerketta, R., Chuang, Y.L., Dogra, P., Butner, J.D., Brocato, T.A., Day, A., Xu, R., Shen, H., Simbawa, E., Al-Fhaid, A.S., Mahmoud, S.R., Curley, S.A., Ferrari, M., Koay, E.J., Cristini, V. (2016). Theory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell Kill. PLoS Comput Biol. 10;12(6):e1004969. [PMC4902302]

49. Paine, I., Chauviere, A., Landua, J., Sreekumar, A., Cristini, V., Rosen, J., Lewis, M.T. (2016). A Geometrically-Constrained Mathematical Model of Mammary Gland Ductal Elongation Reveals Novel Cellular Dynamics within the Terminal End Bud. PLoS Comput Biol. 26;12(4):e1004839. [PMC4845990]

50. Hosoya, H., Dobroff, A.S., Driessen W.H., Cristini V., Brinker L.M., Staquicini, F.I., Cardó-Vila, M., D'Angelo, S., Ferrara, F., Proneth, B., Lin, Y.S., Dunphy, D.R., Dogra, P., Melancon, M.P., Stafford, R.J., Miyazono, K., Gelovani, J.G., Kataoka, K., Brinker, C.J., Sidman, R.L., Arap, W., Pasqualini, R.(2016). Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Proc Natl Acad Sci U S A. 2016. 16;113(7):1877-82. [PMC4763738]

51. Frieboes, H.B., Smith, B.R., Wang, Z., Kotsuma, M., Ito, K., Day, A., Cahill, B., Flinders, C., Mumenthaler, S.M., Mallick, P., Simbawa, E., Al-Fhaid, A.S., Mahmoud, S.R., Gambhir, S.S., Cristini, V. (2015). Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma. PloS one. 10:e0129433. [PMC4464754]

52. Wang, Z.,Butner, J., Kerketta, R., Cristini, V., Deisboeck, T.S. (2015). Simulating cancer growth with multiscale agent-based modeling. Seminars in Cancer Biology 30:70-78. [PMC4216775] (Invited)

53. Kirui, D.K., Koay, E.J., Guo, X., Cristini, V., Shen, H., Ferrari, M. (2014). Tumor vascular permeabilization using localized mild hyperthermia to improve macromolecule transport. Nanomedicine: Nanotechnology, Biology and Medicine 2014 10(7):1487-96. [PMC4025989]

54. Koay, E., Truty, M., Cristini**, V., et al. (2014). Transport properties of pancreatic cancer describe gemcitabine delivery and response. J. Clinical Investigation 124(4):1525-1536. [PMC3973100] (** co-first author)

55. Wu, M., Frieboes, H.B., S.R., Chaplain, M.A.J., Cristini, V., Lowengrub, J.S. (2014).The effect of interstitial pressure on therapeutic agent transport: coupling with the tumor blood and lymphatic vascular systems. J Theor Biol. 355:194-207.

56. Koay, E.J., Baio, F.E., Ondari, A., Truty, M.J., Cristini, V., Thomas, R.M., Chen, R., Chatterjee, D., Kang, Y., Zhang, J., Court, L., Bhosale, P.R., Tamm, E.P., Qayyum, A., Crane, C.H., Javle, M., Katz, M.H., Gottumukkala, V.N., Rozner, M.A., Shen, H., Lee, J.E., Wang, H., Chen, Y., Plunkett, W., Abbruzzese, J.L., Wolff, R.A., Maitra, A., Ferrari, M., Varadhachary, G.R., JB Fleming. (2014). Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Physical biology. 11:065002. [PMC4266401]

57. Brocato, T., Dogra, P., Koay, E.J., Day, A., Chuang, Y-L., Wang, Z., Cristini, V. Understanding Drug Resistance in Breast Cancer with Mathematical Oncology. Current Breast Cancer Reports 2014 6(2): 110-120. [PMC4039558] (Invited)

58. Tang, L., Van de Ven, A.L., Guo, D., Cristini, V., Li, K.C., Zhou, X. (2014) Computational Modeling of 3D Tumor Growth and Angiogenesis for Chemotherapy Evaluation. PLoS One. 9(1):e83962 [PMC3880288]

59. Wang, Z., Butner, J.D., Cristini, V., Deisboeck, T.S. (2014). Integrated PK-PD and agent-based modeling in oncology. J Pharmacokinetics and Pharmacodynamics. 42:179-189. [PMID: 25588379]

60. Wang, Z., Deisboeck, T.S., Cristini, V. (2014). Development of a sampling-based global sensitivity analysis workflow for multiscale computational cancer models. IET Systems Biology 8(5):191-7. [PMC4180114]

61. Das, H., Wang Z., Niazi, K., Aggarwal, R., Lu, J., Kanji, S., Das, M., Joseph, M., Gurcan, M., Cristini, V. (2013) Impact of Diffusion Barriers to Small Cytotoxic Molecules on the Efficacy of Immunotherapy in Breast Cancer. PloS One. 8:e61398. [PMC3631240]

62. Pascal, J., Bearer, E.L., Wang, Z., Koay, E.J., Curley, S.A., Cristini, V. (2013). Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements. Proc. Natl. Acad. Sci. USA. 110: 14266-14271. [PMC3761643]

63. Pascal, J. Ashley, C.E.,Wang, Z., Brocato, T.A., Butner, J., Carnes, E.C., Koay, E.J., Brinker, C.J., Cristini, V. (2013). Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nanocarrier-mediated response. ACS Nano. 7(12): 11174-11182. [PMC3891887]

64. Wu, M., Frieboes, H.B., McDougall, S.R., Chaplain, M.A.J., Cristini, V., Lowengrub, J.S. (2013).The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. J Theor Biol. 320:131-151. [PMC3576147]

65. Frieboes, H.B., Wu, M., Lowengrub, J., Decuzzi, P., Cristini, V. (2013). A computational model for predicting nanoparticle accumulation in tumor vasculature. PloS One. 8:e56876. [PMC3585411]

66. Frieboes, H.B., Smith, B.R., Chuang, Y.L., Ito. K., Roettgers, A.M, Gambhir, S.S., Cristini, V. (2013). An integrated computational/experimental model of lymphoma growth. PLoS Computational Biology. 9:e1003008. [PMC3610621]

67. Hatzikirou, H., Chauviere, A., Bauer, A., Leier, A., Lewis, M., Macklin, P., Marquez-Lago, T, Bearer, E., Cristini, V. (2012) Integrative Physical Oncology. WIREs Syst. Biol. Med. 4(1): 1-14. [PMC3622087]

68. Macklin, P., Edgerton, M.E., Thompson, A.M., Cristini, V. (2012) Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): From microscopic measurements to macroscopic predictions of clinical progression. J. Theor. Biol. 301:122-40. [PMC3322268]

69. Seamster, P.E., Loewenberg, M., Pascal, J., Chauviere, A., Gonzales, A., Cristini, V., Bearer, E. (2012). Quantitative measurements and modeling of cargo-motor interactions during fast transport in the living axon. Phys Biol. 9:055005. [PMC3625656]

70. Pham, K., Chauviere, A., Hatzikirou, H., Li, X., Byrne, H.M., Cristini, V., Lowengrub, J. (2012). Density-dependent quiescence in glioma invasion: instability in a simple reaction-diffusion model for the migration/proliferation dichotomy. Journal of Biological Dynamics. 6 Suppl 1:54-71. [PMC3623708]

71. Chauviere, A., Hatzikirou, H., Kevrekidis, I.G., Lowengrub, J.S., Cristini, V. (2012). Dynamic density functional theory of solid tumor growth: Preliminary Models. AIP Advances 2, 011210, special topic on Physics of Cancer [PMC3321520]

72. Van de Ven, A., Wu, M. Lowengrub, J.S., McDougall, S.R., Chaplain, M.A.J., Cristini, V., Ferrari, M., Frieboes, H.B. (2012). Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Advances, 2:011208, special topic on Physics of Cancer. [PMC3321519]

73. Deisboeck, T., Wang, Z., Macklin, P.,Cristini, V. (2011). Multiscale Cancer Modeling. Annual Review of Biomedical Engineering.13(1):127-155. [PMC3883359]

74. Pham, K., Frieboes, H., Cristini, V., Lowengrub, J. (2011). Predictions of tumour morphological stability and evaluation against experimental observations. J R Soc Interface. 8(54): 16-29. [PMC3024820]

75. Edgerton, M., Chuang, Y.-L., Macklin, P., Yang, W. , Bearer, E. L., Cristini, V. (2011). A Novel, Patient-Specific Mathematical Pathology Approach For Assessment Of Surgical Volume: Application To Ductal Carcinoma In Situ Of The Breast. Anal. Cell. Pathol. 34(5):247-63. [PMC3613121]

76. Lowengrub, J., Frieboes, H., Jin, F., Chuang, Y.-L., Li, X., Macklin, P., Wise, S., Cristini, V. (2010). Nonlinear modeling of cancer: Bridging the gap between cells and tumors. Nonlinearity. 23:R1-R91.

77. Frieboes, H.B., Jin, F., Chuang, Y.L., Wise, S.M., Lowengrub, J.S., Cristini, V. (2010). Three-Dimensional Multispecies Nonlinear Tumor Growth II: Tumor Invasion and Angiogenesis. J. Theor. Biol. 264(4):1254-78.

78. De Magalhaes, N., Liaw, L., Berns, M., Cristini, V., Chen, Z., Stupack, D., Lowengrub, D. (2010). Applications of a new In vivo tumor spheroid based shell-less chorioallantoic membrane 3-D model in bioengineering research. J Biomed Sci Eng. 3(1): 20-26.

79. Chauviere, A., Hatzikirou, H., Lowengrub, J., Frieboes, H., Thompson, A., Cristini, V. (2010). Mathematical Oncology: How Are the Mathematical and Physical Sciences Contributing to the War on Breast Cancer?. Curr Breast Cancer Rep. 2(3): 121-129.

80. Frieboes, H., Chaplain, M.A.J., Thompson, A., Bearer, E. L., Lowengrub, J., Cristini, V. (2011). Physical oncology: a bench-to-bedside quantitative and predictive approach. Cancer Research. 71(2): 298-302.

81. SM Wise, JS Lowengrub, V Cristini. An adaptive multigrid algorithm for simulating solid tumor growth using mixture models. Mathematical and Computer Modelling 53 (1-2), 1-20, 2011

82. Bearer, E.L., Lowengrub, J.S., Chuang, Y.-L., Hermann, B., Frieboes, H.B., Jin, F., Wise, S.M., Ferrari, M., Agus, D., Cristini, V. (2009) Multiparameter Computational Modeling of Tumor Invasion. Cancer Research. 69: 4493-4501.

83. Frieboes, H. B., Edgerton, M.E., Fruehauf, J. P., Rose, F.R.A.J., Worrall, L. K. R., Gatenby, A., Ferrari, M., Cristini, V. Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Research. 69: 4484-4492. 2009

84. Sinek, J., Sanga, S., Zheng, X., Ferrari, M., Cristini, V. (2009). Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulations. Journal of Mathematical Biology. 58(4-5):485-510. (Invited)

85. Macklin, P., McDougall, S., Anderson, A.R.A., Chaplain, M.A.J., Cristini, V., Lowengrub, J. (2009). Multiscale modeling and nonlinear simulation of vascular tumour growth, Journal of Mathematical Biology. 58(4-5):765-98.

86. Cristini, V., Li, X., Lowengrub, J.S., Wise, S.M. (2009) Nonlinear simulations of solid tumor growth using a mixture model: invasion and branching. Journal of Mathematical Biology. 58(4-5):723-63.

87. Sanga, S., Broom, B.M., Cristini, V., Edgerton, M.E. (2009). Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Medical Genomics. 2:59.

88. Wise, S.M., Lowengrub, J., Frieboes, H.B., Cristini, V. (2008). Three-dimensional multispecies nonlinear tumor growth—I Model and numerical method. J Theor Biology. 253(3):524-43.

89. Young, Y.-N., Blawzdziewicz, J., Cristini, V., Goodman, R. (2008). Hysteretic and chaotic dynamics of viscous drops in creeping flows with rotation. Journal of Fluid Mechanics. 607:209-34.

90. Lemaire, J.J., Coste, J., Ouchchane, L., Caire, F., Nuti, C., Derost, P., Cristini, V., Gabrillargues, J., Hemm, S., Durif, F., Chazal, J., (2007). Brain Mapping in Stereotactic Surgery: A Brief Overview From the Probabilistic Targeting To the Patient-Based Anatomic Mapping. NeuroImage; 37, S 1. S109-S115 (review).

91. Frieboes, H., Lowengrub, J., Wise, S., Zheng, X., Bearer, E., Cristini, V. (2007). Computer simulation of glioma growth and morphology. NeuroImage; 37, S 1. S59-S70.

92. Sanga, S., Frieboes,H., Zheng, X., Gatenby, R., Bearer, E., Cristini, V. (2007) Predictive oncology: a review of multidisciplinary, multiscale in-silico models connecting phenotype, morphology and growth. NeuroImage; 37, S 1. S120-S134 (invited review).

93. Li, X, Cristini, V., Nie, Q., Lowengrub, J. (2007). Nonlinear three-dimensional simulation of solid tumor growth. Discrete and Continuous Dynamical Systems B. 7(3):581-604. (invited)

94. Frieboes, H., Zheng, X., Sun, C.-H., Tromberg, B., Gatenby, R., Cristini, V. (2006). An integrated computational/experimental model of tumor invasion. Cancer Research. 66(3):1597-604.

95. Madsen, S. J., Sun, C.-H., Tromberg, B. J., Cristini, V., DeMagalhaes, N., Hirschberg, H. (2006). Multicell tumor spheroids in photodynamic therapy. Lasers in Surgery and Medicine. 38(5):555-64 (review).

96. Sanga, S., Sinek, J., Frieboes, H., Ferrari, M., Fruehauf, J., Cristini, V. (2006). Mathematical modeling of cancer progression and response to chemotherapy: towards the development of a multiscale computer simulator. Expert Review of Anticancer Therapy. 6(10):1361-76.

97. Tan, Y.-C., Cristini, V., Lee, A. P. (2006). Monodispersed microfluidic droplet generation by shear focusing microfluidic device. Sensors & Actuators B: Chemical 2006;114(1):350-6.

98. Cristini, V., Renardy, Y. (2006). Scalings for droplet sizes in shear-driven breakup: non-microfluidic ways to monodisperse emulsions. Fluid Dynamics and Materials Processing. 2(2):77-94 (invited review).

99. Dunn, J. C. Y. , Chan, W. Y., Cristini, V., Kim, J. S., Lowengrub, J.,Singh, S., Wu, B. M. (2006). Analysis of cell growth in three-dimensional scaffolds. Tissue Engineering. 12(4):705-16.

100. Sibillo, V., Pasquariello, G., Simeone, M., V. Cristini, V., Guido, S. (2006). Drop deformation in microconfined shear flow. Physical Review Letters. 97:054502.

101. Yang, X., James, A.J., Lowengrub, J., Zheng, X., Cristini, V. (2006). An adaptive coupled level-set/volume-of-fluid interface capturing method for unstructured triangular grids. J. of Computational Physics 2006;217(2): 364-394.

102. Cristini, V., Frieboes, H., Gatenby, R., Caserta, S., Ferrari, M., Sinek, J. (2005). Morphological instability and cancer invasion. Clinical Cancer Research. 11(19):6772-9.

103. S Li, JS Lowengrub, PH Leo, V Cristini. Nonlinear stability analysis of self-similar crystal growth: control of the Mullins–Sekerka instability. Journal of Crystal Growth 277 (1-4), 578-592, 2005

104. Zheng, X., Wise, S., Cristini, V. (2005). Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method. Bulletin of Math Biology. 67(2):211-59.

105. Cristini, V., Kassab, G.S. (2005). Computer modeling of red blood cell rheology in the microcirculation: A brief overview. Annals of Biomedical Engineering. 33(12):1724-7 (invited review).

106. A Anderson, X Zheng, V Cristini. Adaptive unstructured volume remeshing–I: The method. Journal of Computational Physics 208 (2), 616-625, 2005

107. X Zheng, J Lowengrub, A Anderson, V Cristini. Adaptive unstructured volume remeshing–II: Application to two-and three-dimensional level-set simulations of multiphase flow. Journal of Computational Physics 208 (2), 626-650, 2005

108. Xie, F., Sheu, P., Lander, A., Cristini, V. (2005). Semantic Analysis and Synthesis of Complex Biological Systems. International J. of Software Engineering and Knowledge Engineering. 15(3):547-69.

109. Sinek, J., Frieboes, H., Zheng, X., Cristini, V. (2004). Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles. Biomed Microdev. 6(4):297-309 (invited).

110. Tan, Y.-C., Fisher, J.S., Lee, A.I., Cristini, V., Lee, A.P. (2004). Design of Microfluidic Channel Geometries for the Control of Droplet Volume, Chemical Concentration, and Sorting. Lab on a Chip. 4(4):292-8.

111. Cristini, V., Tan, Y.-C. (2004). Theory and numerical simulation of droplet dynamics in complex flows-A review. Lab on a Chip. 4(4):257-64 (invited review).

112. Cristini, V., Lowengrub, J. (2004). Three-dimensional crystal growth-II: Nonlinear simulation and control of the Mullins-Sekerka instability. Journal of Crystal Growth. 266(4):552-67.

113. Li, S., Leo, P., Lowengrub, J., Cristini, V. (2004). Nonlinear theory of self-similar crystal growth and melting. Journal of Crystal Growth. 267(3-4):703-13.

114. Cristini, V., Lowengrub, J., Nie, Q. (2003). Nonlinear simulation of tumor growth. Journal of Mathematical Biology. 46(3):191-224.

115. Khismatullin, D., Renardy, Y., Cristini, V. (2003). Inertia-induced breakup of highly viscous drops subjected to simple shear. Physics of Fluids. 15(5):1351-4.

116. Patel, P., Shaqfeh, E., Butler, J.E., Cristini, V., Blawzdziewicz, J., Loewenberg, M. (2003). Drop breakup in the flow through fixed fiber beds: An experimental and computational investigation. Physics of Fluids. 15(5):1146-57.

117. V. Cristini, V., Guido,S., Alfani, A., Blawzdziewicz, J., Loewenberg, M. (2003). Drop breakup and fragment size distribution in shear flow. Journal of Rheology. 47(5):1283-98.

118. Blawzdziewicz, J., Cristini, V., Loewenberg,M. (2003). Multiple stationary states for deformable drops in linear Stokes flows. Physics of Fluids. 15(5):L37-40.

119. Cristini, V., Blawzdziewicz, J., Loewenberg, M., Collins, L. (2003). Breakup in stochastic Stokes flows: sub-Kolmogorov drops in isotropic turbulence. J. of Fluid Mechanics. 492:231-50.

120. Li, X., Lowengrub, J., Nie, Q., Cristini, V., Leo, P. (2003). Microstructure evolution in three-dimensional inhomogeneous elastic media. Metallurgical and Materials Transactions A. 34A(7):1421-31.

121. Renardy, Y.Y., Renardy, M., Cristini, V. (2002). A new volume-of-fluid formulation for surfactants and simulations of drop deformation under shear at a low viscosity ratio. European J. of Mechanics B/Fluids. 21(1):49-59.

122. Renardy, Y., Cristini, V., Li, J. (2002). Drop fragment distributions under shear with inertia. International J. of Multiphase Flow. 28(7):1125-47.

123. Cristini, V., Hooper, R., Macosko, C.W., Simeone, M., Guido, S. (2002). A numerical and experimental investigation of lamellar blend morphologies. Industrial & Engineering Chemistry Research. 41(25):6305-11.

124. Cristini, V. (2002). Flow-independent drop deformation with zero surface tension. Physics of Fluids. 14(8):2929-32.

125. Blawzdziewicz, J., Cristini, V., Loewenberg, M. (2002). Critical behavior of drops in linear flows: I. Phenomenological theory for drop dynamics near critical stationary states. Physics of Fluids. 14(8):2709-18.

126. Cristini, V., Macosko, C.W., Jansseune, T. (2002). A note on transient stress calculation via numerical simulations. Journal of Non-Newtonian Fluid Mechanics. 105(2-3):177-87.

127. Cristini, V., Lowengrub, J. (2002). Three-dimensional crystal growth-I: linear analysis and self-similar evolution. Journal of Crystal Growth 2002; 240(1-2):267-76.

128. Renardy, Y.Y., Cristini, V. (2001). Effect of inertia on drop breakup under shear. Physics of Fluids. 13(1):7-13.

129. Renardy, Y.Y., Cristini, V. (2001). Scalings for fragments produced from drop breakup in shear flow with inertia. Physics of Fluids. 13(8):2161-4.

130. Cristini, V., Blawzdziewicz, J., Loewenberg, M. (2001). An adaptive mesh algorithm for evolving surfaces: simulations of drop breakup and coalescence. Journal of Computational Physics. 168(2):445-63.

131. Blawzdziewicz, J., V. Cristini, V., Loewenberg, M. (1999). Near-contact motion of surfactant-covered spherical drops: Ionic surfactants. Journal of Colloid and Interface Science. 211(2):355-66.

132. Blawzdziewicz, J., V. Cristini, V., Loewenberg, M. (1999). Stokes flow in the presence of a planar interface covered with incompressible surfactant. Physics of Fluids. 11(2):251-8.

133. Cristini, V., Blawzdziewicz, J., Loewenberg, M. (1998). Near-contact motion of surfactant-covered spherical drops. J. of Fluid Mechanics. 366:259-87.

134. Cristini, V., Blawzdziewicz, J., Loewenberg, M. (1998). Drop breakup in three-dimensional viscous flows. Physics of Fluids. 10(8):1781-3.

135. Ferrari, M., Anzidei, L., Cristini, V., Simbolotti, G. (1995). Impact of the passive stabilization system on the dynamic loads of the ITER first-wall/blanket during a plasma disruption event. Fusion Eng and Design 1995; 27:507-14.

Papers Submitted

1. Kabil NN, Bayraktar R, Ivan C, Kahraman N, Hamada A, Mokhlis HA, Caner A, Wang Z, Cristini V, Ram PT, Siddik ZH, Calin GA, Lopez-Berestein G, Ozpolat B. MicroRNA-484 acts as an “Onco-miR” by targeting HOXA5 in Triple Negative Breast Cancer. Molecular Cancer Therapeutics. Under review.

2. Peláez MJ†, Goel S, Cristini V, Wang Z, Dogra P*†. “Mechanistic modelling and machine learning to establish structure-activity relationship of nanomaterials for improved tumour delivery” (Invited Book chapter, Under Review Cancer Systems Biology and Translational Mathematical Oncology, Oxford University Press) 3. Migliaccio G, Ferraro R, Wang Z, Cristini V, Dogra P, Caserta S. Cellular Automata Modelling Reveals Dynamics of Wound Healing Assay. SSRN. 2022 Sep 26. url: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4227003 (Research article, Under review)

4. Rizvi S, Awasthi A, Peláez MJ, Wang Z, Cristini V, Nguyen HV, Dogra P. Deep learning-derived optimal aviation strategies to control pandemics. arXiv. 2022 Oct 12. doi: 10.48550/arXiv.2210.10888. (Research article preprint)

5. Amereh M, Shojael S, Walsh T, Dogra P, Cristini V, Nadler B. “Unveiling the role of metabolic rates variation in driving tumor heterogeneity and controlling growth and invasion: insights from an integrated multiscale in-vitro in-silico framework.” Research Square. 2023 May 22. doi: 10.21203/rs.3.rs-2828746/v1 (Research article, Under review)

Papers in Preparation (selected)

1. Nizzero S, Schiavone C, Cristini V, Dogra P. Mathematical model of Covid-19 mRNA vaccines in pregnancy and lactation: unraveling the fetus response. In preparation.

2. Nizzero S, P Oertle, M Wasley, G Srivastava, M Kim, Appenzeller T, Barsoumian H, Loparic M, Wang Z, A Cortez, N Puebla, P Dogra, Cristini V, M Plodinec M, Welsh J. Nanomechanics predicts PD1 resistance in lung adenocarcinoma. To be submitted to Nature.

3. Nizzero S, Zhang L, Xu L, Peláez Soní MJ, Dogra P, Menegaz BA, Jordan LB, Purdie CA, Quinlan PR, Nagi, Sepulveda K, Oertle P, Appenzeller T, Chen SH, Loparic M, Wang Z, Cristini V, Plodinec M, Thompson AM. Spatial patterns of microenvironmental biomarkers drive long-term breast cancer outcome. To be submitted to Nature.

4. Ferrari R, Ascione F, Dogra P, Cristini V, Guido S, Caserta S. Diffusion induced anisotropic cancer invasion: a novel experimental method based on tumour spheroids. To be submitted to Cancer Research.

5. Dogra P, Butner JD, Ruiz-Ramirez J, Cristini V, Calin GA, Ozpolat B, Wang Z. A mathematical model for predicting treatment efficacy based on miR-155 in lung cancer. To be submitted to Science Translational Medicine.

6. Dogra P, Chuang YL, Hanson JA, Butner JD, Cristini V, Brinker CJ, Wang Z. A multiscale hybrid model to study nanomedicine delivery in tumors. To be submitted to ACS Nano.

7. Nizzero S, Ruiz-Ramirez J, Goel S, Kim M, Tong SQ, Li F, Cristini V, Blanco E, Li Z, Wang Z, Ferrari M. A quantitative approach to discover predictors of biodistribution reveals the synergistic role of myeloid-derived cells on the in vivo biodistribution of injectable inorganic particles. To be submitted to Nanomedicine.

8. Dodoo G, Jacobson G, Grandgenett P, Hollingsworth M, Cristini V, Wang Z, Koay E, and Butner JD. A mathematical model for predicting CA19-9 normalization and patient survival in pancreatic ductal adenocarcinoma. To be submitted to Journal of Clinical Oncology.

9. J.D. Butner, M. Farhat, V. Cristini, J. Welsh, C. Chung, and Z. Wang. Hybridizing mechanistic mathematical model with deep learning methods to predict individual cancer patient survival after immune checkpoint inhibitor therapy. To be submitted to Nature Computational Science.

10. Dodoo G, Jacobson G, Grandgenett P, Hollingsworth M, Cristini V, Wang Z, Koay E, and Butner JD. Predicting CA19-9 normalization and patient survival in pancreatic ductal adenocarcinoma using a combination of mathematical modeling and deep learning. To be submitted to Nature Biomedical Engineering.

11. Butner JD, Dogra P, Chung C, Cristini V, Wang Z. Mathematical Modeling of Cancer Immunotherapy: Towards Individualized Treatment. To be submitted to npj Precision Oncology. (invited) 12. Amereh M, Shojael S, Walsh T, Dogra P, Cristini V, Nadler B. “Unveiling the role of metabolic rates variation in driving tumor heterogeneity and controlling growth and invasion: insights from an integrated multiscale in-vitro in-silico framework.” Research Square. 2023 May 22. doi: 10.21203/rs.3.rs-2828746/v1 (Research article, Under review)

13. Cave J, Wang Z, Cristini V, Dogra P, Fujita M. “Modeling the transport kinetics of 11C-ER176 PET ligand to study the role of blood-CSF barrier in neuroinflammation.” (Research article, Under preparation)

14. B De, P Dogra, M Zaid, D Elganainy, K Sun, AM Amer, C Wang, MK Rooney, E Chang, HC Kang, Z Wang, P Bhosale, BC Odisio, TE Newhook, CD Tzeng, HST Cao, YS Chun, J Vauthey, SS Lee, A Kaseb, K Raghav, M Javle, BD Minsky, SS Noticewala, EB Holliday, CM Taniguchi, GL Smith, AC Koong, P Das, V Cristini, EB Ludmir, EJ Koay. Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response. (Research article, Under preparation)

15. Cave J, Schiavone C, Nguyen HV, Campen M, Staquicini D, Brinker CJ, Cristini V, Wang Z, Noureddine A, Dogra P*. Modeling for rational design of nanoparticles: enabling safer and targeted nanomedicines. (Review article, In preparation)

16. Schiavone C, Cave J, Caserta S, Cristini V, Adelman M, Wang J, Wang Z, Dogra P*. A quantitative guide to vaccine immunology: enabling model-informed vaccine development. (Review article, In preparation)

Invited Reviews, Editorials, etc. in Journals and Magazines

1. Butner JD, Dogra P, Chung C, Pasqualini R, Arap W, Lowengrub J, Cristini V, Wang Z. Mathematical Modeling of Cancer Immunotherapy for Personalized Clinical Translation. Nature Computational Science 2, 785–796 (2022 Dec). https://doi.org/10.1038/s43588-022-00377-z

2. Open Access Government, April, 2021. Is the Pandemic Obeying the Elliott Wave Principle of Financial Markets? (with P Dogra). https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=4bc1adac-723d-4261-a012-f8ebe5f8ad14

3. Open Access Government, January 2021. Personalized prediction of immunotherapy efficacy: improving clinical approaches via mechanistic mathematical modeling (with JD Butner and Z Wang). Open Access Government, 2021: p. 116-117. https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=abe4b9c2-2198-40d4-9b41-c05d7aaff94f

4. Open Access Government, May, 2020. Modeling the whole-body dynamics of SARS-CoV-2 to investigate treatment strategies for effective management of COVID-19 (with P Dogra, K Sinha, Z Wang). https://www.openaccessgovernment.org/body-dynamics-of-sars-cov-2-treatment-of-covid-19/86929/

5. Open Access Government, March 10, 2020. Graph theory in the study of Alzheimer’s disease progression (with M Pelaez, P Dogra, Z Wang). https://www.openaccessgovernment.org/graph-theory-in-the-study-of-alzheimers-disease-progression/83621/

6. Open Access Government, December 6, 2019. Giving oncology its power back: A clinical technology revolution is conquering the US from Texas (with S Nizzero, M Plodinec, Z Wang). https://www.openaccessgovernment.org/oncology/78946/

7. Open Access Government, October 1, 2019. Profile: Ductal Carcinoma in Situ: Gaining new Biological Insights from Multiscale Mathematical Modeling (with J Butner, Z Wang). https://www.openaccessgovernment.org/wp-content/uploads/2019/10/OAG24-WEB.pdf

8. Open Access Government, July 9, 2019. In vivo imaging and mathematical modelling in nanoparticle pharmacokinetics (with P Dogra, MJ Pelaez, Z Wang). https://www.openaccessgovernment.org/mathematical-modelling-nanoparticle-pharmacokinetics/68801/

9. Open Access Government, October 11, 2018. Regenerative medicine to trump cancer (with B Corradetti, P Dogra, M Ferrari). https://www.openaccessgovernment.org/regenerative-medicine-to-trump-cancer/53150/

10. Open Access Government, Profile: Towards Precision Oncology in Breast Cancer: Predicting Response to Neoadjuvant Chemotherapy Using Tumor Vasculature Characteristics (with U Brown-Glaberman, TA Brocato, R Selwyn, Z Wang). https://www.openaccessgovernment.org/precision-oncology-breast-cancer/60456/.

11. Open Access Government, May 1, 2018. Profile: Non-invasive radiofrequency hyperthermia (with S Curley, P Dogra, JD Butner, Z Wang). https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=558600cb-8de9-4616-9242-f8f3b41da315&pnum=78

12. Open Access Government, Aug 31, 2017. Health & Social Care Reports: Targeting stem cell trans-differentiation could eradicate glioblastoma (with J Lowengrub and Chris Hughes) https://www.openaccessgovernment.org/stem-cell-transdifferentiation/36169/

13. Open Access Government, July 26, 2017, Health & Social Care News: The dilemma of over diagnosis of pancreatic cysts (with A Maitra and E Koay) https://www.openaccessgovernment.org/dilemma-diagnosis-pancreatic-cysts/35088/

14. Open Access Government, June 26, 2017, Health & Social Care News: Identifying pancreatic cysts that might turn into cancer (with A Maitra and E Koay) https://www.openaccessgovernment.org/identifying-pancreatic-cysts-might-turn-cancer/34409/

15. Open Access Government, May 18, 2017,Health & Social Care Reports: Multimodal feedback control can lead to self-organizing morphogenesis (with J Lowengrub and Arthur Lander). https://www.openaccessgovernment.org/multimodal-feedback-control-can-lead-self-organizing-morphogenesis/34429/

16. Wang, Z., Cristini, V. Research Profile: Tissue-scale factors in predicting cancer treatment outcome. Open Access Government. March 8, 2017. https://www.openaccessgovernment.org/tissue-scale-factors-predicting-cancer-treatment-outcome/32302/

17. Wang, Z. Sen, S., Cristini, V. Special Report: Development of Integrated Non-Invasive Methods for Cancer Diagnosis and Treatment. Open Access Government Special Report January 23, 2017. https://www.openaccessgovernment.org/integrated-non-invasive-cancer-diagnosis/31174/

18. Corr, S.J., S Curley, S., Wang, Z., Cristini, V. Development of Integrated Non-Invasive Methods for Cancer Diagnosis and Treatment. Open Access Government Special Report. April, 15, 2016. https://www.openaccessgovernment.org/cancer-diagnosis-and-treatment/25598/

19. Koay, E.J., Fleming, J.B., Wang, Z., Cristini, V. Understanding cancer through physics. Open Access Government May 4, 2016. https://www.openaccessgovernment.org/understanding-cancer-physics/25938/

20. Wang, Z., Cristini, V. A Spatio-temporal Mathematical Model for Predicting Cancer Treatment Outcome. Open Access Government March 9, 2016. https://www.openaccessgovernment.org/spatio-temporal-mathematical-model-cancer/28963/

21. Koay, E.J., Cristini, V., Wang, Z.. Profile: Mathematical pathology in determining surgical volume for breast cancer treatment. Open Access Government Feb 1, 2016. https://www.openaccessgovernment.org/profile-mathematical-pathology-determining-surgical-volume-breast-cancer-treatment/23968/

22. Martin, G.V., Koay, E.J., Cristini, V. The Mathematical Relationship between the Immune System and Cancer and its Implications for Cancer Therapy. Open Access

Government Report. November 11, 2015. https://www.openaccessgovernment.org/mathematical-relationship-immune-system-cancer-implications-cancer-therapy/22262/

23. Koay, E.J., Wang, Z., Cristini, V. Profile: Combining biology with physics to solve the cancer problem. Open Access Government November 11, 2015. https://www.openaccessgovernment.org/profile-combining-biology-physics-solve-cancer-problem/22371/

24. Cristini, V., Koay, E.J., Wang, Z. Prediction of Cancer Treatment Outcome using Physics. Open Access Government. Special Report. September 30, 2015. https://www.openaccessgovernment.org/prediction-cancer-treatment-outcome-using-physics/21432/

25. Cristini, V., Koay, E.J., Wang, Z. Prediction of Cancer Treatment Outcome using Physics. Open Access Government. Special Report. Oct 6, 2015. https://www.openaccessgovernment.org/prediction-cancer-treatment-outcome-using-physics-2/21536/

26. Cristini, V., Koay, E.J., Wang, Z. Taking cancer out of the equation. International Innovation. 2015. 191: 38-40.

27. Brocato, T., Dogra, P., Koay,E.J., Day, A., Chuang, Y.L., Wang, Z., Cristini, V. Understanding Drug Resistance in Breast Cancer with Mathematical Oncology. Current Breast Cancer Reports. 2014. 6(2): 110-120. [PMC4039558]

28. Sinek, J., Sanga, S., Zheng, X., Ferrari, M., Cristini, V. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulations. J of Mathematical Biology. April 2009. 58(4-5):485-510.

29. Li, X., Cristini, V., Nie, Q., Lowengrub, J., Nonlinear three-dimensional simulation of solid tumor growth. Discrete and Continuous Dynamical Systems B. 2007. 7(3):581-604.

30. Sanga, S., Frieboes,H., Zheng, X., Gatenby, R., Bearer, E., Cristini, V. Predictive oncology: a review of multidisciplinary, multiscale in-silico models connecting phenotype, morphology and growth. NeuroImage; 37, S 1. 2007. S120-S134.

31. Sanga, S., Sinek, J., Frieboes, H., Ferrari, M., Fruehauf, J., Cristini, V. Mathematical modeling of cancer progression and response to chemotherapy: towards the development of a multiscale computer simulator. Expert Review of Anticancer Therapy. 2006. 6(10):1361-76.

32. Cristini, V., Renardy, Y.Scalings for droplet sizes in shear-driven breakup: non-microfluidic ways to monodisperse emulsions. Fluid Dynamics and Materials Processing. 2006. 2(2):77-94.

33. Cristini, V., Kassab, G.S. Computer modeling of red blood cell rheology in the microcirculation: A brief overview. Annals of Biomedical Engineering. 2005. 33(12):1724-7.

34. Cristini, V., Tan, Y.-C. Theory and numerical simulation of droplet dynamics in complex flows-A review. Lab on a Chip. 2004. 4(4):257-64.

35. Sinek, J., Frieboes, H., Zheng, X., Cristini, V. Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles. Biomed Microdev. 2004. 6(4):297-309.

Book Chapters

1. Butner JD, Dogra P, Cristini V, Deisboeck TS, Wang Z. Computational approaches in multiscale modeling. In Encyclopedia of Cell Biology (Second Edition), R.A. Bradshaw, G.W. Hart, and P.D. Stahl, Editors. 2023, Academic Press: Oxford. p. 251-260.

2. Noureddine A, Butner JD, Zhu W, Naydenkov P, Peláez MJ, Goel S, Wang Z, Brinker CJ, Cristini V, Dogra P. Emerging lipid-coated silica nanoparticles for cancer therapy. In: Saravanan M., Barabadi H. (eds) Cancer Nanotheranostics, Vol 1. Nanotechnology in the Life Sciences. Springer, Cham. 2021 Oct 6; pp 335-361. doi: 10.1007/978-3-030-74330-7_12

3. Wang, Z., Cristini, V., Deisboeck, T.S. (2016). Computational approaches for multiscale modeling. In R.A. Bradshaw & P.D. Stahl (Eds.), Encyclopedia of Cell Biology. Vol. 4 (pp. 80-85). Elsevier.

4. Wang, Z., Cristini, V. (2013). Integration of Molecular Signaling into Multiscale Modeling of Cancer, Multiscale Computer Modeling in Biomechanics and Biomedical Engineering. In A. Gefen (Ed.), Studies in Mechanobiology, Tissue Engineering and Biomaterials Volume 14. (pp. 381-394). Springer.

5. Hatzikirou, H., Chauviere, A., Lowengrub, J., De Groot, J., Cristini, V. (2012). Effect of vascularization on glioma tumor growth. In L. Trachette, Jackson (Eds.) Modeling Tumor Vasculature: Molecular, Cellular, and Tissue Level Aspects and Implications. (pp. 237-259). Springer.

6. Frieboes, Hermann B., Lowengrub, J., Cristini, V. (2011). Diffusional Instability as a Mechanism of Tumor Invasion. In T.S. Deisboeck & G.S. Stamatakos (Eds.), Multiscale Cancer Modeling. (pp. 193-21). Boca Raton: CRC Press: Taylor & Francis Group.

7. Chaplain, M.A.J., Macklin, P., McDougall, S., Anderson, A.R.A., Cristini, V., Lowengrub, J. (2011). Multiscale Mathematical Modeling of Vascular Tumor Growth: An Exercise in Transatlantic Cooperation. In In T.S. Deisboeck & G.S. Stamatakos (Eds.), Multiscale Cancer Modeling. (pp. 253-308). Boca Raton: CRC Press: Taylor & Francis Group.

8. Macklin, P., Kim, J., Tomaiuolo, G., Edgerton, M., Cristini, V. (2009). Agent-Based Modeling of Ductal Carcinoma in Situ: Application to Patient-Specific Breast Cancer Modeling. In T. Pham (Ed), Computational Biology: Issues and Applications in Oncology. (pp. 77-112). New York: Springer.

9. Lowengrub, J., Cristini, V., Frieboes, H., Li, X., Macklin, P., Sanga, S., Wise, S., Zheng, X. (2009). Nonlinear tumor growth: Modeling and simulation. In B.C. Khoo, Z. Li, &P. Lin (Eds.), IMS Lecture Notes Series, Vol 17: Interface Problems and Methods in Biological and Physical Flows. (pp. 69-134).

10. Frieboes, H., Decuzzi, P., Sinek, J., Ferrari, M., Cristini, V. (2008). Computational Modeling of Tumor Biobarriers: Implications for Delivery of Nano-based Therapeutics. In M. Zhang & N. Xi (Eds.), Nanomedicine: A Systems Engineering Approach. (pp. 201-243). Pan Stanford Publishing. (invited)

11. Cristini, V., Frieboes, H.B., Li, X., Lowengrub, J.S., Macklin, P., Sanga, S., Wise, S.M., Zheng, X. (2008). Nonlinear modeling and simulation of tumor growth. In N. Bellomo, M.A.J. Chaplain, & E. de Angelis (Eds.), Selected topics in cancer modeling: Genesis, evolution, immune competition, and therapy. Modelling and Simulation in

Science, Engineering, and Technology. (pp. 113-82). Birkhäuser, Boston, MA USA. (invited)

12. Sanga, S., Frieboes, H., Sinek, J., Cristini, V. (2006). A multiscale approach for computational modeling of biobarriers to cancer chemotherapy via nanotechnology. In T. Webster & H. S. Nalwa (Eds.), Cancer Nanotechnology. (pp. 1-21). American Scientific Publishers. (invited)

13. Sinek, J., Frieboes, H., Sivaraman, B., Sanga, S., Cristini, V. (2006). Mathematical and computational modeling: Towards the development and application of nanodevices for drug delivery. In C Kumar (Ed.), Series: Nanotechnologies for the Life Sciences; Vol. 4: Nanodevices for the Life Sciences. (pp. 29-66) Wiley-VCH. (invited)

14. Frieboes, H., Sinek, J., Nalcioglu, O., Fruehauf, J., Cristini, V. (2006). Nanotechnology in cancer drug therapy: a biocomputational approach. In A.P. Lee, L.J. Lee (Eds.), BioMEMS and Biomedical Nanotechnology 2006; Vol. 1: Prospectus, Biological and Biomedical Nanotechnology. (pp. 435-460). Springer-Verlag. (invited)

BOOKS (MONOGRAPHIES)

1. Cristini, V., Lowengrub, J., Wang, Z. Biophysical Modeling of Cancer in Silico. Springer. To be published in July 2024.

2. Vittorio Cristini, Eugene Koay, Zhihui Wang. An Introduction to Physical Oncology. CRC Press, Taylor & Francis Group. July 2017. https://www.crcpress.com/An-Introduction-to-Physical-Oncology-How-Mechanistic-Mathematical-Modeling/Cristini-Koay-Wang/p/book/9781466551343

ISBN-13: 978-1466551343

3. Cristini, V., Lowengrub, J. (2010). Multiscale Modeling of Cancer: an Integrated Experimental and Mathematical Modeling Approach. Cambridge University Press. ISBN-13: 978-0521884426

E-Books

1. Invited e-book: “Mathematical Pathology” in Global Health & Pharma 2016, www.ghp-magazine.com

2. Wang, Z., Cristini, V. (2016) Mathematical Modeling of Drug Delivery via Nanoparticles in Cancer Treatment. Open Access Government. eBook. https://www.openaccessgovernment.org/mathematical-modeling-drug-delivery-via-nanoparticles-cancer-treatment/27830/

3. Cristini, V., Koay, E.J., Wang, Z. (2016). The Clinical Application of Mathematical Pathology. Open Access Government. eBook: http://www.adjacentgovernment.co.uk/wp-content/uploads/2016/01/Uni-of-Texas-ebook-web.pdf

Other Professional Communications

Selected: Presentation and Lecture Invitations (mentee involved)

• Cave J, Wang Z, Cristini V, Dogra P. Machine learning-based rational design of nanoparticles for improved safety in biomedical applications. Weill Cornell Graduate School of Medical Sciences Retreat, Weill Cornell Medicine, Nov 2, 2023, New York, NY, USA. (Poster, Presenter: Cave J)

• Dogra P, Cave J, Butner J, Cristini V, Wang Z. Multiscale Modeling-Identified Synergistic Combinations of Anti-microRNA-155 and Standard-of-Care Drugs for Improved Outcomes in Non-small Cell Lung Cancer. American Association of Pharmaceutical Scientists PharmSci 360 Conference, October 22-25, 2023, Orlando, FL, USA. (Presenter: P Dogra)

• Banerjee D*, Cave J, Cristini V, Wang Z, Dogra P. Machine Learning-Based Feature Selection to Identify the Determinants of Tumor Delivery Efficiency of Nanoparticles. 6th Annual MAPTA Summer Science Symposium, Houston Methodist Research Institute, Aug 3-4, 2023, Houston, TX, USA. (Poster)

• Christiono A*, Cave J, Cristini V, Wang Z, Dogra P. Predicting Nanoparticle Toxicity Through Machine Learning Models. 6th Annual MAPTA Summer Science Symposium, Houston Methodist Research Institute, Aug 3-4, 2023, Houston, TX, USA. (Poster)

• “Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer”. 45th Annual International IEEE Engineering in Medicine and Biology Society (EMBC) Conference. Sydney, Australia. July 24-27, 2023. (Presenter: Z Wang)

• “Mechanistic modeling for optimal design of dissolvable microneedle-based patches for transdermal drug delivery”. 45th Annual International IEEE Engineering in Medicine and Biology Society (EMBC) Conference, Sydney, Australia, July 24-27, 2023. (Presenter: P Dogra)

• “Mechanistic model-based simulator to support clinical vaccine development”, Infectious Diseases Journal Club, Division of Infectious Diseases, Houston Methodist Hospital, Houston, TX, USA, Jul 18, 2023. (Presenter: P Dogra)

• “Artificial intelligence in research”, Methodist Association for Postdoctoral and Trainee Affairs (MAPTA) Seminar Series, Houston Methodist Research Institute, Houston, TX, USA, Jul 17, 2023. (Presenter: P Dogra)

• Capuani S, Hernandez N, Paez-Mayorga J, Dogra P, Wang Z, Cristini V, Chua CYX, Nichols JE, Grattoni A. Local Delivery of Drugs in a 3D Bioengineered Subcutaneous Niche: Biodistribution and Pharmacokinetics. 8th Nano Today Conference. April 22-25, 2023. San Diego, California, USA. (Presenter: Capuani S)

• Dogra P, Shinglot V, Cave J, Cristini V, Wang Z. Muliscale Mechanisic Modeling of Nanoparticle-Delivered Anti-microRNA-155 Therapy and Its Combination with Standard-of-Care Drugs in Lung Cancer. 17th U. S. National Congress on Computational Mechanics, Albuquerque, NM, USA. July 23-27, 2023.

• Houston Methodist Association for Postdoctoral and Trainee Affairs (MAPTA) presents: “The Receiver Operator Characteristic Plot: the rest of the story,” Houston Methodist Research Institute, Houston, TX, USA, 4/26/2023 (Presenter: JD Butner).

• “Mechanistic modeling-based first-in-human predictions of cancer remission with a novel microRNA therapy”, Expanding Texas Leadership in Computational Oncology Throughout the Cancer Continuum: A CPRIT Symposium, The University of Texas at Austin, Austin, TX, USA, Apr 20, 2023. (Presenter: P Dogra)

• “Characterizing the systemic and brain pharmacokinetics of TSPO radioligand 11C-ER176” Department of Neurology, Houston Methodist Hospital, Houston, TX, USA, Apr 18, 2023. (Presenter: P Dogra)

• “Mathematical Modeling of Biological Systems for Oncology Applications: From Basic Science to Clinically Translatable Methods,” The Image Guided Cancer Therapy Research Program and the Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA, 4/13/2023 (Presenter: JD Butner).

• “Modeling and simulations to support vaccine development”, Vaccine Research Center Baylor College of Medicine, Houston, TX, USA, Apr 11, 2023.

• “Navigating the valley of death with mathematical modeling”, Dr. Mary and Ron Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA, Feb 9, 2023. (Presenter: P Dogra)

• “Mathematical modeling applications in cancer treatment optimization”, Gordon Research Seminar (Physical Science of Cancer), Galveston, TX, USA, Feb 4, 2023. (Presenter: P Dogra)

• “Predicting Personalized Immunotherapy Outcomes using Mathematical Biomarkers,” Houston Methodist Cancer Center Working Group, Houston Methodist Research Institute, Houston, TX, USA, 2/2/2023 (Presenter: JD Butner).

• “Navigating the valley of death with computational medicine”, Department of Chemical and Biological Engineering Seminar Series, University of New Mexico, Albuquerque, NM, USA, Dec 14, 2022. (Presenter: P Dogra)

• “Navigating the valley of death with computational medicine”, Centre for BioSystems Science and Engineering, Indian Institute of Science, Bengaluru, India (Virtual), Oct 26, 2022. (Presenter: P Dogra)

• “Crossing the valley of death with mathematical modeling and simulation”, The Department of Electrical & Computer Engineering Speaker Series, Cullen College of Engineering, University of Houston, Houston, TX, USA (Virtual), Sep 12, 2022. (Presenter: P Dogra)

• Dogra P, Schiavone C, Caserta S, Wang Z, Cristini V. “Mathematical modeling identifies optimal dosing schedules for COVID-19 vaccines to minimize breakthrough infections”. American Association of Pharmaceutical Scientists PharmSci 360 Conference, October 16-19, 2022, Boston, MA, USA. (Presenter: P Dogra)

• Weill Cornell Medical College, Cornell U, NYC 2022

• Birur RM, Peláez MJ, Puri A, Wang Z, Cristini V, Dogra P. “Mathematical modeling of microneedle-based transdermal drug delivery for immediate- and extended-release applications” 5th Annual MAPTA Summer Science Symposium, Houston Methodist Research Institute, Aug 4-5, 2022, Houston, TX, USA. (Presenter: R Birur)

• Butner J, Z Wang, V Cristini. “Development of Mathematical Biomarkers for Predicting Cancer Immunotherapy Outcome” The Society for Industrial and Applied Mathematics (SIAM) Conference on Life Sciences (LS22), Pittsburgh, Pennsylvania, July 11-14, 2022. (Presenter: J Butner)

• Mathematical Modeling in Drug Discovery and Development”, Guest lecture at Strategic Consideration for Healthcare Informatics Course, Master in Clinical Translation Management, University of St. Thomas, Houston, TX, USA, 06/27/2022 – 07/01/2022. (Presenter: P Dogra)

• Nizzero S, Pelaez MJ, Zhang L, Xu Y, Zheng J, Menegaz BA, Dogra P, Butner J, Jordan LB, Purdie CA, Quinlan PR, Nagi C, Sepulveda KA, Oertle P, Appenzeller TA, Loparic M, Chen S, Wang Z, Cristini V, Plodinec M, Thompson AM. Spatial patterns of microenvironmental biomarkers drive long-term breast cancer outcome. American Association of Cancer Research Annual Meeting 2022. April 8-13, 2022, New Orleans, LA, USA. (Presenter: S Nizzero)

• “From bench to bedside with mathematical modeling”, Neuroscience Seminar Series, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA (Virtual), Apr 22, 2022. (Presenter: P Dogra)

• “Houston Methodist Association for Postdoctoral and Trainee Affairs (MAPTA) presents: R Coding Bootcamp, Day 4: Importing & fitting data with built-in and user-defined equations”, Houston Methodist Research Institute, Houston, TX, USA, Jan 24, 2022. (Presenter: J Butner)

• “Navigating the valley of death with mathematical modeling and simulation”, 30th University Grants Commission-Networking Resource Center training course: New Era Technologies in Formulation Design Space, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India (Virtual), Jan 19, 2022. (Presenter: P Dogra)

• “Houston Methodist Association for Postdoctoral and Trainee Affairs (MAPTA) presents: R Coding Bootcamp, Day 3: Boolean logic, loops, and writing functions”, Houston Methodist Research Institute, Houston, TX, USA, Jan 17, 2022. (Presenter: J Butner)

• Weill Cornell Medical College, Cornell U, NYC 2021

• Universita’ degli studi di Napoli “Federico II” 2021, Naples, Italy

• Dompe’ Pharma, L’Aquila, IT 2021

• “Modeling transport phenomena in diseases to support the development of drugs and drug delivery systems”, Università degli Studi di Napoli Federico II, Italy (Virtual), Dec 15, 2021. (Presenter: P Dogra)

• “Bench to Bedside with Mathematical Modeling”, Methodist Association for Postdoctoral and Trainee Affairs (MAPTA) Seminar Series, Houston Methodist Research Institute, Houston, TX, USA, Dec 8, 2021. (Presenter: P Dogra)

• “Modeling and simulation in clinical translation”, Guest lecture at Clinical Translation Management Program, University of St. Thomas, Houston, TX, USA, November 15, 2021. Instructors: JD Butner, P Dogra.

• Dogra P, Ruiz Ramírez J, Butner JD, Peláez MJ, Cristini V, Wang, Z, 2021. A Multiscale Model to Identify Limiting Factors in Nanoparticle-Based miRNA, Delivery for Tumor Inhibition. Proceedings of the 2021 43nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society;2021 Oct-Nov; Guadalajara, Mexico. Oral presentation (Wang Z).

• “Interfacing Mathematics and Medicine: Predicting Cancer Patient Response to Checkpoint Inhibitor Immunotherapy” The Wolfram Virtual Technology Conference 2021, Wolfram Alpha, Oct 12-15, 2021 (Presenter: JD Butner).

• “Modeling and Simulation of Human Biology, Disease, and Treatment”, Physiology, Biophysics & Systems Biology Faculty Research Presentations, Weill Cornell Medical College (Virtual), Sep 21, 2021. (Presenters: P Dogra, JD Butner)

• Dogra P., Peláez J. M., Ramirez, J.R., Sinha, K., Butner, J.D., Cristini, V., Wang Z. “Investigating the role of innate immunity in the control of SARS-CoV-2 infection using a mathematical model” American Association of Pharmaceutical Scientists PharmSci 360 Conference, Oct 17-20, 2021, Philadephia, PA. Poster presentation (Dogra P)

• Delk, J., Messina, L., Terracciano, R., Filgueira, C., Wang, Z., Cristini, V., Dogra, P. “Mathematical Modeling Identifies the Mechanism for Variable Intratumoral Distribution Patterns of Nanoparticles” 4th Annual MAPTA Summer Science Symposium, Houston Methodist Research Institute, Aug 5-6, 2021, Houston, TX, USA. Poster presentation (Delk J.)

• Gordon Research Conference, Galveston TX 2020

• Dompe’ Pharma, L’Aquila, IT 2020

• “Alzheimer’s disease progression and treatment modeling”, Presentation at NeuralCODR Fall 2020 Course, Houston Methodist Research Institute, Houston, TX, USA, Dec 14, 2020. (Presenter: P Dogra)

• Dogra, P., Peláez J. M., Ramirez, J.R., Butner, J.D., Cristini, V., Wang Z. “Identifying parameters to improve the pharmacokinetics and tumor delivery efficiency of nanomedicine”. Special poster presentation session at the American Association of Pharmaceutical Scientists PharmSci 360 Conference. Oct 26-Nov 5, 2020 (Virtual). Poster presentation (Dogra P)

• Physical targeting strategies for enhanced therapeutic efficacy: bridging physics and biology through rational design’. 11th Annual Symposium "Physics of Cancer", September 22 - 24, 2020, University of Leipzig, Germany. Invited talk (Nizzero S)

• “Investigating the Effect of Aging on the Pharmacokinetics and Tumor Delivery of Nanomaterials using Mathematical Modeling.” 42nd Annual International IEEE Engineering in Medicine and Biology Society (EMBC) Conference. Montreal, Canada. July 20-24, 2020. Oral presentation (Z Wang)

• “Emerging mechanistic biomarkers of cancer chemo-radiation and immunotherapy from mathematical bio-physics”. American Physiological Society (APS) Interface of Mathematical Models and Experimental Biology: Role of the Microvasculature Conference 2019. September 11-14, 2019. Oral presentation (Butner JD)

• Mathematical Modeling and Radiation Oncology, MD Anderson Cancer Center, September, 2019.

• Seminar, “Emerging mechanistic biomarkers of cancer chemo-radiation and immunotherapy from mathematical biophysics”, Houston Methodist Research Institute, March 2019.

• Gordon Research Conference, Physical Sciences of Cancer, Galveston, TX (February 2019). Poster presentation. “Unraveling synergistic biological transport barriers for injectable inorganic delivery systems.” (Nizzero S)

• Gordon Research Seminar, Physical Sciences of Cancer, Galveston, TX (February 2019). Poster presentation. “Unraveling synergistic biological transport barriers for injectable inorganic delivery systems.” (Nizzero S)

• Rice University Smalley-Curl Institute, Rice University, Houston, TX (February 2019). Selected talk. “Unraveling synergistic biological transport barriers for injectable inorganic delivery systems.” (Nizzero S)

• Workshop on silicon nanoparticles, Bertinoro, Italy (October 2018). Selected talk. “Mathematical design of iNPG silicon vectors for site-selective vascular targeting.” (Nizzero S)

• Lecture, “Emerging mechanistic biomarkers of cancer chemo-radiation and immunotherapy from mathematical biophysics,” November, 2018; December 2018

• Rutgers Cancer Institute of NJ, June 2018

• The Fields Institute, Toronto, May 2018

• Moffitt Cancer Center, Tampa, FL, June 2018

• MIT Engineering Mechanics Institute Conference (EMI), May 29th-June 1st, 2018. Mini-Symposium MS42 “Mechanics of growth in biology and engineering”

• “Come Alla Corte di Federico II,” (transl.: Like at the Court of King Federico II) symposium organized by the University of Naples, Italy 2018. http://www.comeallacorte.unina.it

• Symposium: MULTISCALE IN-SILICO MODELLING OF CANCER BIOPHYSICS AND THERAPY, 6th European Conference on Computational Mechanics and 7th European Conference on Computational Fluid Dynamics, Glasgow UK 2018

• Symposium on “Imaging in Tumor Modeling,” American Association of Physicists in Medicine (AAPM) Annual Meeting (Nashville TN | July 29 - August 2, 2018)

• Houston Methodist Research Institute, 2/26/2018

• Keynote presentation, Houston Methodist Research Institute Center for Immunotherapeutic Transport Oncophysics (CITO) Winter Symposium on “Patient Advocacy and the Physical Sciences for Cancer Immunotherapy” February 20, 2018

• Symposium: Ductal Carcinoma In Situ of the Breast (DCIS) @ MDAnderson – a multidisciplinary approach, 16th February 2018

• MD Anderson Cancer Center, Department of Systems Biology 2018

• Keynote speaker, “International Conference and Expo on Nanotechnology,” April 19-21, 2018, Dubai, UAE

• Universidade de Sao Paulo Brazil 2018, Instituto de Química - Dept. Bioquímica, and Medical Genomics, AC Camargo Cancer Center

• The University of Naples Federico II, Italy, Department of Chemical and Biomedical Engineering. November 2017, 2018.

• CNR (National research Center), Naples Italy. November 2017, 2018. Institute for Experimental Endocrinology and Oncology

• Division of GI Cancer, Moffitt Cancer Center, Tampa, FL, October 2017, 2018

• UC Irvine, Dept. of Mathematics September 2017, 2018

• American Society for Radiation Oncology (ASTRO) Annual Meeting. Presidential Symposium I - The Scientific State of the Art, San Diego Convention Center, Sept 24, 2017. “Cutting Edge Translational Science: Early Lessons from RT-Immunotherapy combinations.” (J Welsh)

• 6th International Conference on Tissue Engineering and Regenerative Medicine, August 23-24, 2017, San Francisco. “Importance of Tissue Engineering and Regenerative Medicine for the Future of Health Care”.

• 2017 NCI PreCancer Atlas Think Tank Meeting – “Bridging genotypes to phenotypes”, Discussion Session I: Technologies and Standardized Methodologies, Rockville, MD (E Koay)

• SMB Minisymposium "Agent-based modeling as a tool to represent and understand complex multi-scale biological systems". Annual Meeting of the Society for Mathematical Biology, Salt Lake City 7/17-20 2017 (J Lowengrub)

• 2017 NRG Semi-Annual meeting – “Changes in mass transport as a biomarker of response in pancreatic cancer”, Houston, TX (E Koay)

• Drug Discovery & Therapy World Congress 2017. "Mechanistic Patient-Specific Predictive Correlation of Tumor Drug Response with Microenvironment and Perfusion Measurements," Boston, July 10-13th. (Invited by Renata Pasqualini)

• Gordon Research Conference on Cancer Nanotechnology - Multimodal Nano-Therapies Against Cancer. "Mechanistic Patient-Specific Predictive Correlation of Tumor Drug Response with Microenvironment and Perfusion Measurements," Mount Snow in West Dover, Vermont 6/18-23 2017

• Astrazeneca Immuno-Oncology Tumor Modeling Advisory Board Meeting, 5/12 2017, The Loews Philadelphia Hotel, Philadelphia, Pennsylvania

• Gordon Research Conference on Physical Science of Cancer. "Patient-Specific Mechanistic Modeling of Drug Response," 02/05/2017-02/10/2017, Hotel Galvez in Galveston TX

• Society for Brain Mapping & Therapeutics (SBMT) - World Brain Mapping World Congress, Silicon Valley, CA 2017 (Babak Kateb).

• 2016 NCI Alliance for Pancreatic Cancer Consortia – “Imaging biomarkers of pancreatic cancer: we see them, so now what?”, Rockville, MD (E Koay) * Delaware Valley Drug Metabolism Discussion Group (www.dvdmdg.org) at Bucks County, PA. September 19, 2016. Symposium on Mechanistic PK/PD Modeling and Bio-imaging.

• 2016 MDACC Imaging Physics Research Retreat, La Torretta Lake Resort & Spa, Montgomery, Tx. 9/16/2016 (invited by J Hazle)

• The University of Naples Federico II, Italy. 1998, 2000, 2001, 2005, 2007, 2015, 2016.

• Mount Sinai Cancer Center. 2016.

• Boston, MA. May 19-20, 2016. “Cancer Immunotherapy Congress”.

• Systems Biology of Mammalian Cells, Munich, Germany. April 6-8, 2016.

• MD Anderson Imaging Physics invited seminar. Dec 15, 2015.

• Stanford University. 2015.

• CNR (National research Center), Naples Italy. 2015, 2017. Institute for Experimental Endocrinology and Oncology

• Wolfgang Pauli Institute, Vienna, Austria. July 2-3, 2015. Meeting on mathematics and cancer.

• King Abdulaziz University, Department of Mathematics. 2015-2016.

• University of New Mexico Cancer Center. June 26, 2015. Joint Los Alamos National Lab/UNM Cancer Center research retreat on Biotechnology & Bioengineering in Science and Medicine.

• The University of New Mexico 50th Anniversary of the Department of Pathology. 2014.

• Sandia National Laboratories, Albuquerque, NM. 2014. “Mechanistic mathematical modeling to understand intra-tumoral heterogeneity”,

• University of New Mexico. August 2014. Q-Bio Summer School: guest lecture in the “Cancer Dynamics Course”.

• Q-Bio conference, Santa Fe, NM. 2014. Special lecture.

• The Methodist Hospital Research Institute, Houston TX. 2014.

• The University of Arcavacata, Calabria, IT. 2014-2016.

• King Abdulaziz University, King Fahad Medical Research Center. 2014, 2015 (2).

• Universita’ della Calabria – Arcavacata. November 22, 2014. Keynote lecture, Event: “I quattro matematici italiani più influenti al mondo incontrano gli studenti calabres” (The 4 Most Influential Italian Mathematicians World-Wide Meet in Calabria).

• The University of Texas Health Science Center, Houston, TX. 2014.

• Baylor College of Medicine, Houston, TX. 2014.

• Columbus, OH. 2014. Mathematical Biosciences Institute (MBI) Workshop: Metastasis and Angiogenesis.

• Los Alamos National Labs, New Mexico Consortium Workshop to launch NMC/LANL joint initiatives in Biomedical Technology. May 9, 2013. “Diffusion properties limit effectiveness of chemotherapy in cancer”.

• 4th Annual NCI PS-OC Network Investigators’ Meeting, Scottsdale, AZ. April 17-19, 2013. Keynote talk, “Clinical Applications” session. “Mathematical Models of Tumor Microenvironment Transport Accurately Predict Limitations to Chemo/Radiation Delivery and Outcome”.

• Duke University. 2013.

• The University of Texas Health Science Center, San Antonio, TX. February 7-9 2013. Cancer Systems Epigenomics workshop, “Diffusion properties limit effectiveness of chemotherapy in cancer”.

• Advances in Computational Mechanics, San Diego, CA. February 24-27, 2013.

• NIH. December 2012. New Frontiers in Physical Sciences and Oncology Symposium.

• 9th Annual Computational & Theoretical Biology Symposium, Biophysical Approaches to Systems and Synthetic Biology, Biomedical Engineering, Rice University, Houston, TX. November 30-December 1, 2012. “Mathematical modeling of Transport Onco-Physiscs”.

• Department of Biomathematics Seminar Series: Frontiers in Systems and Integrative Biology, UCLA. November 2012. “Modeling Tumor Growth in an Evolving Organ: A Diffuse Domain Approach”. (Y.-L. Chuang).

• CTO-Physical Sciences in Oncology Annual Site Visit, The Methodist Hospital Research Institute, Houston. 2012. “Project 3: Identification of cancer biomarkers using mathematical modeling”. (E. Koay).

• CTO-Physical Sciences in Oncology Annual Site Visit, The Methodist Hospital Research Institute, Houston, TX. 2012. “Mathematical Core 1: Integrated Computational/Experimental Modeling of Mass Transport in Tumors”.

• The Methodist Hospital Research Institute, Department of Nanomedicine, Houston, TX. October 2012. “Mathematical Modeling of Drug Delivery to Tumors”. (J. Pascal)

• Center for Transport Oncophysics Seminar Series, The Methodist Hospital Research Institute, Houston, TX. 2012. Prediction of Tumor Growth and Treatment Response using Integrated Computational/Experimental Modeling. (H.B. Frieboes).

• University of New Mexico. 2012. The Art of Lecturing and Making Presentations. (J Pascal).

• University of New Mexico. 2012. Problem Based Learning workshop. (J Pascal).

• Physical Sciences in Oncology Annual Site Visit, University of Southern California, Los Angeles, CA. 2012. “RP3: Integrated Computational/

• University of New Mexico Cancer Center biotechnology program meeting. 2012. Experimental Modeling of Lymphoma Growth.“Mathematical modeling of mass transport in tumors.”

• University of New Mexico Cancer Center retreat. October 27, 2012. “Identification of cancer biomarkers using mathematical modeling.”

• University of New Mexico Center for Biomedical Engineering. September 5, 2012. “A novel, patient-specific mathematical pathology approach for assessment of surgical volume: Application to ductal carcinoma in situ of the breast,”

• Tennessee Technological University, Department of Chemical Engineering, Cookeville, TN. August 2012. “Multi-scale Modeling of Biological Systems.” (J. Pascal).

• SIAM conference on the life sciences, San Diego, CA. August 7-10, 2012. “A Novel, Patient-Specific Physical Pathology Approach for Prediction of Tumor Growth and Chemotherapy Outcome”.

• Knoxville, TN. July 2012. Communication in Collaboration: Leading Collaborative Groups Workshop. (J Pascal).

• Spring School, Saint Flour, France. June 2012. ”Societe Francophone de Biologie Theorique”. (A. Chauviere).

• Northwestern University, Boston, MA. June 2012. NSF Future Faculty Workshop. (J Pascal).

• University of New Mexico, Albuquerque, NM. April 2012. DAMSIG group of the SpatioTemporal Modeling Center. (A. Chauviere).

• Meeting of the American Physical Society, Boston, MA. March 2012. “Dynamic Density Functional Theory of Solid Tumor Growth: Preliminary Models.” (A. Chauviere).

• The New Mexico Center for Translational Science (CTSC), University of New Mexico. February 2012. “Mathematical Modeling of Diabetes.”. Invited presentation.

• Present Challenges of Mathematics in Oncology and Biology of Cancer: Modeling and Mathematical Analysis, Marseille (CIRM, Luminy). March 2012. “A Novel, Patient-Specific Mathematical Pathology Approach for Prediction of Tumor Growth.”

• University of New Mexico, Department of Physics Colloquium. September 16, 2011. “Multiparameter Computational Modeling of Tumor Invasion”.

• University of New Mexico, Spatio-Temporal Modeling Center (STMC) External Advisory Board. August 2011. Mathematical modeling of intracellular motor-cargo dynamics. (E. Bearer).

• Conference Abstract: 5th Annual q-bio Conference on Cellular Information Processing. Santa Fe, New Mexico. 2011. “A Novel, Patient-Specific Mathematical Pathology Approach for Accurate Prediction of Tumor Growth”.

• Sandia/University of New Mexico Cancer Center Symposium on “Nanoparticle Human Interactions”. June 2-3, 2011. Multiscale in-silico modeling of drug/nanoparticle transport barriers and tumor response.

• University of New Mexico Computer Science Colloquium. May 2011. “Multiparameter computational modeling of tumor invasion”.

• University of New Mexico Cancer Center, Cancer Biology and Biotechnology Program Mini-Retreat. April 30, 2011. Topic: Prediction of Breast Surgical Volumes using Computational Modeling.

• University of New Mexico, Math Department. April 28, 2011. CNTC presentation, Multiparameter Computational Modeling of Tumor Invasion.

• Special Topics in Computational Biology, BIOM 505, Org.: S Steinberg, UNM Mathematics and Statistics, and E Bearer. March 10, 2011. Path: Multiscale breast cancer modeling and development.

• University of New Mexico Center for Biomedical Engineering (CBME) Seminar Series. March 23, 2011. Multiparameter Computational Modeling of Tumor Invasion.

• University of New Mexico Department of Pathology Resident Journal Club. March, 2011. Predicting breast tumor surgical volume using mathematical modeling.

• University of New Mexico Cancer Center Ovarian Cancer Focus Working Group. February 2011. Topic: Multiscale Modeling of Ovarian Cancer Spread

• University of New Mexico Cancer Center Breast Cancer Focus Working Group. February 24, 2011. Topic: Prediction of Breast Surgical Volumes using Computational Modeling.

• University of Southern California, NCI PS-OC Annual Site Visit. 2010-2013.

• World Congress on Computational Mechanics, Sydney, Australia. 2010. Mini-symposium on Tumor Growth Modeling. “Multiscale Multiparameter Modeling of Tumor Growth and Response to Treatment”.

• University of New Mexico, Spatiotemporal Modeling Center. 2010. “Multi-parameter computational Modeling of Tumor Invasion”.

• MDACC institutional grand rounds. September 2010. Session: Innovative, novel, translational imaging methods in breast cancer. “Novel mathematical methods for measuring breast cancer size”.

• Los Alamos National Labs, Center for Nonlinear Studies. 2010. “Multi-parameter computational Modeling of Tumor Invasion”.

• The Methodist Hospital Research Institute, NCI PS-OC Center for Transport Oncophysics, Annual Site Visit. 2010-2013.

• University of New Mexico Department of Pathology. 2010, 2011.

• University of Southern California. 2004, 2005, 2009, 2010, 2011.

• Scottish Universities Life Sciences Alliance Annual Symposium, University of St Andrews, Scotland, UK. 2010. “Multiscale Multi-parameter Computational Modeling of Tumor Growth”.

• Physical Science in Oncology Centers (NIH-National Cancer Institute) first all investigator annual meeting, Maryland. April 2-5, 2010. “Multiparameter Multiscale Physical Modeling of Delivery of Nanotherapeutics to Tumors and Tumor Response”.

• ASME 2010 First Global Congress on NanoEngineering for Medicine and Biology, Houston TX. 2010. Symposium on Multiscale Modeling in Biological Systems. “Multi-parameter Computational Modeling of Tumor Growth and Response to Treatment”.

• European Union Marie Curie Conferences and Training Course Program. 2010.

• Rutgers University. 2010

• The University of Texas Health Science Center at Houston, 2006, 2009, 2010.

• Methodist Hospital, Texas Medical Center, Houston, TX. 2009. “Multi-parameter multiscale computational Modeling of Tumor Growth and Response to Treatment”.

• Biocomplexity X Conference on Quantitative Tissue Biology and Virtual Tissues, Indiana University. October 27- November 1, 2009. “Multi-parameter Computational Modeling of Tumor Growth and Response to Treatment”.

• Cellular Behavior Ontology Workshop, National Cancer Institute, Bethesda. 2009. “Multi-parameter Computational Modeling of Tumor Growth and Response to Treatment”.

• Accelerate Brain Cancer Cure Annual Scientific Retreat, Sausalito, CA. October 1-2, 2009. “Computer Simulation of Glioma Growth and Response to Treatment”.

• NCI/EU 1st Transatlantic Workshop on virtual tissues. 2009. “Multi-parameter Computational Modeling of Tumor Growth and Response to Treatment”.

• European Conference on Complex Systems, Warwick, United Kingdom. September 21-25, 2009. Keynote speaker.

• Oberwolfach Workshop on Mathematical Biology. May 3-9 2009.

• International Academy of Nano Medicine annual meeting. 2009.

• The University of Texas School of Health Information Sciences Center at Houston, TX. 2009. From the Lab to the Marketplace: Highlights in Entrepreneurial Research. “Capitalizing on Computation – New Frontiers in Diagnostics, Treatments, Approaches toward Cures”. Keynote Lecture.

• University of Dundee, United Kingdom, 2006, 2008, 2009. Plenary Talk, Cancer Modeling Workshop, EU Marie Curie Conferences and Training Course Program.

• The University of Minnesota. 1998, 2000, 2001, 2002, 2004, 2007, 2009.

• Vanderbilt University. 2008.

• The University of Texas Health Science Center at San Antonio. 2008. “Virtual Cancer- Reducing Cancer Recurrence and Progression: New Paradigms in Cancer Diagnostics and Treatment Through Computational Modeling of Biological Systems”. Keynote Lecture.

• The University of Texas Health Science Center at Houston, TX. 2008. The World’s Best: The Willerson Years- 2001-2008 celebrating the progress of the health science center during the presidency of James T. Willerson, MD.

• The University of Texas at Austin’s Institute for Computational Engineering & Sciences (ICES), 2008

• The University of Texas at Austin, 2008. “Multi-scale Modeling and Non-Linear Simulation of Vascular Tumor Growth”

• The University of Houston, 2008

• University of California Cedars-Sinai Medical Center, 2008. “Multi-parameter Computational Modeling of Tumor Invasion”

• University of California Irvine, Symposium on Mathematical Systems Biology, 2008. “Multi-parameter Computational Modeling of Tumor Growth and Drug Response”

• Society of Mathematical Biology 2008. “Non-linear Simulation of Tumor Necrosis, Neo-vascularization and Tissue Invasion”

• NCI/EU 1st Transatlantic Workshop on multi-scale cancer modeling, Brussels 2008. “Multi-parameter Computational Modeling of Tumor Growth and Response to Treatment”

• Gordon Research Conference on Theoretical Biology and Biomathematics, 2008. “Modeling of ductal carcinoma in situ: application to patient-specific breast cancer modeling”.

• Pennsylvania State University. 1999, 2008.

• MD Anderson Cancer Center Grand Rounds, Houston, 2007, 2010. “Multi-parameter computational Modeling of Tumor Invasion”

• MD Anderson Cancer Center, Houston 2007, 2008, 2009. “Computer Simulation of Glioma Growth and Morphology”

• Alliance for Nanohealth, 2007.

• Roche, 2007.

• 9th U.S. National Congress on Computational Mechanics, 2007. “Multi-Disciplinary, Multi-scale In-Silico Models Connecting Phenotype, Morphology and Growth”.

• Rice University Keck Seminar Series, 2007. “Multi-disciplinary, multi-scale In-Silico Models Connecting Phenotype, Morphology and Growth”.

• Asia University, Taiwan, 2007.

• International Brain Mapping and Intra-operative Surgical Planning Society Annual Meeting. 2004, 2005, 2007.

• American Academy of Nanomedicine, 2006. “Mathematical Modeling of Cancer Progression and Response to chemotherapy: Towards the Development of a Multi-scale Computer Simulator”.

• University of California Irvine. 2001, 2002, 2003, 2004, 2005, 2006.

• New Jersey Institute of Technology. 2005.

• University of Arizona. 2004, 2005.

• University of California Los Angeles 2003, 2004, 2005

• The University of Nottingham, United Kingdom. 2004.

• Stanford University, 2004. “Non-linear Simulation of Tumor Growth”

• California State University, Northridge. 2004.

• Biofluid Symposium, Caltech, 2003. “Computer Modeling of Red Blood Cell Rheology in the Micro-Circulation,”

• National Cancer Institute. 2002. “Non-linear Simulation of Tumor Growth”

• AMO-Advanced Medical Optics. 2002.

• University of California Davis. 2002.

• Medtronic. 2001, 2002.

• Virginia Tech. 2000.

• Texas Tech University. 2000.

• PPG Industries. 2000.

• Novartis Pharmaceutics. 2000.

• University of Technology at Compiegne, France. 1999.

• Harvard University. 1998.

• Yale University. 1998.

Invention Disclosures

• P Dogra, Z Wang, V Cristini, Y-L Chuang, B Wilson, EL Bearer, CJ Brinker. Invention No. 2018-051, “Multiscale mathematical model to study nanomedicine delivery to solid tumors,” STC Ref. no. 2018-051, University of New Mexico 2018.

• J Freyer, A Shreve, V Cristini. Invention No. 2013-086, “A 3D Tissue Model for Spatially Correlated Analysis of Biochemical, Physiological and Metabolic Microenvironments,” STC Ref. no. 2013-086, University of New Mexico 2013.

• E Koay, V Cristini, J Fleming, P Bhosale, C Crane, H Shen, M Ferrari, Invention No. 2013-031, titled “System and methods for quantitatively describing biophysical markers.” University of New Mexico, UT Health, MD Anderson Cancer Center, US

Poetry and Other Writings

Il mattino

Forse perché della vera realtà
tu sei ombra fedele, a me sì
dolce mi sorprendi, mattino
ancor giovane e scuro.

Quando ti corteggian d’ansia piene
le cose, che dell’essere ancor
voglion sentir la pena;
e quando nell’incerto aere ancor
disfatti, frammenti di esperienze
tu mi meni, mescolati nell’onde
dell'universo tenebrose e lunghe;
sempre scendi caro, e le segrete
vie del mio cor soavemente tieni.

Ma poi l’occhio dei miei pensier si apre:
e ritornan dal nulla senza tempo
la scrivania amata e l’altre cose
familiari; e intanto fugge
la verità profonda;
e si compongon senza lei
le illusioni delle cure
onde meco ognun si strugge.

E mentre io sento ancora la tua pace, dorme quello spirto guerrier
ch'entro mi rugge.

Un sogno di ombre

Nel tempo pieno
di dolcezza inquieta,
quando nel libro della vita,
con mani esitanti,
ancor poche pagin’io voltavo;

in quell’ora della notte
sì tarda e buia,
prima del mattino,
che la familiare realtà nostra
quasi si frantuma
nell’anima che dorme;

come l’aere
agitato e minaccioso
in grandi altezze scuote
un piccolo aquilone, così
un sogno gettò la mente mia:

sì come in folla persona si vede,
e come in voce voce si
discerne, quando una è ferma,
e l’altra va e riede,
io stupito con terrore seguitavo
ombre sole nella stanza oscura:
il vuoto intorno a me;
e nulla all’ombre
dando forma, non io persino;
e non cosa pesante ne’ parete.

Poi di colpo, come
al risveglio del padrone
distratti servitori, innumerabili
le indaffarate particelle
si lanciaron tra l’imposte; e
al posto giusto ritornaron
la lampada, l’armadio
e la scrivania amata,
compagna de’ miei faticosi studi:
incomincio’
l’incantesimo del giorno.

Ma fu troppo tardi.
E col mio segreto
me ne andai zitto,
tra gli uomini che non vedono
per troppa luce
che nasconde l’ombre.

Il Paradiso

La gattina che zompetta intorno
intorno, dentro’l cespuglio amato
era posata a nutrir li dolci nati;
ma già previene il tempo
della nova fame, e va cercando
per trovar lo cibo ancora onde li pasca;
in che gravi labor le sono aggrati
per legge universal che non perdona!

Scende la sera intanto. E a gruppetti,
fuor dalle biblioteche e dalle aule
si ritrova la gioventù, e mira ed
è mirata, e’n cor s’allegra, discorrendo
del giorno che muore e quell’altro
che vien, e novità promette.
Mi va così il pensier ai nostri padri,
che nella primavera della vita, e
del secolo buio che già è passato,
così di vita lor il tempo ignoto
ancor che fosse tardi immaginaron.
Tornata e’ la stagion più bella, ma quell’anime no, più non ritornano,
fuor se nei sogni il cor
ombre care mi scuotono.

Ma quando sento il pianto dei suoi nati,
io penso a tutte quante le innumerevoli
generazioni del passato, e a questa
mia, cui oggi è dato vedere il giorno,
e passeggiar in rumorosi viali.
Allora io un altro mondo m’immagino
diverso; e mentre quasi vedo, tra
colli e boschi e calme acque, più felici
genti e famiglie di animali un più
benigno sole irraggiare: in questo
vaneggiar la mente mia si perde;
e al fin sfamato, tra quei nati, nel
grembo della madre mi addormento.

A una giovane morta

Gettando la lenza
nello stagno de’ ricordi,
che taglia ahimè per acque
immobili e scure, t’ho ritrovato
anima fragile, immagine cara
d’infinita bontà.

Il tuo amor per lo mondo,
più forte di me,
fu come l’umile albero
che, tra tempeste e siccità
sempr’al ciel puntando,
schivo del rumor del mondo,
ma conscio e sicuro del proprio valor, guarda passar della storia
le stagion, e in fin muore, con coraggio
in piedi restando, al contrario di noi.

Derubata del giorno,
che la sorte ci die’,
tropp’ancor che sera fosse,
impronta sol pur rimani
silenziosa e forte.

Ne’ sogni della notte
ombra frequente e amata
due figlie tue t’abbraccian;
l’occhi lor di giovani donne
ancor ti portano il sol.

Alla luna

Cara luna gentile, tu assomigli
al grigio deserto della mente mia
che splende sulla notte del mondo.

Da quei luoghi, a tutte le genti
familiari, onnipresenti eppur
dal mondo abbandonati;
ove se non di dolor,
abusi e violenza cieca,
malanni ed abbandono,
muor a poco a poco,
non solo il vecchio
ma ancor di più il bambino
per lo cibo che manca,
e piange lacrime morendo,
che pesan di più che tutta la terra;

lor con te via porti, o luna,
quando tramonti e quando sorgi,
come scaglia dopo scaglia
scolpite dall’artista che, levando,
della materia rivela vera forma;
infino ai fortunati pochi, che
un amor e qualcos’hanno!
A lor l’amate cose e i dolci cari
pur togli, che perduti, ancor stanno:
impronte fisse nell’anima
com’in tua polvere antica.

Forse nelle tue vaste valli silenti
si raggruppano infine,
a far la guardia all’eterno,
vecchi, giovani e infanti
nei reggimenti come’l mondo antichi
di quel temuto general
che mai un soldato perse?

E sulle secche tue spiagge,
ridotte in sabbia fina da mani
di roccia gittate nell’oscurità:
s’abbracceranno ancora,
quando nessuno vede,
quelli che se ne sono andati?

Non so: però sul tuo corrugato
volto antico, con vetri e strumenti
che la faticosa ragion ci die’,
crateri solo deserti io vedo uscir
dal limitar dell’ombra.

La luna e la stellina

Tu la luna sei, ed io
della sera
la stella piccolina.

Sorgiamo insieme
quando’l giorno tramonta;
e’l mondo tutto si scolora.
Poi nella notte t’inseguo
che le cose ci nasconde.

Nell’oscurità io spingo
i bracci esili di luce:
ma mai io ti raggiungo;
solo mirarti posso
di lontano.

Society

• https://youtu.be/mfIlqoNcpDs?si=sVbtNROZTyHIFmC4